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Abstract:
The evaluation of new vaccines that are urgently needed against tuberculosis (TB) is 
hampered by the lack of an immune correlate of protection. One of the main measures of immune 
function utilised in TB vaccine studies is the assessment of interferon (IFN)-y, as it is known that 
this cytokine is essential for immunity against infection.
The studies conducted in this thesis uses the non-human primate model of TB to address 
whether two measurements of IFN-y (the frequency of IFN-y secreting cells and the 
concentration of IFN-y secreted) can be related to survival and thus provide a correlate of 
protection. The Mycobacterium-specific IFN-y profiles have been assessed in two primate 
species (rhesus macaques and cynomolgus macaques) following immunisation with BCG, or 
aerosol infection with Mycobacterium tuberculosis. Additionally, one of the most advanced 
novel TB vaccines (modified vaccinia virus Ankara expressing antigen 85A; MVA85A) has also 
been tested in this model.
When human clinical trial data (provided by Oxford University) using BCG and BCG 
with an MVA85A boost were compared with results generated in similarly vaccinated macaques, 
it was observed that rhesus macaques have kinetically similar IFN-y responses, but at different 
magnitudes. During a vaccine efficacy study, rhesus macaques were shown to be protected from 
M. tuberculosis infection by BCG vaccination. This allowed the opportunity for responses in 
animals protected against disease to be compared with those which were not protected.
Although results showed that the capability to secrete larger concentrations of PPD- 
specific IFN-y early after M. tuberculosis infection correlated with longer survival periods, this 
was not solely due to prior vaccination. Most of the IFN-y responses during the vaccination 
periods did not relate to survival after challenge, except peak frequencies of IFN-y secreting cells 
after BCG vaccination. Therefore, it was concluded that measuring IFN-y alone does not provide 
the correlate of protection that is presently lacking in TB vaccine research.
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1 GENERAL INTRODUCTION
1.1 MYCOBACTERIUM TUBERCULOSIS
1.1.1 The pathological agent
Tuberculosis (TB) is one of the oldest infectious diseases known to humankind (Salo et 
al., 1994). It is an infectious disease caused by infection with mycobacteria, mainly 
Mycobacterium tuberculosis (M tuberculosis). It was during a lecture delivered in 1882 
that Robert Koch identified the causative agent of TB disease (Koch, 1882). All 
members of the Mycobacterium genus are rod-shaped Gram-positive bacteria that share 
the property of acid-fastness, due to their mycolic acid-rich cell wall structure (Girard et 
al., 2005). The cell wall is mainly comprised of a large cell-wall core that contains 
peptidoglycan, arabinogalactan and mycolic acids. The outer layer, which is generally 
referred to as the capsule, contains mainly polysaccharides such as glucan and 
arabinomannan (Abdallah et al., 2007) (Figure 1.1).
Growth of many mycobacteria, in particular the pathogenic species, is slow with a 
generation time of 12 h for M. tuberculosis (Kaufmann & Andersen, 1998). This results 
in M tuberculosis requiring 3-4 weeks to produce a visible colony (Andersen, 1997).
Since the first encounter between M. tuberculosis and man usually happens within the 
airways, the disease occurs mainly in the lungs, known as pulmonary TB. Successful 
elimination of the intracellular bacteria depends mainly on the efficient interaction 
between the infected macropahges and antigen-specific T cells (Stenger & Modlin, 
1999).
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Figure 1.1: Diagram of the mycobacterium cell wall. 
(Adapted from Abdallah et al., 2007)
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1.1.2 Incidence and prevalence of tuberculosis
During the 10 years preceding 2001, 90 million new TB infections occurred, resulting in 
approximately 20 million deaths (Collins & Kaufmann, 2001). In 2006, the annual rate in 
the development of active TB was 8.8 million with 1.6 million deaths resulting from TB 
disease (WHO, 2006). It has been estimated that one-third to one-half of the world’s 
population is latently infected with M. tuberculosis (Kaufmann, 1993). In the vast 
majority of infected people a long-lasting balance between the host immune response 
and persistent mycobacteria develops, meaning that the individual remains healthy 
(Kaufmann, 1993).
Infection with M. tuberculosis is generally associated with a 10% life-time risk of 
clinical disease; however, in human immunodeficiency virus (HIV) co-infected 
individuals this becomes a 10% annual risk (Young & Stewart, 2002). TB co-infection 
with HIV has become an issue as both pathogens circulate in similar populations, with 
disease being chronic and requiring long treatment regimes. Simultaneous treatment of 
TB and HIV requires 6-10 different drugs (Wells et a l , 2007). Both diseases contribute 
to the pathogenesis of one another; TB accelerates the course of HIV-induced disease by 
activating viral replication and contributing to the decline in CD4+ T-cell numbers, 
whereas HIV enhances the risks of reactivating latent TB, increases the progression of a 
new infection or re-infection to active disease and enables a more rapid spread of strains 
(Goldfeld & Ellner, 2007).
Treatment against TB is not easy to comply with and can be expensive for countries with
limited resources (Sierra, 2006), especially as TB drugs must be taken for a long time.
The main antibiotics used in treatment of TB are: isoniazid, rifampicin, pyrazinamide,
streptomycin and ethambutol (Sierra, 2006). These are part of the directly observed
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therapy, short-course (DOTS) strategy that consists of five elements: political will, case 
detection, standardised observed therapy, effective drug supply, and monitoring and 
evaluation (Maartens & Wilkinson, 2007). A combination of at least three antibiotics are 
required to prevent the emergence of resistance, as a UK national survey in the mid- 
1950s showed that most drug-resistant strains were only resistant to one antibiotic (Fox 
et al., 1957). Increasingly though, antibiotic resistant strains are emerging for multiple 
drugs (Kremer & Besra, 2002), thus compounding the TB peril even further.
Multidrug-resistant TB (MDR-TB) is defined as mycobacteria that are resistant to 
isoniazid and rifampicin, two of the primary antibiotics used to treat the disease 
(Matteelli et al., 2007). In 2006 it was estimated that >4% of the global cases of TB were 
caused by MDR-TB (Zignol et al., 2006). Treatment of MDR-TB is more difficult as the 
second-line drugs are harder to access and handle, are weaker, have more adverse side 
effects and are much more expensive, generating treatment costs up to $250,000 
(Kaufmann, 2000) compared with approximately $20 per patient for a 6 month standard 
course of chemotherapy (Matteelli et al., 2007).
More recently, extensively drug-resistant TB (XDR-TB) has been reported where MDR- 
TB bacilli are also resistant to any fluoroquinolone and at least one of three injectable 
second-line drugs (Jain & Mondal, 2008). The worldwide prevalence of XDR-TB is 
reported to be 6.6% among all MDR-TB isolates (Jain & Mondal, 2008).
In order to control TB it is apparent that further control measures are needed. New
antibiotics against MDR-TB are being developed and tested (reviewed in (Dover et al.,
2008), but there have been few new anti-tubercular drugs introduced into widespread use
since rifampicin in the 1960s (Kremer & Besra, 2002). An example of a new anti-TB
drug which has demonstrated strong potential is a diarylquinoline, named R207910, that
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blocks the function of an essential membrane-bound enzyme that makes adenosine 
triphosphate (Sharma & Mohan, 2006). This compound has been shown to be 
bactericidal with specific activity against mycobacteria, including MDR-TB strains 
(Andries et al., 2005), and has entered clinical trials (Matteelli et al., 2007). However, it 
can be hypothesized that mycobacteria will develop resistance against any new drugs 
introduced, in much the same way as resistance has developed against the other 
antimycobacterial compounds. For example, in Italy two patients were diagnosed with 
TB that was resistant to all known anti-TB drugs (Migliori et al., 2007). Therefore, 
unless treatment against TB is improved and control measures successfully implemented, 
then the development of drug resistance is expected to continue (Fauci, 2008) for current 
agents, and perhaps future ones too.
Generating immunity against M. tuberculosis may prove to be a more long-term and 
successful approach that circumvents the issues of antibiotic resistance. Additionally, 
vaccines that confer protection against TB disease will eliminate the requirement for 
extensive chemotherapeutic treatment. Another advantage with vaccines is that they are 
administered at only a few timepoints, whereas treatment against TB disease requires 
continual administration of anti-TB drugs and monitoring lasting several months, so 
vaccination is far more convenient and economical. The only currently available licensed 
vaccine against TB is the bacille Calmette Guerin (BCG) vaccine.
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1.2 VACCINATION AGAINST TUBERCULOSIS
1.2.1 BCG vaccine: history and effectiveness
In the 1920s, two students of Louis Pasteur, Calmette and Guerin, succeeded in 
attenuating M. bovis by sequential culture on potato-bile broth (Roche et al., 1995). This 
process repeated 230 times over 13 years yielded a strain of bacillus, M. bovis bacille 
Calmette Guerin, which had no pathogenicity in guinea-pigs or cattle (Roche et al., 
1995). This attenuated strain was subsequently used as a vaccine against TB, and still 
remains the only licensed vaccine against this disease.
It is estimated that 76% of children worldwide are vaccinated with BCG, with meta­
analysis of 18 case-control studies revealing efficacies of 73% and 77% against 
childhood TB meningitis and miliary TB, respectively, in the first 5 years of life (Trunz 
et al., 2006). However, while BCG is very effective against childhood and disseminated 
TB, it is less effective against adult pulmonary TB (Roche et al., 1995). In the general 
population an average efficacy of 50% (0-80%) was reported in a meta-analysis of the 
literature covering 1264 articles from which 70 clinical trials were selected spanning a 46 
year period (Colditz et al., 1994). These extremes in variation of protection against 
pulmonary TB are highlighted by experiments reported in the 1970’s where extensive 
trials in India showed a protective efficacy of 0% (Tuberculosis Prevention Trial, 1979; 
Tuberculosis Research Centre, 1999), whereas in the UK trial efficacies of 78% were 
observed (MRC, 1972). The causes of these variations may include inherent deficiencies 
of the BCG vaccine, or by differences in the study populations, particularly in regard to 
pre-existing immune responses in those individuals where BCG failed to protect against 
TB.
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1.2.2 Limitations of the BCG vaccine
There is evidence that the immunity induced by BCG is not life-long. From a meta­
analysis of trials, there is no strong evidence that BCG provides protection for more than 
10 years after vaccination (Sterne et a l , 1998). Contrary to these results, studies in North 
American Indians and Alaskan Natives have demonstrated that there was only a slight 
decrease in the protective efficacy of BCG vaccination after 50 years of observations 
(Aronson et al, 2004).
By the 1980s, it was apparent that BCG from different localities had evolved into strains 
with some distinct antigenic differences (Roche et al., 1995), with over 16 separate 
strains of BCG vaccine available worldwide (Behr et al., 1999). Major BCG vaccine 
strains differ from the original BCG strain and from each other, with “stronger” strains 
(Pasteur 1173, Danish 1331) being more reactogenic and, presumably, more 
immunogenic, than “weaker” strains (Glaxo 1077, Tokyo) (Girard et al., 2005). 
However, even when the same strain (Danish) was used, there was good protection in the 
UK but poor protection in India (Roche et al., 1995). A meta-analysis of human BCG 
vaccination with different strains also found that the strain of BCG was not a significant 
determinant of the overall efficacy in the prevention of TB (Brewer & Colditz, 1995).
Over time, BCG vaccines may have lost a number of genes with potential relevance for
protective immunity or, in other words, have been “gradually attenuated to impotence”
as seen by reduced efficacies with increasing passage number (Behr & Small, 1997).
With over 100 genes deleted in BCG compared to M. tuberculosis (Behr et al., 1999) the
vaccine lacks important immunodominant antigens expressed in virulent mycobacteria,
such as 6kDa early secreted antigenic target (ESAT-6) (Harboe et al., 1996). It could be
that some of these antigens will be needed to mount an effective immune response
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against M. tuberculosis. However, losing some of the virulence genes also benefits the 
use of BCG as it contributes to the bacilli being made into a safe vaccine.
1.2.3 Pre-existing immunity and the effect on BCG vaccination
Protective immunity from BCG requires bacterial replication in the host leading to the
generation of mycobacterial immunity. This protective immune response may be blocked
by pre-existing immunity cross-reacting to BCG (Dietrich et al, 2006). Environmental
mycobacteria are ever-present in nature, and contact between them and humans and
animals is therefore a frequent and regular occurrence (Zumla & Grange, 2002). One of
the areas where BCG is ineffective as a vaccine is in Malawi, South-Eastern Africa.
Using six atypical mycobacterial strains isolated from soil and sputum samples in
Malawi, two strains of M. avium were found to block BCG protective efficacy
completely in mice (Brandt et a l, 2002). A large study undertaken in Malawi also
demonstrated patterns of immune response against M. tuberculosis purified protein
derivative (PPD) in healthy, HIV-seronegative, Malawian young adults with no history
or scar evidence of prior BCG vaccination (Black et a l, 2001). These results suggest that
an appreciable proportion of the individuals living in this rural area of northern Malawi
had been exposed to mycobacterial antigens by the age of 12, and that such responses
increase with age (Black et a l, 2001). Exposure to M. avium in the Malawian population
was much more frequent compared to M. tuberculosis and M. bovis as assessed by using
PPD preparations from the different mycobacterial species (Black et a l, 2003). These
data suggest that individuals living in Malawi may be less able to generate protective
immune responses to BCG than their UK counterparts (Bennett et a l, 2006) due to prior
sensitisation with environmental mycobacteria blocking subsequent vaccine responses.
However, in UK school children who had not been BCG-vaccinated, IFN-y responses
were detected to PPD derived from M. avium (60% responding) and M. tuberculosis
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(27% responding), indicating that this population also had background responses from 
pathogenic and environmental mycobacteria (Weir et a l , 2003).
Based on animal studies, it has been suggested that infection with environmental 
mycobacteria changed the immune reaction towards a detrimental humoral response that 
could not be overridden by a subsequent BCG vaccination (Hemandez-Pando et a l , 
1997). Another argument is that in areas where BCG fails to work, people have 
concurrent infections with helminths. Individuals with helminth infections are 
chronically immune-activated and also have pronounced humoral immune profiles 
(Borkow & Bentwich, 2000), thus likely effecting BCG vaccination responses which 
require T cell induced immunity.
With the evidence that BCG protects against disseminated disease in childhood and 
confers reliable protection against leprosy (Ponnighaus et al., 1992), until it is clearly 
demonstrated that a replacement vaccine can confer an equal level of protection to BCG 
it would be unethical to withdraw BCG vaccination (Fletcher & McShane, 2006). With 
roughly one case of severe childhood tuberculosis being prevented for every 2500 BCG 
inoculations (Novelli, 2006) there is still extreme value in immunising children against 
TB disease in areas with high endemnicity.
As BCG vaccination was thought to be a success in the eradication of TB, it has been
said that, “Research on tuberculosis and BCG seems to have suffered from its own early
success; that is, it seems as though the global BCG campaigns were more successful in
eradicating tuberculosis research than in eradicating tuberculosis” (Fine, 1989).
However, historical evidence has demonstrated that improvements on socio-economic
conditions have contributed more to the decline in TB in the last century than have
medical interventions (Grange, 1999). This is also reflected by the fact that developing
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countries attribute to 97% of TB cases and 98% of TB deaths in the world (Benatar,
2003).
With the realisation that the current BCG vaccine will not eradicate TB, there has been 
considerable interest in developing new vaccines to replace, or enhance, the BCG 
vaccine.
1.2.4 New TB vaccine candidates
A large number of potential candidates are being evaluated in the search for a new 
vaccine against TB. These vaccines are based on different approaches: (i) subunit 
vaccines; (ii) live attenuated vaccines; and (iii) combination vaccines. These are 
discussed below, with examples given of the main candidates currently at the furthest 
stage of development.
1.2.4.1 Subunit vaccines
Subunit vaccination assumes that one or only a few antigens are required to generate 
protective immunity (Kaufmann, 2000). However, the immune response may be limited 
in the required intensity and duration, so subunit vaccines may require the addition of an 
adjuvant formulation (Sierra, 2006) or prior vaccination with BCG.
1.2.4.1.1 Protein subunit vaccines
A fusion protein of Ag85B-ESAT-6 has shown protection in the guinea-pig model
(Olsen et al., 2004). This vaccine has been shown to confer protection in cynomolgus
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macaques, as assessed by reduced bacterial load and lung pathology (Langermans et al.,
2005). Also in cynomolgus macaques, the protein was coupled with a phosphoantigen 
and after vaccination two waves of immune response were observed successively by y8 
and ap T lymphocytes (Cendron et al., 2007). However, this vaccine may suffer because 
of the inclusion of ESAT-6 which may compromise the specificity of new 
immunodiagnostic tests (Sander & McShane, 2007) which use ESAT-6-specific 
responses to diagnose TB infection.
Ag85 complex proteins, when formulated with adjuvant and delivered intranasally, have 
been shown to impart protection comparable to that of BCG when delivered in mice 
(Giri et al, 2006). Also, Ag85A protein has been administered subcutaneously to boost 
BCG immune responses in mice, thus extending the protection against aerosol M. 
tuberculosis infection into later age (Brooks et al, 2001). Priming mice with Ag85A 
DNA before vaccinating with BCG increased significantly the protective efficacy of the 
BCG vaccine (Romano et a l, 2006).
1.2.4.1.2 Vector-based subunit vaccines
Mycobacterial antigens have been engineered into non-mycobacterial bacteria such as 
Salmonella (Hess & Kaufmann, 2001), which can induce strong mucosal responses 
(Sierra, 2006). Viral vectors have also been used (Goonetilleke et al., 2003), which have 
the potential to induce cytotoxic T-lymphocyte (CTL) responses (Sierra, 2006). 
However, vaccines that have been attenuated but are still live will require critical safety 
evaluation, especially for use in immunodeficient populations (Sierra, 2006). Vaccines 
that use replication incompetent organisms to deliver antigens would offer an easier 
route through the regulatory process.
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Recombinant pox-viruses and recombinant adenoviruses are efficient at boosting 
previously primed T cell responses as these vectors induce non-specific co-stimulated 
responses that facilitate the amplification of pre-existing memory immune responses 
(McShane & Hill, 2005). Ag85A has been expressed in numerous viral vectors, 
including Modified Vaccinia Ankara (MVA) (Goonetilleke et a l , 2003), fowlpox 
(Williams et al., 2005a), vesicular-stomatitis virus (Xing & Lichty, 2006) and adenovirus 
(Xing & Lichty, 2006). In mice, MVA85A was shown to boost BCG-induced Ag85A 
specific CD4+ and CD8+ T cell responses (Goonetilleke et a l, 2003). When MVA85A 
and fowlpox expressing Ag85A (FP85A) were used in the guinea pig model to boost 
BCG vaccination responses, the poxvirus-boosted animals gave 100% protection up to 
26 weeks post-M tuberculosis high-dose challenge (Williams et al., 2005a). In phase I 
human clinical trials, MVA85A boosting of BCG vaccination responses was found to 
induce high levels of antigen-specific IFN-y-secreting T cells (McShane et al., 2004). 
The BCG-MVA85A prime-boost regime is currently being tested in phase II clinical 
trials in South Africa (Pathan et al., 2007), where is has been shown to be safe and 
immunogenic (Hawkridge et al., 2008).
Ag85A inserted into an adenovirus vector (AdAg85A) has been used as a boost vaccine 
after BCG vaccination in mice (Santosuosso et al., 2006). However, only when 
AdAg85A was delivered intranasally was protection observed (Santosuosso et al., 2006). 
Other investigators have inserted genes encoding M. tuberculosis antigens Ag85A, 
Ag85B, and TB10.4 into an adenovirus vector (Ad35-TBS). When this vaccine was used 
without prior BCG vaccination, mice were protected against an M. tuberculosis 
challenge (Radosevic et al., 2007).
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1.2.4.2 Live attenuated vaccines
Whole bacterial vaccines contain many antigens to enhance protection and benefit from 
having adjuvanticity properties (Kaufmann, 2000). These vaccines may induce long- 
lasting immune responses, but may be disadvantaged in having the potential to cause 
immunopathology (Sierra, 2006). Multiple mutations are essential to ensure that there is 
no potential for the vaccine organism to revert to virulence (Young & Stewart, 2002). 
The two main approaches used for live attenuated vaccines against TB include using 
BCG and M. tuberculosis bacilli.
1.2.4.2.1 Attenuated BCG vaccines
A BCG strain with the urease gene deleted and a listeriolysin gene from Listeria 
monocytogenes inserted has shown greater potential than the parental BCG strain in a 
mouse model (Grode et al., 2005). The lack of urease allows the phagosome to acidify, 
and the listeriolysin enables the phagosome to be punctured; allowing passage of the 
organism into the cytoplasm and access to MHC class I molecules. Another live 
attenuated BCG vaccine uses BCG overexpressing antigen 85B, a mycolyl transferase 
involved in mycobacterial cell wall synthesis, which has shown protection in guinea pigs 
(Horwitz & Harth, 2003) and has completed a phase I clinical trial (Skeiky & Sadoff,
2006).
Ag85A has also been introduced into a recombinant form of BCG which, when boosted 
with Ag85A peptide, improved lung pathology and reduced pulmonary bacterial load 
significantly in guinea pigs after infection (Sugawara et al., 2007b). This vaccine
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approach has also been assessed in non-human primate models (Sugawara et al., 2007a; 
Sugawara et al., 2009).
1.2.4.2.2 AttenuatedM. tuberculosis vaccines
An advanced live attenuated vaccine that uses M. tuberculosis is a strain with a 
disruption in the phoP gene, which regulates mycobacteria lipids implicated in the 
virulence of M. tuberculosis (Ludwiczak et al., 2002; Walters et al., 2006) called S02. 
Recently, it has been shown that the phoP gene controls secretion of the major antigens 
ESAT-6 and CFP10 (Frigui et al., 2008). This S02 strain has been used as a vaccine in 
mice, where protection against challenge with M. tuberculosis was similar to BCG 
vaccinated animals (Aguilar et al., 2007). Furthermore, M. tuberculosis S02 has been 
tested in guinea pigs and severe combined immunodeficiency disease (SCID) mice, 
demonstrating better protection against a high-dose challenge in guinea pigs compared to 
BCG vaccination and safety in immunocompromised subjects (Martin et al., 2006).
1.2.4.3 Combination vaccines
Instead of using a single vaccine to control M. tuberculosis, a combination of
vaccinations may prove essential in order to allow sufficient immunity to be generated.
One such approach uses two different vaccines - each containing the same antigen -  to
allow a directed response against this antigen to be developed; so-called ‘heterologous
prime-boost’ (McShane & Hill, 2005). Instead of ignoring previous BCG inoculation, as
BCG vaccination is routinely administered to the young in countries where tuberculosis
is endemic, targeting an antigen present in BCG that has some memory T cell activity
has the potential to induce a fresh immune response (Brooks et al., 2001). As Ag85A is
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conserved amongst all mycobacterial species and is present in all strains of BCG 
(D'Souza et al., 2003) this antigen has been identified as an ideal candidate for boosting 
BCG vaccination responses. As mentioned in section 1.2.4.1.2, the advanced MVA85A 
vector vaccine delivered after BCG vaccination is currently in human clinical trials.
Boosting BCG responses with proteins has also successfully been tested. Mtb72F, a 
fusion protein of Mtb39 (PPE protein) and Mtb32 (serine protease) administered with a 
CD4 T-cell adjuvant (AS02A), has shown protective efficacies greater than using BCG 
alone in guinea pigs (Brandt et al, 2004). This vaccine has also completed clinical trials 
in the United States and Europe (Sander & McShane, 2007).
1.3 ANIMAL MODELS OF TUBERCULOSIS
As immunological correlates of protection have yet to be identified in any animal models 
of TB, the only way to assess the protective efficacy of new vaccines is to conduct 
challenge studies (McMurray, 2000b; 2001b; McMurray et al., 1999). The use of 
relevant animal models in TB research is therefore critical to allow the onward 
development and testing of new vaccines and treatments. These animal models should 
ideally produce levels of infection and disease at high prevalence, yet the pathogenesis of 
disease that occurs after artificial infection must mimic disease patterns that occur 
naturally (Griffin, 2000). Animal species that contract TB following natural exposure to 
M. tuberculosis provide representative experimental model systems which are most 
relevant for the study of human disease (Griffin et al., 2001). Animal models for 
tuberculosis have been used since 1882, when Robert Koch first described the causative 
agent backed up by experimental infection in animals including mice, rats, guinea pigs, 
hamsters, cats and dogs (Koch, 1882). Since then, in excess of 100 tuberculosis vaccines 
have been tested in animal models (Girard et al., 2005).
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Although it is acknowledged that animal models of M. bovis infection closely resemble 
events with M. tuberculosis infection, due to the latter organism being used for this 
project only this is introduced in this section.
1.3.1 Murine models
The mouse provides a sophisticated and cost-efficient model for TB disease. The inbred 
mouse is the most popular model in TB research, and has provided a large amount of 
information in terms of understanding mechanisms of immunity that are relevant to 
humans (Orme, 2003).
Mice are more resistant than humans to infection with M. tuberculosis, and the disease 
process differs significantly from human TB. The granulomas of mice rarely progress to 
necrosis, caseation and liquefaction as they often do in humans and they are able to 
sustain very high levels of mycobacteria in their lungs for months without apparent 
disease (Kremer & Besra, 2002). Using the low-dose aerosol model of infection it has 
become clear that certain inbred mouse strains differ in their susceptibility to M. 
tuberculosis infection. Certain strains (e.g. DBA/2, A/J, CBA/J) are unable to control 
infection in the lungs and subsequently show evidence of a form of reactivation or 
regrowth that is fatal to the animal (Orme, 2003). In contrast, mice on the C57 genetic 
background maintain a chronic bacterial load (Orme, 2003).
The resistant nature of the mouse model makes it a suitable animal in which to study
latency. The Cornell model can also be used to mimic latency and involves treating M
tuberculosis infected mice with antimycobacterial drugs to reduce the bacterial burden to
undetectable levels. Reactivation of disease can then occur spontaneously or in response
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to immunosuppressive agents (Flynn & Chan, 2001b). The advantage of this latency 
model is the low bacterial burden in mice; however, the introduction of antibiotics does 
not replicate the situation in natural human latent tuberculosis and may influence the 
development of a protective immune response.
To try to recreate the slow progression from M. tuberculosis infection to disease, as 
usually found in humans, the intraperitoneal route of infection has shown some signs of 
success (Mustafa et al., 1999). Additionally, to try and recreate the intragranulomatous 
lung necrosis that the mouse model usually lacks, but in human disease commonly 
develops, lipopolysaccharide (LPS) has been inoculated via the intranasal route in M 
tuberculosis infected mice (Cardona et al., 2001). This provided a feasible and 
reproducible tool to recreate the histopathology of human TB in the murine model.
As studies involving animal models of TB need to be carried out in Containment Level 3 
facilities, the mouse has a clear advantage in this regard as many more mice than guinea 
pigs or rabbits can be housed in the same space, and the cost of maintaining mice is 
much less (McMurray, 2000b). However, the small size also means that there are 
differences in the mouse model compared to humans. The bronchial tree is far less 
complex in mice, and there are differences in the structure, such as no second circulatory 
supply to bronchial associated lymphoid tissue. As the lymphatics are less complex in 
mice, with limited drainage into the alveolar regions (Orme, 2003), the development of 
immunity and presentation of antigens will be different to those occurring during human 
infection.
Preliminary screening of TB vaccines in mice is a cost-effective strategy, and 
challenging small animals with aerosolised organisms has been accepted to be one of the
first stages in evaluating potential vaccines against mycobacteria (Skinner et al., 2001).
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Large numbers of candidates can be narrowed down to the most promising few, that then 
can undergo secondary screening in larger animal models (Orme, 2003). One such 
example is the fusion protein 72f, that has been found to have protective effects in the 
guinea pig and primate models after its activity was initially observed in the mouse 
(Orme, 2003). However, mice are not infallible in predicting efficacy in larger animal 
species. While DNA vaccination has proven to be an efficient immunisation strategy in 
mice, it has been shown to be less effective in larger animals so further improvements 
will need to be made before DNA can be used in human vaccination (Reed et al., 2003).
Effects of prior exposure to mycobacteria studied in the mouse model have demonstrated 
that sensitisation with environmental mycobacteria inhibited BCG multiplication and 
thereby prevented the induction of an efficient BCG-mediated response and subsequent 
protection against M. tuberculosis challenge (Brandt et al., 2002). This experimental 
model is therefore relevant to the many tropical regions where BCG is not protective 
against pulmonary TB.
A lot of our understanding of the T cells involved in protection against M. tuberculosis 
(covered in section 1.4) is based on evidence from studies of TB in mice (Mogues et al., 
2001). Work on murine immunology is greatly assisted by the vast number of reagents 
that are available for this model, including monoclonal antibodies to T cell surface 
markers, primers and probes for the growing array of cytokines and chemokines 
involved, and the availability of inbred mouse strains (Orme, 2003). Mice generate a 
strong cellular response, which controls bacterial growth and limits damage to the lungs 
(Baldwin et al., 1998) and extensive studies carried out using TB vaccines in inbred mice 
have identified a variety of responses that may be involved in protective immunity 
following vaccination.
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Although mice constitute an excellent model to monitor fundamental parameters of 
immunity, they lack some of the components that are present in humans, e.g. group I 
CD1 molecules (Kaufmann, 2001) and granulysin (Lazarevic & Flynn, 2002). Therefore, 
when the contribution of these components need to be studied, mice are not the most 
appropriate models to use.
1.3.2 Guinea pig models
The guinea pig is an invaluable animal model of human TB, the central reason being the 
fact that guinea pigs develop ‘classical’ granulomas similar to those seen in humans with 
active disease (Reed et a l , 2003). This provides a distinct advantage over the mouse 
model, where this phenomenon is absent, whilst maintaining the benefit of being a small 
animal.
After infection with low doses of virulent M. bovis or M. tuberculosis guinea pigs are 
particularly susceptible to progressively fatal disease (Griffin, 2000); infection in guinea 
pigs can result from just a single virulent organism (McMurray, 2001c). This may be a 
result of the animal initially developing a strong immune response, which eventually 
leads to considerable tissue damage resulting in extensive caseation and tissue necrosis 
that leads to death (Baldwin et al., 1998). These processes mimic responses in infected 
humans, and so the guinea pig provides a useful model to study these events.
The series of events following M. tuberculosis aerosol challenge in guinea pigs has been
well documented (Balasubramanian et a l , 1994a). The first event after delivery of a low
aerosol challenge dose is the development of one or more primary lesions in the pleural
surface of the lungs. Following this, the virulent bacilli multiply at the site of
implantation in the lung, and some bacilli get transported to the lymph nodes draining
-43-
that specific region of the lungs. The bacilli then multiply in the lymph node which 
enlarges, creating a situation in which some bacilli escape and enter the bloodstream, to 
be observed later in the spleen and in other lung lobes (Balasubramanian et al., 1994a).
The aerosol challenge of guinea pigs has been used extensively to evaluate novel TB 
vaccines (Vipond et al., 2006a; Vipond et al., 2006b; Williams et al., 2005b). As BCG 
vaccination protects well in the guinea pig model (Williams et al., 2000), it may prove 
difficult for a candidate vaccine to improve upon this performance. Successful 
immunisation of guinea pigs leads to reduced necrosis, with small lesions characterised 
by infiltrating lymphocytes, decreased weight loss and prolonged survival. Recently, 
more rigorous vaccine evaluations in guinea pigs have tended towards using disease and 
survival as endpoints instead of only short-term bacterial counts, which are not 
necessarily predictive of long-term disease outcome (Baldwin et al., 1998; Reed et al.,
2003).
Immunological studies on guinea pigs is restricted by the lack of available reagents and 
due to their small size, sequential sampling of blood is difficult in this model. However, 
several guinea pig cytokine and chemokine genes have now been cloned, so reagents are 
being developed to address this requirement and allow the study of immunological 
determinants of resistance to TB in this model (McMurray, 2001c), including guinea pig 
micro-arrays (Tree et al., 2006) and antibodies to IFN-y (Schafer et al., 2007). This will 
greatly enhance the use of the guinea pig model and allow the generation of important 
immunological data.
1.3.3 Rabbit model
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Although the rabbit is more costly compared to the mouse and guinea pigs models in 
terms of purchase, maintenance, and the amount of high containment space required, it 
does reproduce the range of pathological consequences seen in human TB (McMurray, 
2001c). Although rabbits are highly susceptible to infection with virulent M. bovis, they 
are much more resistant to infection with M. tuberculosis (McMurray, 2001c).
Pulmonary granulomas in rabbits often undergo liquefaction, so this model allows the 
process of lung cavitation to be studied, which is important as cavitation is also observed 
in human TB disease. Tubercle bacilli may grow extracellularly in these cavities, from 
where bacilli can enter the bronchial tree and spread to other parts of the lung and also to 
other people (Converse et al., 1996). The spread to other people is usually through the 
coughing mechanism which distributes the bacilli around the patient’s environment. 
Therefore, liquefaction and cavitation are important implications that enable the spread 
of TB (Converse et al., 1996).
Pulmonary TB in rabbits, therefore, represents an excellent model for pulmonary TB in 
humans. Neither species is inbred, so considerable variation in the amount and extent of 
disease occurs. These factors make studies of both rabbits and humans more difficult and 
more expensive, but cavitary TB cannot be produced in mice and only rarely in guinea 
pigs (Converse et al., 1998).
To further analyse information from this model, cytokine reagents are being developed 
for the rabbit (McMurray, 2001c) to allow more immunological analyses to be carried 
out. However, mainly due to its size, the model is limited in its use as a widely available 
vaccine testing model, and is instead used more prominently as a model for the study of 
cavitary disease formation.
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1.3.4 Non-human primate models
1.3.4.1 Introduction
Non-human primates are susceptible to tuberculosis infection by the aerosol route, 
develop a human-like disease, exhibit antigen-induced T lymphocyte reactivity both in 
vitro and in vivo, and can be protected effectively by BCG vaccination (McMurray, 
2000a). The similarity in responses may be because host molecules are present in both 
man and non-human primates, but differ in mice and guinea pigs (Langermans et a l, 
2001). In their natural habitats, non-human primates are essentially free from 
tuberculosis (Mulder, 1976) so the infection is primarily induced through human 
intervention.
The course of M. tuberculosis infection in macaques can be followed by chest X-ray and 
weight loss, as well as by a variety of haematological tests, including erythrocyte 
sedimentation rate, lymphocyte proliferation, cytotoxic T-lymphocyte activity and 
cytokine production (Reed et al., 2003). The ability to perform detailed analyses of both 
pathology and immune responses demonstrates the potential of non-human primates in 
TB vaccine development.
Due to the large size of the non-human primates, sequential blood sampling can be 
undertaken to assess longitudinal responses in the same animal. Macaque blood has been 
used successfully in modem immunological assays, such as the whole blood cytokine 
flow cytometry methodology (Keeney et a l , 2003) and enzyme-linked immunosorbent 
spot (ELISPOT) assays (Makitalo et al., 2002). Results from these assays allow 
comparison with data obtained from human studies. Additionally, the role of CD4+, 
CD8+ and y8 cell populations can be studied in this model (Lai et al., 2003; Shen et a l , 
2002).
There are some difficulties in using non-human primates for research; the major factors 
being containment of biohazards and cost. Experimentation with airborne infections in 
primates imposes two major requirements: animals must receive known dosages of the 
infecting agent and secondly, the exposure and subsequent handling of the animals 
should present a minimal hazard to those carrying out the work (Wolochow et a l , 1957). 
Additionally, although the outbred nature of macaques can be viewed as a limitation on 
performing some studies, this also likely contributes to the wide range of clinical 
manifestations seen in this model (Capuano et al., 2003), so this resemblance to humans 
may in fact prove to be an advantage.
Because of their similarities to humans, non-human primates represent the best animal
models for assessing the relative safety and immunogenicity of vaccines (Pehler et a l ,
2000). Non-human primates also demonstrate many comparable gross and microscopic
pathological changes consistent with the different disease stages in people (Capuano et
a l , 2003). The macaque model can simulate various important aspects of human TB,
including primary disease as well as latent infection (Flynn et a l, 2003; Gormus et a l,
2004). However, primate testing should be reserved for the final stages of evaluation of
vaccine candidates that have already shown significant protective activity in smaller
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animal models (McMurray, 2000a), and should be used to supplement data from these 
animals, not to replace them (Schmidt, 1972).
It is also possible to co-infect macaques with other pathogens in order to produce models 
of infection that are similar to situations found in humans, for example, using simian 
immunodeficiency virus (SIV) as a model for human immunodeficiency virus (HIV) 
infection. Results from SIV/BCG co-infected monkeys have confirmed the hypothesis 
that mycobacterial coinfection can enhance viral pathogenicity as well as accelerate the 
progression to clinical AIDS in HIV-infected people (Zhou et al., 1999).
There have been some studies reported on the use of baboons (Papio cynocephalus 
anubis) in the areas of immunogenicity of M. tuberculosis-secreted protein antigens 
(Pehler et al., 2000) and during an outbreak of disease in a captive colony (Tribe & 
Welbum, 1976). However, most non-human primate tuberculosis work has been carried 
out in the rhesus and cynomolgus macaque models (tables 1.1 and 1.2, respectively). 
Rhesus macaques are generally heavier (average adult size 9509g) compared to 
cynomolgus macaque (5454g) (Andrade et al., 2004). Both animals have similar crown- 
to-rump lengths (rhesus macaques, 46.53cm; cynomolgus macaques, 41.25cm), but tails 
are far larger in adult cynomolgus macaques (54.79cm) than in the rhesus macaques 
(24.20cm) (Andrade et al., 2004). These figures are from 175 rhesus macaques and 36 
cynomolgus macaques housed for biomedical research, and are from adult macaques 
defined as being aged over 45 months.
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Year
Macaque
species
(number)
Vaccination/Purpose of 
study Challenge Reference
1956 Rhesus
(221)
Assess treatment with isoniazid Naturally infected 
beforehand
(Schmidt, 1956)
1968 Rhesus
(>1300)
BCG and mycobacterial cell 
walls (intravenously)
Mtb 5159 strain via 
bronchus instillation 
(145-500 viable units)
(Good, 1968)
1970 Rhesus
(x26)
BCG (intravenously) Mtb H37Rv via aerosol 
(12-49 infectious units)
(Barclay et al., 1970)
1971 Rhesus
(x40)
Mycobacterial cell walls and 
BCG (intravenously)
Mtb H37Rv via aerosol 
(21 infectious units)
(Ribi et al., 1971)
1972 Rhesus
(59)
BCG and BCG cells walls 
(intramuscularly and 
intravenously)
Mtb H37Rv via aerosol 
(62 units)
(Anacker et al., 1972)
Rhesus
(-417)
BCG (intracutaneously, 
intravenously and intratracheal)
Mtb H37Rv and strain 
5159 & 4941 via 
bronchial instillation (50- 
5000 viable units)
(Schmidt, 1972)
1973 Rhesus
(x55)
BCG (aerosol and 
intracutaneously)
Mtb H37Rv via aersol 
(11.6-16.5 infectious 
units)
(Barclay et al., 1973)
Rhesus
(x50)
BCG (intravenously and 
intracutaneously)
Mtb H37Rv via aerosol 
(14 viable units)
(Janicki et al., 1973)
2000 Rhesus
(x4)
Culture filtrate proteins 
(intramuscular)
ND (Attanasio et al., 2000)
2001 Rhesus
(x6)
BCG (intradermally) Mtb Erdman via 
intratracheal instillation 
(3000 cfu)
(Langermans et al., 
2001)
2002 Rhesus
(x8)
BCG (intravenously) Mtb H37Rv via aerosol 
(400-500 cfu)
(Shen et al., 2002)
2003 Rhesus
(x20)
BCG (intravenously and 
bronchial inoculation)
ND (Lai et al., 2003)
2004 Rhesus
(x20)
ND (pathogenesis study) Mtb Erdman and H37Rv 
via intrabronchial 
inoculation (10-2xl06 
cfu)
(Gormus et al., 2004)
2008 Rhesus
(xl5)
rBCG expressing perfringolysin 
and rAd expressing Ag85A, 
Ag85B and TB 10.4.
ND (Magalhaes et al., 
2008)
Rhesus
(x4)
ND (pathogenesis study) Mtb H37Rv via aerosol 
(400-500 cfu)
(Huang et al., 2008)
2009 Rhesus
(x!5)
rBCG-Ag85A Mtb H37Rv via 
intratracheal instillation 
(3000 cfu)
(Sugawara et al., 
2009)
Table 1.1: Summary of tuberculosis vaccine and pathogenesis studies carried out in 
rhesus macaques
(ND = Not done, Mtb = M. tuberculosis, cfu = colony forming units).
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Year
Macaque
species
(number)
Vaccination/Purpose of 
study Challenge Reference
1996 Cynomolgus
(x24)
ND (pathogenesis study) Mtb Erdman via 
intratracheal instillation 
(10-105 cfu)
(Walsh e ta l . , 1996)
2001 Cynomolgus
(x6)
BCG (intradermally) Mtb Erdman via 
intratracheal instillation 
(3000 cfu)
(Langermans et al., 
2001)
2003 Cynomolgus
(xl7)
ND (pathogenesis study) Mtb Erdman via 
bronchoscope instillation 
(-25 cfu)
(Capuano et al., 2003; 
Flynn et al., 2003)
Cynomolgus
(x9)
(Fuller et al., 2003)
2005 Cynomolgus
(xl2)
Ag85B-ESAT-6 fusion protein Mtb Erdman via 
intratracheal instillation 
(1000-3000 cfu)
(Langermans et al., 
2005)
2006 Cynomolgus
(x8)
ND (pathogenesis study) Mtb Erdman by 
bronchoscopic 
instillation (25 cfu)
(Lin et al., 2006)
2007 Cynomolgus
(xl6)
ESAT-6-Ag85B fusion protein 
+/- phosphoantigen
ND (Cendron et al., 2007)
Cynomolgus 
(xl 8)
rBCG-Ag85A Mtb H37Rv by 
intratracheal instillation 
(3000 cfu)
(Sugawara et al., 
2007a)
2008 Cynomolgus
(x3)
ND (pathogenesis study) Mtb Erdman via 
bronchoscope instillation 
(1000 cfu)
(Huang et al., 2008)
Table 1.2: Summary of tuberculosis vaccine and pathogenesis studies carried out in 
cynologus macaques
(ND = Not done, Mtb = M. tuberculosis, cfu = colony forming units).
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1.3.4.2 Rhesus macaques
Since 1956, rhesus macaques have been regarded as suitable models for carrying out 
controlled studies on new agents for the treatment of human TB (Schmidt, 1956). Early 
vaccine experiments on non-human primate TB research from the 1970s utilised only the 
rhesus model. Most of the experiments focused on the effects of vaccination with BCG 
including using different routes of immunisation (Barclay et a l, 1970; Barclay et al., 
1973; Janicki et a l, 1973) and the use of mycobacterium cell walls as a vaccine 
(Anacker et a l, 1972; Ribi et a l, 1971; Schmidt, 1972). These experiments showed that 
BCG provided protection against M. tuberculosis challenge. After 1973, there were no 
published experiments using rhesus macaques for over 25 years.
Recent experiments have included studies on the immunogenicity and safety of M 
tuberculosis culture filtrate proteins (Attanasio et al, 2000) and models of asymptomatic 
TB (Gormus et a l, 2004). The latter study showed that asymptomatic TB has similarities 
to latent tuberculosis and is of particular significance as rhesus macaques are also the 
best characterised models for human AIDS research. Therefore, the rhesus macaque 
provides the best model for the studies of interactions between TB and SIV disease. With 
one-third of the world’s population being infected with M. tuberculosis (Kaufmann, 
1993), this organism represents the leading cause of death in HIV-infected persons 
(Medaglini & Hoeveler, 2003) so these co-infection studies are of utmost importance.
Although the rhesus macaque model does not always predict accurately the actions and 
toxicities of drugs and biological agents for man, in the 1970s it was reported to have an 
“enviable record for predictability better than that of any other laboratory animal” 
(Schmidt, 1972). It has also been suggested the rhesus macaque may be best used for
-51-
efficacy studies on improved live attenuated vaccines that may show a clear 
improvement over BCG vaccination (Langermans et al., 2001). However, this was 
suggested from a study where BCG vaccination in rhesus macaques was unsuccessful, 
which is in contrast to other reports where BCG conferred protection against M. 
tuberculosis infection (Anacker et a l , 1972; Barclay et a l, 1970; Barclay et al., 1973; 
Janicki et al., 1973; Ribi et al., 1971; Schmidt, 1972).
1.3.4.3 Cynomolgus macaques
Low dose infection of cynomolgus macaques can provide a relevant model for the study 
of pathogenesis and immunology of M. tuberculosis infection as the profile of disease 
represents the full spectrum of human M. tuberculosis infection (Capuano et a l, 2003). 
BCG vaccination has been shown to protect cynomolgus macaques challenged 
intratracheally with 3,000 cfu M. tuberculosis, resulting in >2-log reduction of the 
bacterial loads and diminished lung pathology (Langermans et al., 2001).
It has been proposed that the cynomolgus model of TB more closely resembles human 
disease than the rhesus model (Walsh et al., 1996). First, cynomolgus monkeys 
inoculated with moderate or low doses of M. tuberculosis develop a chronic, slowly 
progressive form of TB, similar to that of adult humans. Secondly, a significant 
proportion of cynomolgus macaques administered a low dose of M. tuberculosis are able 
to contain the infection in a subclinical state similar to humans (Walsh et al., 1996). 
However, others have reported asymptomatic TB in the rhesus model (Gormus et al.,
2004), contradicting this argument.
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Immunological reagents to determine lymphocyte subsets and cytokine levels for 
humans can be used for cynomolgus macaque samples. A wide range of human 
immunochemical assays have been screened for use with this species; however, it was 
noted that spurious values can be obtained with different kits for the same cytokine 
(Verdier et a l, 1995). Additionally, anti-human monoclonal antibodies have been 
assessed for their cross-reaction with various antigens from cynomolgus monkeys with 
good success allowing flow cytometric analysis to be carried out (Yoshino et a l , 2000). 
This is also identical to rhesus macaques, where human reagents cross-react allowing 
detailed immunological analysis to be undertaken.
1.4 IMMUNE RESPONSES IN TUBERCULOSIS
The innate response is the first line of host defence against pathogens, including M 
tuberculosis, with the adaptive response becoming prominent after several days as 
antigen-specific cells have undergone clonal expansion (Chaplin, 2006). It should be 
noted that dissecting innate and acquired host defence mechanisms is an artificial 
approach, as in real life the two components are complementary and synergistic (van 
Crevel et al, 2002).
1.4.1 Innate immunity
The innate immune systems includes: (i) the epithelial barriers and the mucociliary 
surfaces; (ii) soluble proteins and bioactive small molecules that can be present in 
biological fluids (e.g. complement) or are secreted from activated cells (e.g. cytokines); 
and (iii) cell surface receptors that bind molecular markers on the surfaces of microbes 
(Chaplin, 2006).
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1.4.1.1 Cells involved
1.4.1.1.1 Alveolar macrophases
Macrophages and dendritic cells are the primary cell types involved in the innate 
immune response to mycobacteria. However, they also play a crucial role in the initiation 
of adaptive immunity (van Crevel et al., 2002). Alveolar resident macrophages are the 
primary cell types involved in the initial encounter and uptake of M. tuberculosis in the 
lung (van Crevel et al., 2002). Infection with M. tuberculosis induces the release of 
interferon (IFN)-y by human alveolar macrophages (Fenton et al., 1997), suggesting that 
this early release of IFN-y may play a role in innate immunity against M. tuberculosis. It 
has been shown that IFN-y secretion, along with tumour necrosis factor (TNF)-a, is 
needed to stimulate macrophages to produce interleukin (IL)-12 (Flesch et al., 1995). 
Secreting IL-12 shortly after mycobacterial challenge established the long-term 
persistence of IFN-y-secreting T cells (Lagranderie et al., 2003). IL-12 plays an 
irreplaceable role in the initiation of Thl responses, and the loss of its function cannot be 
compensated for by alternative mechanisms in the lung (Wakeham et al., 1998).
Another response to intracellular infection by M. tuberculosis is apoptosis of alveolar 
macrophages (Komfeld et al., 1999). Highly attenuated mycobacterial stains (e.g. H37Ra 
and BCG) are significantly more potent inducers of apoptosis than virulent strains such 
as H37Rv, Erdman, and wild-type M. bovis (Komfeld et al., 1999). This apoptosis 
mechanism eliminates the protected intracellular environment required for bacterial 
replication and latency (Keane et al., 1997; Komfeld et al., 1999), and this may in part 
explain why the more vimlent strains are less apoptotic.
1.4.1.1.2 Dendritic cells
Dendritic cells and monocyte-derived macrophages also take part in the phagocytic 
process in the lung (Henderson et a l, 1997; Hope et al., 2004). Dendritic cells lining the 
trachea encounter mycobacteria that have not reached the lung, and thus are also likely to 
be responsible for the ensuing immune response (Hope et a l , 2004). Dendritic cells have 
multiple roles: they participate in innate immunity by internalising bacteria at the site of 
infection and represent the main link between innate and adaptive immunity via 
trafficking from lung to lymph node (Hope et a l , 2004; Lanzavecchia & Sallusto, 2001).
After detecting microbial products or proinflammatory cytokines, immature dendritic 
cells transform into mature dendritic cells with a reduced capacity for antigen uptake but 
with an increased capacity for T cell stimulation (Mellman & Steinman, 2001). M 
tuberculosis-infected dendritic cells have been shown to become activated (Henderson et 
a l , 1997) and to be superior to macrophages in stimulation of antigen-specific cytokine 
production by both CD4+ and CD8+ T cells (Serbina & Flynn, 1999). Whilst activated 
macrophages are capable of killing intracellular bacteria, M. tuberculosis within dendritic 
cells are not killed, suggesting that dendritic cells may serve as a reservoir for M 
tuberculosis in tissues, including the lymph nodes and lungs (Bodnar et al., 2001). It is 
unsure whether this mechanism benefits the host or the pathogen as a continuous supply 
of antigen from a living bacterium may be advantageous for the priming and 
maintenance of an effective immune response in the host (Bodnar et al., 2001). 
Alternatively, it may be that M. tuberculosis has evolved a strategy to evade killing by 
the dendritic cells and uses this cell to disseminate from the lung to the lymph nodes and 
other organs (Bodnar et al., 2001).
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1.4.1.2 Effector functions of the innate immune system
The major effector functions of mononuclear phagocytes include: generation of reactive 
oxygen intermediates; production of reactive nitrogen intermediates (RNI); limitation of 
intracellular iron availability; phagosome acidification plus phagosome-lysosome fusion; 
and production of defensins (Kaufmann, 1993).
RNI are formed from the amino acid L-arginine by the inducible nitric oxide synthase 
(iNOS) found in the cytoplasm of macrophages (Flesch & Kaufmann, 1993). M 
tuberculosis is sensitive to nitric oxide (NO) made by iNOS, but whether enough iNOS 
can be induced in human macrophages to produce sufficient levels of NO remains 
controversial (Boom et a l, 2003). RNI play a more important role than reactive oxygen 
intermediates (ROI) in the expression of macrophage anti-mycobacterial activity (Sato et 
al., 1998). This may be because M. tuberculosis resists killing by oxygen radical 
intermediates through enzymes such as superoxide dismutases (Boom et a l, 2003). 
Alternatively, it could be due to mycobacterial components, such as glycolipids, which 
are potent oxygen radical scavengers (Chan et a l, 1989).
In contrast to the normal course of events during which the phagocytosed material is 
taken to lysosomes where it is efficiently destroyed, following uptake, mycobacteria are 
able to block their delivery to lysosomes (Houben et a l, 2006). The cell wall protects the 
bacteria and promotes their intracellular persistence by inhibiting phagosome-lysosome 
fusion, keeping them sequestered away from terminal endocytic organelles (Deretic & 
Fratti, 1999). In so doing, these pathogens manage to circumvent immediate destruction, 
enabling them to establish a niche inside the macrophage where they can survive and 
even replicate (Houben et al, 2006). Mycobacteria have evolved strategies to enhance
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their survival and replication within the macrophage by preventing maturation of the 
phagosomes which contain them (Komfeld et al., 1999), leading to persistent infection.
Functional Toll-like receptors (TLRs) are required for phagocytosis to lead to immune 
activation (van Crevel et al., 2002). The primary function of the TLR is to signal that 
microbes have breached the body’s barrier defences by recognition of common structural 
features of microbes known as pathogen-associated molecule patterns (PAMPs) 
(Chaplin, 2006; Schnare et al., 2006). Two TLRs (TLR2 and TLR4) have been 
implicated in the activation of macrophages by mycobacteria (reviewed by (Collins & 
Kaufmann, 2001; Schnare et al., 2006)). TLRs direct the innate immune responses, and 
these responses in turn guide the subsequent adaptive immune reaction that is even more 
targeted (Wickelgren, 2006). In mice Thl cells are stimulated by TLR2, but not by other 
TLRs, and directly induce IFN-y production, cell proliferation, and cell survival without 
T-cell receptor (TCR) stimulation (Imanishi et a l, 2007).
1.4.2 Adaptive immunity
Two to three weeks after infection with M. tuberculosis, T-cell immunity develops, with 
antigen-specific T lymphocytes that arrive at the site of infection, proliferate within the 
early lesions or tubercles, and then activate macrophages to kill the intracellular 
mycobacteria (van Crevel et a l, 2002).
1.4.2.1 CD4+ lymphocytes
CD4+ T cells recognise antigens presented by MHC class II molecules. For these 
antigens to become presented on MHC class II molecules they need to be processed in
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phagosomal or phagolysosomal compartments in professional antigen-presenting cells 
(van Crevel et al., 2002). As M. tuberculosis can reside in these areas, CD4+ T cells are 
thus extremely important in TB immunity.
Transgenic mice deficient in either MHC class II or CD4 molecules demonstrate 
increased susceptibility to M. tuberculosis compared to wild-type mice (Caruso et al., 
1999). Although IFN-y production was reduced at 2 weeks post-infection, by 4 weeks the 
CD8+ T cells were producing as much IFN-y as wild-type controls (Caruso et al., 1999). 
However, these data suggest that early production of IFN-y by CD4+ T cells is essential 
to control M. tuberculosis infection, and that IFN-y production by other cells cannot 
substitute for the CD4+ T cell contribution. Other investigators have also reported that in 
mice the majority of IFN-y is produced by CD4+ T cells early in infection (Serbina & 
Flynn, 1999).
Antibody-induced depletion of CD4+ cells in mice latently infected with M tuberculosis 
causes reactivation of disease, despite the continuous presence of IFN-y and iNOS 
(Scanga et al., 2000). These results suggest that CD4+ cells may have an additional role, 
independent of IFN-y production, in preventing the reactivation of tuberculosis. Some 
have suggested that this role may involve CD4+ T cells having a cytolytic function (Tan 
et al., 1997), which would lyse M. tuberculosis-infected cells (Canaday et al., 2001).
Further proof that CD4+ T cells are essential players in TB immunity is illustrated by 
increased incidence of tuberculosis in people infected with HIV (Barnes & Modlin, 
1996), as an increased susceptibility to TB is seen in these individuals with low CD4+ T 
cell counts (Havlir & Barnes, 1999). This observation has also been confirmed in SIV- 
infected macaques, where the reactivation of SIV-related tuberculosis-like disease
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coincided with a severe depletion of CD4+ T cells (Shen et al., 2004). However, in HIV- 
infected patients, there was no correlation between the CD4+ T cell count and M. 
tuberculosis-induced IFN-y production, suggesting that CD8+ T cells were the most 
likely source of IFN-y production in these patients (Sodhi et al., 1997).
1.4.2.2 CD8+ lymphocytes
CD8+ T cells recognise mycobacterial proteins presented on MHC class I molecules, 
which are expressed on all nucleated cells (van Crevel et a l, 2002). Using mice which 
lacked MHC class I and class I-like molecules (p2m-gene disrupted), functional CD8+ T 
cells were found to be a necessary component of a protective immune response to M 
tuberculosis (Flynn et al., 1992). P2m gene-disrupted mice succumbed to M. 
tuberculosis infection quicker than controls, indicating that CD4+ T cells alone were not 
sufficient to control M. tuberculosis infection (Flynn et al, 1992). When these results 
were further investigated, it was found that not only CD8+ T-cells were affected in p2m- 
gene disrupted mice, but also CD ld-restricted T cells, as well as other class I-restricted 
cell types which were not determined (Sousa et al., 2000).
The kinetics of CD8+ T cells in the lung have been shown to be identical to those of 
CD4+ T cells (Feng et al., 1999), being present during both early and late stages of M. 
tuberculosis infection. In mice, M. tuberculosis-specific CD8+ T cells have been detected 
as early as 3 weeks post-infection and have been shown to be recruited to the lung 
(Kamath et al., 2004). Using CD8-knockout mice, increased bacterial load in the lungs 
was a relatively late event, suggesting that CD8+ T cells may be more important in 
controlling the chronic phase of the disease (Orme & Cooper, 1999). This was also 
reported in another mouse study, where depletion of CD8+ cells during the latent phase
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of infection resulted in a 10-fold increase in lung bacterial load (van Pinxteren et a l , 
2 0 0 0 a).
CD8+ T cells are able to lyse antigen-presenting cells, and have been shown to 
preferentially recognise heavily infected cells (Lewinsohn et a l, 2003). The central role 
of CD8+ T cells may be that of surveillance, where they recognise cells in which the 
containment of M. tuberculosis is no longer effective (Lewinsohn et al, 2003). This may 
be due to a high bacterial load leading to increased entry of mycobacterial antigens into 
the cytosol, or with heavy infection the early endosome may become disrupted allowing 
entry of antigens into the cytosol.
Human CD8+ T cells have been demonstrated to directly kill intracellular mycobacteria 
via a granule-associated protein, granulysin (Stenger et a l, 1998). Using transgenic 
mice, CD8+ T-cells only functioned if they produced IFN-y, suggesting that they may 
exert their effects through cytokine-mediated macrophage activation rather than through 
a cytotoxic mechanism (Tascon et a l, 1998). However, mice do not have a granulysin 
homologue, so data from murine studies detailing the role of CD8+ T cells should take 
into account the absence of this key mechanism by which CD8+ T cells participate in 
anti-tuberculosis immunity (Lazarevic & Flynn, 2002).
CD8+ T cells may play a role in protective immunity, as M. tuberculosis-specific CD8+
cytotoxic T-lymphocyte (CTL) responses have been detected in asymptomatic contacts
over a period of almost 2 years (Pathan et a l, 2000). However, this study only reported
CTL responses in two people. M. tuberculosis-specific CD8+ responses were also found
in 4 out of 39 infected individuals, but this may be an underestimation of CD8+ responses
due to: (i) epitopes being restricted through only certain HLA class I alleles; (ii) M
tuberculosis secreting many other antigens; and (iii) CD8+ cells having been at the site of
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infection and not circulating (Lalvani et al., 1998). Therefore, the other M. tuberculosis- 
infected individuals may have had CD8+ responses that were not detected using the 
methods employed in the report. As mycobacteria-specific CD8+ T cells were detected in 
patients without any symptoms of TB disease, it was hypothesised that they contributed 
to protection against M. tuberculosis growth.
In human M. tuberculosis infection, reactive CD8+ T cells produce IFN-y in response to 
stimulation with M. tuberculosis-infected target cells (Lewinsohn et al., 1998). However, 
in infected mice there is little IFN-y production by activated CD8+ T cells in the lungs, so 
it was proposed that their role was in cytotoxicity (Serbina & Flynn, 1999). It has been 
shown that CD8+ T cells use different effector functions during acute and chronic phases 
of the immune response, where CD8+ T cells produce negligible amounts of IFN-y early 
in infection, but switch to cytokine production during the chronic stage of infection 
(Lazarevic et al., 2005a). Therefore, the function of the CD8+ T cells is dependent on the 
stage of M. tuberculosis infection.
Using macrophages infected with M. tuberculosis it was shown that by adding CD8+ T 
cells antimycobacterial activity was observed, but this did not correlate with macrophage 
lysis or the induction of apoptosis of infected cells (Brookes et al, 2003). Instead, as cell 
contact was required, it was identified that CD8+ T cells turned on an activation signal, 
subsequently found to be through receptors that included CD95 (Fas) (Brookes et al., 
2003).
Through their many functions, including cytotoxicity, cytokine production and 
macrophage activation, it is evident that CD8+ T cells make an important contribution to 
the immune defence against M. tuberculosis.
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1.4.2.3 Other T cell subsets
CD4+ and CD8+ T cells have T cell receptors (TCRs) composed of two glycoprotein 
chains called a- and P- TCR chains, and are thus referred to as ap T cells. However, in 
y8 T cells, the TCR is made up of one y-chain and one 8 -chain. y5 T cells react to 
phosphoantigen components of mycobacteria in a non-MHC restricted manner (Cairo et 
a l , 2007). y8 T cells might help to control mycobacterial infection in the period between 
innate and classical adaptive immunity (Dieli et a l , 2003).
y8 T cells in the lungs of BCG-infected mice secrete IFN-y (Dieli et a l , 2003) and have 
been shown to be more efficient producers of IFN-y than CD4+ T cells after stimulation 
with mycobacteria-primed autologous monocytes (Tsukaguchi et a l , 1995). IFN-y is 
already secreted by mycobacterium-reactive y8 cells before ap T cells come into play 
(Vanham et a l , 1997), due to the peak of y8 T cell expansion being seen at 7 days post­
infection compared to 30 days for the peak of ap  T cell expansion (Dieli et a l , 2003). 
Unlike CD4+ T cells though, yS T cells do not respond to culture filtrate antigens of PPD 
(Tsukaguchi et a l , 1995). The recognition of nonpeptide antigens is conserved in non­
human primates, including rhesus macaques (Cairo et a l , 2007; Wang et a l , 2003) and 
cynomolgus macaques (Cairo et a l , 2007), suggesting that non-human primates can 
provide an animal model for human y8 T cell antigen-specific responses.
y8 T cells have been demonstrated to be cytotoxic against BCG-infected peritoneal 
macrophages (Dieli et a l, 2003). However, it has been shown that although y8 T cells are 
cytotoxic to BCG-infected monocytes, they are not cytotoxic against BCG-infected 
dendritic cells (Martino et al, 2007).
CD 1-restricted T cells, like yS T cells, do not react with mycobacterial proteins (van 
Crevel et al., 2002). Instead, these T cells present mycolic acids, lipoarabinomanan and 
other components of the mycobacterial cell wall bound to CD1 on antigen-presenting 
cells (Kaufmann, 2003; Porcelli & Modlin, 1999). The CD1 molecules are divided into 
two groups -  Group I (CDla,b,c) and Group II (CDId). Humans possess both groups, 
whereas in rabbits and mice only group II CD Id is present (Collins & Kaufmann, 2001). 
Guinea pigs, like humans, express group I CD1 molecules (Kaufmann, 2001), so 
experiments concerned with the role of CD 1-restricted antigens can, therefore, take 
advantage of the guinea pig as an experimental model (Kaufmann, 2003). Macaques also 
have conserved group I (Morita et al., 2008) and group II CD1 molecules (Saito et al., 
2005).
1.4.3 Humoral immunity
Until recently, humoral immunity has been somewhat neglected in TB research due to 
the mycobacteria residing within cells. However, it is important to note that intracellular 
pathogens can be found in the extracellular space during their life cycle, either before 
entering into host cells or after cell death, and can then be easily reached by antibodies 
(Glatman-Freedman, 2006). Antibody-producing B cells have been shown to modulate 
the host response and are involved in optimal containment of the tubercle bacillus 
(Maglione et al., 2007). The importance of CD4+ T cells for adequate B cell responses is 
known; understanding the effects of CD4+ T cells on these cells in TB awaits a clearer 
picture of the role of B cells in this infection (Flynn & Chan, 2001a).
Evidence of antibody responses in TB have been observed. Patients with active TB had
higher mycobacteria-specific IgG antibody responses than patients without TB (Raqib et
al., 2003). Children with disseminated TB had significantly lower IgG levels to LAM as
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compared to controls with localised disease (Costello et al., 1992). It has also been 
demonstrated that the ESAT-6  antigen of M. tuberculosis and M. bovis contains multiple 
B-cell epitopes, as assessed in infected macaques (Kanaujia et al., 2004).
When high dose immunoglobulin (Ig) was given to M. tuberculosis infected mice a 
reduction in bacterial loads was observed (Roy et al., 2005). However, no inhibitory 
effect was seen in vitro using M. tuberculosis infected macrophages or when using nude 
mice, indicating that T cells were required as part of the process (Roy et al., 2005).
The presence of antibodies at the site of infection, prior to the entry of M tuberculosis 
into cells, may be of particular importance with regard to the fate of infection (Glatman- 
Freedman, 2003). Because M. tuberculosis bacilli enter the lungs in small numbers, 
specific IgA that is present at pulmonary sites could help to attack invading pathogens on 
first encounter (Kaufmann, 2006a). With the help of complement, such IgA could 
directly damage M. tuberculosis bacilli and may form part of a third generation of TB 
vaccines (Kaufmann, 2006a). The intranasal administration of an IgA monoclonal 
antibody in mice has been shown to confer some protection against aerosol or intranasal 
M. tuberculosis challenge (Williams et al., 2004), which was further improved by the co­
administration of IFN-y (Reljic et al., 2006).
1.4.4 Granuloma formation
If M. tuberculosis survives its initial encounter with the alveolar macrophage a
granulomatous response may develop. As the granuloma develops, monocytes enter from
the blood in large numbers via an adjacent arteriole, giving rise to a characteristic
perivascular cuffing, with some differentiating into epithelioid cells (Orme & Cooper,
1999). As granuloma formation continues, localised collections of epithelioid giant cells,
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macrophages, newly recruited monocytes, and lymphocytes develop (Komfeld et al, 
1999; Orme & Cooper, 1999). Within granulomas, the intricate interplay between T 
cells, cytokines and mononuclear phagocytes succeeds in containing pathogenic 
mycobacteria, but may fail to fully eradicate them (Kaufmann & Andersen, 1998).
The granuloma is highly successful in containing M. tuberculosis in distinct foci and in 
preventing dissemination. However, in some individuals the granuloma may develop into 
necrotic lesions or cavitate, both of which cause damage to the lung (figures 1.2 and 1.3) 
(Kaufmann, 1993). In the latter example, the caseous cavity provides an excellent habitat 
for extracellular M. tuberculosis to increase, which then leads to further lung damage and 
dissemination by the haematogenic or aerogenic routes (Kaufmann, 1993).
For granuloma formation cell recruitment is a highly orchestrated event regulated largely 
by cytokines produced by T lymphocytes (Schaible et al, 1999).
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Epithelioid macrophages 
and lymphocytes 
concentrated at the margins
Necrotic macrophages and 
neutrophils in the centre
Figure 1.2: Example of a "neutrophilic” lung granuloma.
(Picture taken from a rhesus macaque after M. tuberculosis infection. Interpretation 
provided by CEPR Histology department).
Foci of 
calcification
Figure 1.3: Example of a “caseated” lung granuloma.
(Picture taken from a cynomolgus macaque after M. tuberculosis infection. Interpretation 
provided by CEPR Histology department).
impiim  ...... .
Epithelioid macrophages 
and lymphocytes 
concentrated at the margins Caseated centre of 
granuloma
-66-
1.4.5 Involvement of cytokines
Cytokines are small soluble proteins secreted by one cell that can alter the behaviour or 
properties of the cell itself or another cell. Most cytokines have a multitude of functions, 
dependent on where they are secreted and their target cell.
1.4.5.1 Cytokine classification
In 1986, Mossman et al. showed that cloned lines of murine CD4+ T cells were classified 
into two groups: T helper (Th)l and Th2, based on the cytokine profile they produced 
(Mosmann et al., 1986). Thl cells were defined by their production of interleukin (IL)-2, 
IFN-y and TNF-P; Th2 cells were defined by their production of IL-4, IL-5, IL-6 , IL-10 
and IL-13. Both cell types produced IL-3, TNF-a and granulocyte-macrophage colony- 
stimulating factor (GM-CSF). In 1995, this viewpoint was challenged as being too 
simplistic, where instead it was proposed different combinations of cytokines could be 
secreted with no distinct classification of cell types (Kelso, 1995). The following year, 
Mosmann et al published work in the same journal defining further subsets of T cells 
(cytotoxic T-cells (Tc)-l and Tc-2) and re-iterated that the Thl-Th2 dichotomy remained 
an important functional division in the immune response (Mosmann & Sad, 1996). 
Recently, new Th subsets are being reported including IL-17-secreting Thl 7 cells 
(Steinman, 2007).
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1.4.5.2 Major cytokines involved in tuberculosis
Some of the most studied cytokines in TB and their effects are listed in table 1.3. 
However, cytokines often work in synergy with one another. For example, when 
combined, IFN-y, TNF-a and calcitriol (1,25 (OH2), vitamin D3) induced a significant 
amount of intra-monocyte killing of M. tuberculosis (Denis, 1991b; Rook et al., 1987). 
The role of some of the major cytokines in TB disease are briefly described, with the 
exception of IFN-y that is covered separately in section 1.4.5.3.
1.4.5.2.1 IL-10
The main action of IL-lp is the attraction of phagocytes (Sharma & Bose, 2001), 
although being an endogenous pyrogen this cytokine may also contribute to raised body 
temperature seen in TB patients (Dinarello, 1984).
1.4.5.2.2 IL-2
IL-2 is a T-cell growth factor that enables the population of antigen-specific T cells to 
expand (Sharma & Bose, 2001). In TB patients it has been shown that low-dose IL-2 
therapy reduces bacterial load (Johnson et al., 1995) suggesting that this cytokine was in 
sub-optimal concentrations in these individuals.
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1.4.5.2.3 IL-6
IL-6  is critical to resistance against tuberculosis, potentially by inducing the 
inflammatory response and promoting IFN-y production (Ladel et a l, 1997; Saunders et 
al., 2000). However, other investigators have shown that IL-6  inhibits macrophage 
responses to IFN-y (Nagabhushanam et al., 2003) and T cell responses (VanHeyningen 
et al., 1997) including suppressing synthesis of IL-ip and TNF-a (Schindler et al., 
1990). IL-6  is also involved in enhancing B-cell growth and differentiation (Sharma & 
Bose, 2001), so may contribute to the antibody response in TB. These differing effects 
are likely due to which cell type the cytokine interacts with, the concentration of IL-6 , 
and the presence of other cytokines which might enhance or augment IL-6  function.
1.4.5.2.4 IL-10
IL-10 has been shown in vitro to be capable of suppressing IFN-y production from 
alveolar macrophages stimulated with M. tuberculosis H37Ra (Fenton & Vermeulen, 
1996). Additionally, an increase in IL-10 was associated with decreased IFN-y 
production by dendritic cells stimulated with M. tuberculosis cell extract (Latchumanan 
et al., 2005). It has been suggested that by hindering the antimycobacterial action of IFN- 
y, IL-10 helps maintain mycobacterial infection (Murray et a l, 1997). However, using 
multidrug-resistant M. tuberculosis strains, others have found that IL-10 does not have a 
dominant role in defective IFN-y production in patients (Lee et a l, 2002).
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1.4.5.2.5 IL-12
IL-12 contributes to the development of precursor T cells into Thl cells (Trinchieri, 
1995), which are required to generate a successful immune response against M 
tuberculosis. This cytokine is essential for control of mycobacterial infection, as shown 
by increased levels of infection with weakly pathogenic mycobacteria in patients 
genetically deprived of IL-12 immunity (Altare et a l , 1998; de Jong et al., 1998) and in 
IL-12 knockout mice (Cooper et al., 1997). However, its effects are also 
immunoregulatory, limiting pathology associated with aerosol M. tuberculosis infection 
in mice (Nolt & Flynn, 2004) and regulating IFN-y production (Magram et a l, 1996).
1.4.5.2.6 TNF-a
Studies in TNF-a-deficient mice have shown that this cytokine is important in the 
aggregation of leukocytes into functional granulomas capable of controlling virulent 
mycobacterial infection (Roach et a l, 2002). TNF-a-deficient mice also have diminished 
recruitment and activation of T cells and macrophages into the lung (Botha & Ryffel, 
2003). This may be due to changes in chemokine production leading to a cascade of 
inappropriate cellular communication, impaired cell migration within the lung, loss of 
cell-mediated immune response, and substantial lung pathology (Aronson et a l, 2004). 
Without TNF-a, granulomas are still formed in equal numbers to control mice, but 
necrosis is observed as is neutrophilic infiltration of the alveoli (Bean et a l, 1999; Flynn 
et a l, 1995).
Excessive production of TNF-a may lead to necrosis in the lung, and if released into the
systemic circulation may contribute to symptoms including fever (Sharma & Bose,
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2001). TNF-a also immunoregulates inflammatory cytokines, to prevent overproduction 
that could result in immunopathology (Mohan et al., 2001; Zganiacz et al., 2004). 
Therefore, TNF-a exhibits both advantageous and detrimental effects in TB disease.
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Cytokine Function Reference
IFN-y
• Activates macrophages to kill intracellular 
mycobacteria.
• Involved in production of reactive nitrogen 
intermediates.
• Increases MHC and co-stimulatory molecule 
expression.
• Plays role in cell death.
• Down-regulates the macrophage mannose 
receptor.
(Bonecini-Almeida et al., 
1998)
(Flynn et al., 1993)
(Boom et al., 2003)
(Liu & Janeway, 1990) 
(Fenton & Vermeulen, 
1996)
TNF-a
• Recruitment and activation of T cells and 
macrophages into the lung.
• Essential for granuloma formation.
• Affects expression of chemokines by 
macrophages in vitro.
•  Immunoregulates type 1 immune responses.
• Production of reactive oxygen species by 
activating neutrophils.
(Botha & Ryffel, 2003)
(Bean et al., 1999; Botha 
& Ryffel, 2003; Roach et 
al., 2002)
(Algood et al., 2004)
(Zganiacz et al., 2004) 
(McDermott, 2001)
IL-lp • Proinflammatory cytokine.
• Required for granuloma formation.
(van Crevel et al., 2002) 
(Juffermans et al., 2000)
IL-4
• Suppression of IFN-y production.
• Required for the generation of Th2-derived 
cytokines.
• May play a protective role in controlling 
mycobacterial infection.
(Powrie & Coffman, 1993) 
(Kopf et al., 1993)
(Sugawara et al., 2000)
IL-6 • Induction of T-cell mediated resistance to M  tuberculosis and M. avium.
(Appelberg et al., 1994; 
Ladel et al., 1997)
IL-10
• Antagonises the proinflammatory cytokines 
by downregulation of IFN-y, TNF-a and IL- 
12.
(Gong et al., 1996)
IL-12
• Initiation of Thl responses.
• Crucial for protection against M. 
tuberculosis by inducing IFN-y.
(Wakeham et al., 1998) 
(Cooper et al., 1997)
IL-15
• Stimulates T cell and natural killer cell 
proliferation and activation.
• Causes selective stimulation of memory- 
phenotype CD8+ cells in vivo.
(Doherty et al., 1996; Liu 
et al., 2000)
(Zhang et al., 1998)
IL-17
• Enhances IFN-y secretion and granuloma 
formation.
• Involved in lymphocyte migration to the 
lungs.
(Umemura et al., 2007) 
(Rolls & Linden, 2004)
IL-18
• Contributes to type 1 cytokine responses, 
including inducing IFN-y.
(Hunter & Reiner, 2000; 
Sugawara et al., 1999; van 
Crevel et al., 2002; 
Vankayalapati et a l ,  2000)
Table 1.3: Cytokines involved in immunity against M. tuberculosis infection and their
roles.
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1.4.5.3 Interferon-y in tuberculosis
One of the key roles of IFN-y is to aid with the activatation of macrophages to kill 
intracellular mycobacteria along with lymphocyte cells (Bonecini-Almeida et a l, 1998). 
Without the addition of IFN-y, macrophages were unable to reduce the bacterial load of 
M. tuberculosis in an in vitro system. In IFN-y gene-knockout mice, animals failed to 
produce reactive nitrogen intermediates and were unable to restrict the growth of M 
tuberculosis (Flynn et a l , 1993). This has been confirmed using in vitro macrophage 
assays, where IFN-y was shown to be capable of inducing both NO2' (a reactive nitrate 
intermediate) and H2O2 (a reactive oxygen intermediate) release (Ding et a l , 1988; Sato 
etal., 1998).
Mice in which the IFN-y gene has been disrupted are unable to contain or control a 
normally sub-lethal dose of M. tuberculosis, delivered either intravenously or 
aerogenically (Cooper et al., 1993). This indicates that IFN-y plays a pivotal role in 
protective cellular immunity to TB infection. Patients with genetic alterations in the IFN- 
y receptor have also been shown to have increased susceptibility to M. tuberculosis 
infection (Cooke et a l, 2006; Newport et a l, 1996; Sallakci et a l, 2007). Additionally, 
patients with IL-12 receptor deficiencies are also at increased risk of infection (Altare et 
al, 1998; Ottenhoff et al, 1998; Ottenhoff et al, 2005). This could be due to IL-12 
playing an essential role in regulating IFN-y production, as demonstrated in mice lacking 
IL-12 (Magram et a l, 1996).
IFN-y alone does not appear to allow human macrophages/monocytes to have
antituberculous properties (Rook et a l, 1986). In some circumstances, IFN-y may even
promote growth of intramacrophage M. tuberculosis (Douvas et al, 1985). It may be that
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in man, protection against M. tuberculosis depends on the appropriate exposure to 
immunologically active vitamins, such as vitamin D, or an interaction between vitamins, 
cytokines and/or primed cells (Bonecini-Almeida et a l , 1998; Crowle, 1990).
Mice with a targeted disruption of the IFN-y gene have reduced expression of 
macrophage MHC class II antigens (Dalton et a l , 1993). Thus, IFN-y is a critical 
regulator of antigen-presenting cell function by increasing MHC and co-stimulatory 
molecule expression (Boom et a l, 2003). This latter activity is essential for optimal T 
cell responses to M. tuberculosis.
Other functions of IFN-y include: being required in order for CD8+ T cells to exert their 
anti-mycobacterial effect (Tascon et a l, 1998); playing a critical role in cell death, which 
may eliminate activated effector T cells (Liu & Janeway, 1990); and down-regulating the 
macrophage mannose receptor, to which M. tuberculosis can bind in order to gain entry 
into macrophages (Fenton & Vermeulen, 1996). IFN-y also has an important role in the 
stimulation of IgG2a secretion and in the suppression of IgGl production (Finkelman et 
al., 1988). However, this may be more relevant in situations where humoral immunity 
takes precedent.
It has been shown that during M. tuberculosis infection, IFN-y production may be sub- 
optimal. Reduced IFN-y production by PBMCs stimulated with heat-killed M. 
tuberculosis was observed in patients with severe disease as determined by chest 
radiograph and clinical presentation (Sahiratmadja et al., 2007b; Sodhi et al., 1997). In 
naive mice given a lethal dose of M. tuberculosis, infusion of IFN-y resulted in increased 
survival (Denis, 1991a). This observation has been transferred to humans, where some 
patients with mycobacterial infection respond to administration of recombinant IFN-y
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(Condos et al., 1997), suggesting that there could be a relative deficiency of this cytokine 
in some individuals.
It is apparent that production of IFN-y is critical for the control of M. tuberculosis 
infection, whether produced early in infection as a by-product of the activation of 
immune defence mechanisms, or by antigen-specific T cells following the induction of 
specific immunity (Collins & Kaufmann, 2001). The release of IFN-y from CD4+ and 
CD8+ T cells remains the primary assay used to determine the immunogenicity of any 
new TB vaccine (Fletcher & McShane, 2006). Studies of experimental vaccines in the 
mouse model of TB support IFN-y as a relevant marker for the induction of a protective 
immune response (Agger & Andersen, 2001). The relevance of IFN-y as a marker for 
generating adequate protective immunity has been confirmed at the Statens Serum 
Institut (SSI) where all of the subunit vaccines tested so far showing levels of protection 
equivalent to BCG have given strong IFN-y responses (Agger & Andersen, 2001). 
However, others have shown that increasing IFN-y responses does not always result in 
increased protection against M. tuberculosis infection (Leal et a l , 2001).
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1.5 ASSAYS TO MEASURE IFN-y
As IFN-y is shown to be such an important cytokine in TB disease, its production often 
requires evaluation. Two measures of IFN-y are generally used in order to determine the 
kinetics of IFN-y secretion after infection with, or vaccination against, M. tuberculosis: 
the frequency of cells capable of secreting IFN-y and the amount of IFN-y secreted.
1.5.1 IFN-v ELISPOT assay
i
The frequency of IFN-y-secreting cells can be assessed by an enzyme-linked 
immunosorbent spot (ELISPOT) assay. This technique is a modified version of the 
enzyme-linked immunosorbent assay (ELISA). However, the ELISPOT assay relies on 
capturing the substrate’s colour reaction product on a solid surface as the ‘footprint’ of 
the cytokines secreted by individual cells (Cox et al, 2006).
This assay is highly sensitive due to measuring cytokine production of single cells. This 
is in part due to the fact that the product is rapidly captured around the secreting cell 
before it is either diluted in the supernatant, captured by receptors of adjacent cells, or 
degraded. Some investigators have reported frequencies from 50 IFN-y-producing 
cells/106 PBMC (Russell et a l, 2003) to less than 4 per 106 PBMC (Helms et al., 2000). 
The level of detection is 10 to 200 times more sensitive than ELISA performed on 
culture supernatants (Tanguay & Killion, 1994). Due to the nature of the assay it is 
unlikely that the real frequencies of antigen-specific cells are overestimated. This may be 
partly due to the inability of all cells with the right specificity to produce IFN-y and 
several clustered responsive cells could produce a single footprint (Mwau et a l, 2002).
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Due to cells being restimulated with defined antigens the ELISPOT primarily measures 
the relative magnitude of the antigen-specific recall response, which may not reflect the 
responses in the subject at the time the sample was taken (Doherty et a l , 2005). The 
ELISPOT assay has been used in multicentre settings to reliably detect antigen-specific 
T cells induced by various vaccines, such as those to prevent cancer (Scheibenbogen et 
a l , 2 0 0 0 ).
1.5.2 Whole blood IFN-v ELISA assay
The IFN-y ELISA assay measures the concentration of cytokine secreted from cells after 
stimulation with mycobacterial antigen.
The ELISA assay can use diluted whole blood as this mimics the natural environment 
with the in vivo cellular and humoral interactions as well as allowing modulation of 
cytokine production by endogenous or exogenous factors (De Groote et a l , 1992). 
Furthermore, the alternative to using whole blood is to use isolated PBMC. As 
polymorphonuclear cells represent about 60% of leukocytes, and monocyte 
concentrations are substantially reduced in PBMC preparations (e.g., due to attachment 
of monocytes on different structures used during the separation process), these modified 
cell ratios in PBMC may affect qualitative and quantitative production of cytokines (De 
Groote et a l, 1992). It has been reported that monocytes (Weir et a l, 2003) and 
macrophages (Wang et a l, 1999) are significant cytokine producers in mycobacterial 
infections, hence supporting the use of whole blood. When diluted whole blood has been 
compared with PBMC samples, it was found that there were significant differences in 
IFN-y levels after stimulation with phytohaemagglutinin (PHA) (Silberer et a l, 2008). In 
another study, lipopolysaccharide (LPS) induced more IL-lp and IL-6  in whole blood
compared to PBMC (Schindler et al., 1990). The use of whole blood makes this assay 
easy to use in field studies, as processing samples for lymphocyte isolation is not 
required, thus making the assay more practically feasible. However, for some analyses 
(e.g. ELISPOT) whole blood cannot be used due to background interference by blood 
components (e.g. erythrocytes).
In human TB studies, diluted whole blood has been incubated for 6 days in the presence 
of mycobacterial antigen (Black et a l , 2001; Black et al., 2003; Dockrell et al., 2000). 
Results from one of these studies have shown that the 6 -day IFN-y response to M 
tuberculosis PPD has a strong association with induration measured by skin testing to the 
same antigen (Dockrell et al., 2000). When overnight assays were compared with 6  day 
stimulated lymphocytes it was observed that the longer period of stimulation was more 
sensitive for the detection of latent TB (Leyten et al., 2007). Others have also found that 
when comparing overnight and 5 day PBMC incubation periods with varicella-zoster 
antigen, Candida albicans antigen or hepatitis B surface antigen, natural killer (NK) cells 
account for most of the IFN-y secreting cell population after overnight stimulation, 
whereas the T-cell IFN-y contribution increases with the 5 day incubation (Desombere et 
al., 2005). The investigators reported that the NK:T cell ratio of IFN-y secreting cells 
went from <0.5 to >1.5 (Desombere et al., 2005).
1.5.3 Luminex assay
The luminex assay can be used where a range of cytokines are to be measured. This 
technology uses bead-based assays capable of measuring multiple analytes in a single 
well. Beads specific for each cytokine can be distinguished by incorporation of a unique 
ratio of dyes which can be distinguished using lasers in the luminex analyser. The beads
are coated with specific anti-cytokine antibody, and captured cytokine is quantified using 
a fluorescence detection system.
Ready-to-use beads are available for a number of cytokines, but otherwise multiplex 
assays can be developed in-house if a suitable antibody pair exists (de Jager et a l , 2003). 
The assay is sensitive and accurate as each fluorescence signal is the mean of 100 
measurements of a signal microsphere, and each bead represents an assay by itself (de 
Jager et al, 2003). Luminex analysis has been used in macaques during an Ebola 
outbreak (Hutchinson et al., 2001) using beads prepared by the investigators. However, 
other investigators have tested cross-reaction of non-human primate samples with 
commercially-available human beadsets with success for the majority of the cytokines 
tested (Giavedoni, 2005).
1.5.4 Intracellular cytokine staining
Intracellular cytokine staining (ICS) involves using flow cytometry to analyse cells that 
have synthesised cytokines. Similar to the ELISPOT assay, the readout of this assay is 
the frequency of cells capable of producing cytokine.
The major advantage of this assay is that in addition to staining cells with fluorescent 
anti-cytokine antibodies, other phenotypic characteristics of the cells can be determined 
in parallel (Tesfa et al., 2004). This type of analysis has proved useful in showing that a 
significant proportion of IFN-y-producing cells after BCG-vaccination are NK cells 
(Hanekom et al., 2004). However, this assay in the short-term only reliably detects newly 
formed intracellular proteins, such as IFN-y, which is captured in the Golgi apparatus 
(Hanekom et al., 2004), unlike the ELISPOT assay which measures cytokine that is 
actually secreted by the cells.
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Where both assays have been carried out simultaneously, the ELISPOT assay is more 
sensitive (detection limits: lxlO'4 for ELISPOT versus lxlO'3 for ICS) (Sun et a l, 2003). 
Therefore, the ELISPOT is preferable for the determination of low-level responses, 
whereas ICS has a greater dynamic range and also allows for phenotypic discrimination 
of responding cells (Karlsson et al, 2003).
1.6 AIMS OF THE STUDY
1.6.1 Background to hypothesis
A high research priority for TB immunologists and vaccinologists is the identification 
and validation of immunological correlates of protection, and the incorporation of such 
assays into the routine testing of new TB vaccines in both experimental and target 
species (McMurray, 2001a). Understanding natural immune correlates, or biomarkers, of 
protection is important both in guiding vaccine design but additionally in identifying 
potential early markers of efficacy for vaccines (Sander & McShane, 2007). In the 
absence of a pre-defined immunological correlate of protection, the key question when 
developing a new TB vaccine is whether such significantly enhanced immune responses 
seen after vaccination are accompanied by an improvement in protective efficacy (Pathan 
et a l, 2007).
Induction of IFN-y is the primary immune assay for phase I TB vaccine trials (Sander &
McShane, 2007). In clinical studies, IFN-y has been measured by ex vivo ELISPOT assay
(McShane et a l, 2004), the whole-blood ELISA assay (Black et a l, 2002; Gorak-
Stolinska et al, 2006), and intracellular cytokine staining (Hanekom et a l, 2004). The
ELISPOT assay has been shown to provide the most consistent results and is used as the
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main immunological outcome in clinical trials (Hawkridge et al., 2008). The whole- 
blood IFN-y ELISA is considered to have an important role in the field, because of its 
simplicity (Sander & McShane, 2007). Whole-blood production of IFN-y has been 
reported to be the best available correlate of protection (Ellner et al., 2000) and indicator 
of protective immunity (Kaufmann, 2006a).
1.6.2 Hypothesis and objectives
The main hypothesis to be tested in this study is as follows:
“IFN-y measurements in a non-human primate experimental model 
of tuberculosis provide an accurate measure of protective efficacy 
against M. tuberculosis infection.”
This hypothesis will be tested by completion of the following objectives:
Objective 1: Assess differences between IFN-y responses to BCG vaccination and M.
tuberculosis infection in two non-human primate species: rhesus
macaques and cynomolgus macaques.
Objective 2: Evaluate whether trends in production of IFN-y after BCG vaccination in
macaques can be related to those observed in humans.
Objective 3: Determine whether either the number of IFN-y-secreting cells or the
concentration of IFN-y secreted correlates with protection against M. 
tuberculosis challenge following vaccination with BCG and a novel TB 
vaccine.
1.6.3 Scope of the thesis
The methods used in this thesis are detailed in Chapter 2.
Before vaccination and challenge work could be undertaken in non-human primates, 
assays needed to be performed in nai've animals to ensure that they were suitable for 
experimental studies. Chapter 3 details the results for screening antigens and the 
background responses obtained in macaques prior to vaccination with BCG or infection 
with M. tuberculosis. From this work, a cut-off would be defined to help determine 
whether genuine responses occurred following vaccination or challenge.
Chapter 4 reports the measurement of IFN-y responses after aerosol infection of 
macaques with M  tuberculosis. Comparisons between rhesus macaques and cynomolgus 
macaques were undertaken. In animals which succumbed to rapid disease progression, 
the IFN-y measurements were analysed to determine whether they correlated with 
clinical progression of M. tuberculosis infection.
A preliminary comparison of BCG-vaccination responses in rhesus macaques and 
cynomolgus macaques is reported in Chapter 5. A larger cohort of rhesus macaques 
were then vaccinated with BCG, with some animals later receiving immunisation with 
MVA85A -  a novel ‘booster’ TB vaccine currently undergoing evaluation in clinical 
trials. Data available from human clinical trials were used to compare IFN-y secretion 
profiles between macaques and humans in order to assess the relevance of the animal 
model. Having undergone vaccination, animals were challenged with M. tuberculosis 
■ and IFN-y measurements monitored for up to a year. Data were then evaluated to assess
whether IFN-y measurements were a reliable indicator of protection against M. 
tuberculosis.
Although each chapter is discussed individually, Chapter 6 brings together all of the 
results presented in the thesis and discusses their implications on the hypothesis and 
suggestions for further work.
2 MATERIALS AND METHODS
2.1 IN VIVO MACAQUE STUDIES
2.1.1 Housing and behaviour
Studies were performed on Macaca mulatta (rhesus macaques: mean age 45 months, 
range 35-65 months) and Macaca fascicularis (cynomolgus macaques: mean age 50 
months, range 43-62 months). Macaques were housed according to the Home Office 
(UK) guidelines for the care and maintenance of primates. Animals were inspected daily 
for indications of change in behaviour. All animal work was carried out by personnel in 
the Biological Investigations Group and formed part of TB vaccine research in progress 
at the Centre for Emergency Preparedness and Response (CEPR), part of the Health 
Protection Agency (HPA).
2.1.2 Sample collection
For sample collection, animals were sedated with ketamine hydrochloride before 
removal from the cage. Freshly drawn venous blood was mixed with sodium heparin to 
minimise any clot formation.
2.1.3 Experimental study design
Individual experiments assessed IFN-y responses after infection with M. tuberculosis 
and/or vaccination with BCG and/or MVA85A.
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2.1.3.1 Studies assessing IFN-y responses after M. tuberculosis infection
Nine rhesus macaques and twelve cynomolgus macaques were infected with M  
tuberculosis via the aerosol route (refer to section 2.1.5). Animals from each species 
were divided into groups which were subsequently challenged on separate occasions 
over 4 months apart (table 2.1). Disease progression was monitored over a 12-week 
period post-challenge and samples were collected for IFN-y analysis as shown in figure 
2 . 1.
Animal ID
Experimental detailsRhesus
macaques
Cynomolgus
macaques
Challenge 1
D31 4313
Challenged with M. tuberculosis 
(follow-up period of 12 weeks)
D53 9909013
D80 9909187
Challenge 2
C54 109027
D19 109181
D60 109203
Challenge 3
D12 1111
D28 1163
D42 2151
Challenge 4
0111231
0201011
0201191
Table 2.1: Identification of macaques used in M. tuberculosis challenge studies.
Time
(weeks)
Aerosol challenge 
with M. tuberculosis
Pre-bleeds 0  1 ^
----------
4 6 1
------------
0  12
U i 1  J1 i\  \ \ \ 1 J JI
IFN -y analysis
Figure 2.1: Overview of M. tuberculosis infection studies showing the time of sampling 
for IFN-y analysis.
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2.1.3.2 Study assessing longitudinal IFN-y responses following BCG vaccination
A pilot study was performed to determine the dynamics and longevity of the IFN-y 
response post-intradermal vaccination with BCG (refer to section 2.1.4.1). Two 
macaques of each species (rhesus and cynomolgus) were immunised with BCG (table 
2.2) and samples were collected over 74 weeks as shown in figure 2.2.
Animal ID Experimental details
1040 Rhesus macaques
Immunised with BCG 
(follow-up period of 74 weeks)
1252
1007 Cynomolgus
macaques9911021
Table 2.2: Identification of macaques used in longitudinal BCG-vaccination study.
BCG vaccination
Time
(weeks) Pre-bleeds 0 1 2 4 6 8 1 0 1 2  ... (regular intervals) ... 74M  H i  i I I I I  1 1 1 1 1  I
IFN-y analysis
Figure 2.2: Overview of longitudinal BCG-vaccination study showing the time of 
sampling for IFN-y analysis.
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2.1.3.3 Study assessing IFN-y responses after BCG and BCG/MVA85A vaccination.
and following aerosol challenge with M. tuberculosis
Sixteen rhesus macaques were used to determine responses after vaccination with BCG, 
and the effects of MVA85A boosting of BCG-vaccination responses. These animals 
were split into three groups during the vaccination phase of the experiment: (A) BCG 
vaccinated; (B) BCG vaccinated with MVA85A boost; and (C) unvaccinated (table 2.3). 
Figure 2.3 shows a schematic overview of the experimental study; 21 weeks after the 
initial BCG vaccination all animals were challenged by the aerosol route with M  
tuberculosis and followed for up to 52 weeks post-infection.
Animal ID Immunisation/Challenge details
K80
K52 Group A:
K59 Immunised with BCG (for 21 weeks) and
K43 challenged with M. tuberculosis
K50 (follow-up period of 52 weeks)
K44
K65 Rhesus Group B:
Immunised with BCG (for 12 weeks), boosted 
with MVA85A (for 9 weeks) and challenged 
w ithM  tuberculosis 
(follow-up period of 52 weeks)
K20 macaques
K69
K86
K61
K79
K62 Group C:
Challenged with M. tuberculosis 
(follow-up period of 52 weeks)
K54
K32
K47
Table 2.3: Identification of macaques used in BCG or BCG/MVA85A vaccination
studies followed by challenge with M. tuberculosis.
(Group C were unvaccinated control animals).
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Group A: BCG-vaccinated (n=6)
BCG vaccination
M. tuberculosis 
challenge
Time
(weeks) Pre-bleeds 0  1 2 . .(2 weekly intervals).. 12 13 ..(regular intervals).. 21 ■ ■ ..........."1-----■--------------■----- -----1--------  ■1 1 11 111 11 F I  1
IFN -y analysis
Group B: BCG-vaccinated with MVA85A boost (n=6 )
Time
(weeks)
BCG vaccination
i
M V A 85A  boost
I
M. tuberculosis 
challenge
Pre-bleeds 0  1 2  . . (2 weekly intervals). . 1 2  1 3  . . (regular intervals).. 2 1
1 1 U HI
IFN-y analvsis
Group C: Unvaccinated (n=4) M. tuberculosis 
challenge
Time
(weeks) Pre-bleeds 0 1 2 ..(2 weekly intervals).. 12 13 .. (regular intervals).. 2 1
TTTT m Hi
IFN-y analysis
Figure 2.3: Overview of vaccination studies involving BCG and BCG with MVA85A 
boosting showing the sampling times for IFN-y analysis.
(After challenge at week 21, animals were monitored for up to 52 weeks; group C were 
unvaccinated control animals).
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2.1.4 Vaccination
2.1.4.1 BCG vaccination
Macaques were vaccinated with bacille Calmette-Guerin (BCG) (Danish strain 1331, 
Statens Serum Institut, Copenhagen, Denmark) via the intradermal route in the upper left 
arm. Vaccine vials had a concentration of 2-8x106 cfu/ml of BCG. Macaques in the pilot 
study (section 2.1.3.2) were immunised with 50 pi vaccine whereas macaques in the 
vaccine efficacy study (section 2.1.3.3) were immunised with 100 pi vaccine. 50 pi is 
equivalent to a childs dose, whereas 100  pi is the recommended dose for human adults.
2.1.4.2 MVA85A vaccination
One group of animals previously vaccinated with BCG was immunised with modified 
vaccinia Ankara virus expressing Ag85A vaccine (MVA85A, supplied by Helen 
McShane, Oxford) administered via the intradermal route in the upper right arm. The 
MVA85A supplied was at a concentration of 5xl09 pfu (plaque-forming units)/ml and 
macaques were immunised with 100 pi vaccine, equating to a dose of 5x108 pfu being 
delivered.
2.1.5 Aerosol challenge of macaques with M. tuberculosis
Macaques of each species were exposed to an aerosol of M. tuberculosis Erdman strain 
(KOI, obtained from CBER/FDA) generated by a Collison nebuliser in conjunction with 
a Hendersen apparatus, as described by Williams et al (Williams et al, 2000). Nose-
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only delivery was ensured by the use of a mask, and plethysmography was used to 
measure and control the volume of aerosol inhaled. This took into account differences in 
animal’s size and breathing rate and was used to estimate inhaled doses. Individual doses 
for each of the animals are shown in appendix 1 (section 8 .1).
2.1.6 Necropsy of macaques
Upon completion of experimental schedules, or when animals had reached a humane 
clinical endpoint (i.e. 2 0 % weight loss from maximal weight or showing signs of 
malaise), animals were euthanised by the administration of an overdose of anaesthetic. 
Dissection of the animal and tissue collection was then performed by trained personnel 
experienced in non-human primate anatomy and physiology.
2.1.6.1 Pathology scoring
During the post-mortem procedure, organs in the animals were scored according to the 
system shown in figure 2.4. This score was developed by researchers trying to 
standardise protocols in assessing extent of M. tuberculosis disease in non-human 
primates (Flynn-J, Reed-S and Langermans-J. World Health Organisation: proposed 
recommendations for evaluation of TB vaccine efficacy in non-human primates -  kindly 
supplied by J. Langermans). Pathology scoring was assisted by personnel who had 
previous experience in assessing the extent of M. tuberculosis infection in the guinea pig 
model of TB infection.
2.1.6.2 Tissue collection
At necropsy, samples were taken for immunological studies from the hilar lymph node, 
axillary lymph node, inguinal lymph node and spleen. These were dissected from the 
animal and put into a dry sterile tube.
Lung scoring system
0 No visible lesion
1 1 gross lesion <10 mm diameter (in 
case of calcification 
score = 2)
2 2-5 gross lesions <10 mm diameter
3 >6 gross lesions 
or
1 gross lesion
<10 mm diameter 
>10 mm diameter
4 >1 gross lesion >10 mm diameter
5 Gross coalescing lesions
Lymph node and other organs scoring system
0 No lesion/no necrosis
1 1 small focus
2 Several foci/necrotic or caseous area 5x5mm or greater
3 Extension necrosis/caseation
Pathology score = scores from lung
(left lower lobe, left upper lobe, right lower lobe, right middle 
lobe and right upper lobe)
+
Scores from other tissues
(hilar lymph node, spleen, liver and other affected organs)
Figure 2.4: Diagram showing the pathology scoring of macaques at necropsy.
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2.2 EX VIVO AND IN VIVO TECHNIQUES
2.2.1 Prior exposure of macaques to mycobacteria
The PRIMAGAM test kit was used to determine that none of the macaques used in the 
experiments had previously been exposed to environmental or pathogenic mycobacteria. 
This commercial diagnostic test is divided into three parts: (i) stimulation of blood; (ii) 
an enzyme immunoassay; and (iii) interpretation of the results. All reagents were 
supplied as part of the PRIMAGAM kit (Biocor Animal Health, Omaha, USA).
2.2.1.1 PRIMAGAM: stimulation of blood
Three ml heparinised blood from each animal was distributed into three wells of a 24- 
well plate. To the first well 2 drops of nil antigen were added, to the second well 2 drops 
of M. avian PPD, and to the third well 2 drops of M. bovis PPD. Blood and antigen were 
mixed thoroughly by swirling the plate for 1 minute and incubated at 37°C in 5% CO2 
overnight.
Plates were then spun in a plate-spinning centrifuge at 500 g  for 10 minutes. The 
supernatants were then aspirated off into sterile plastic vials and stored at 2-8°C for up to 
a week.
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2.2.1.2 PRIMAGAM: enzyme immunoassay
Pre-coated (anti-IFN-y) strips were filled with 50 pi green diluent followed by 50 pi test 
sera. Each sample was tested in duplicate. 50 pi negative control solution was added to 
two wells, and 50 pi of positive control (recombinant IFN-y) was added to another two 
wells. Samples were mixed by gently swirling the plate for 1 minute and incubated for 1 
hour at room temperature.
Plates were then washed six times with 300 pi per well of wash buffer. After the last 
cycle the plates were dried by tapping on absorbent paper and 100  pi of diluted conjugate 
was added per well. Conjugate was supplied as a lOOx concentrate and was diluted in 
green diluent solution. Plates were incubated for 1 hour at room temperature.
Plates were washed six times with 300 pi per well of wash buffer as before. Following 
the last wash, 100 pi diluted chromogen was added per well. This was supplied in a lOOx 
solution, and was diluted in the supplied enzyme substrate buffer. Plates were incubated 
for 30 minutes at room temperature with protection from direct light achieved by 
wrapping the plates in foil.
To each well, 50 pi of enzyme stopping solution was added to terminate the colorimetric 
reaction. Absorbance values were then measured using a plate spectrophotometer at a 
wavelength of 450 nm. Plates were read within 5 minutes of adding enzyme stopping 
solution.
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2.2.1.3 Interpretation of results
For the assay to be valid the absorbance values for the control samples were as follows:
• Negative control: ' Absorbance less than 0.150
(replicates must not vary by more than 0.040)
• Positive control: Absorbance more than 1.000
(replicates must not deviate by more than 15% from mean)
To determine whether animals had prior exposure to M. tuberculosis the absorbance 
would need to be 0.050 higher than those seen in nil antigen- or avian PPD-stimulated 
samples. The kit was also used to assess whether animals had been exposed to 
environmental mycobacteria by ensuring that the results in the avian PPD-stimulated 
samples did not exceed by 0.050 the levels in the nil antigen-stimulated samples.
2.2.2 Medium
The medium for lymphocyte isolation and assay incubation consisted of RPMI 1640 
media (Sigma-Aldrich, Dorset, England) supplemented with 2mM L-glutamine (Sigma- 
Aldrich), 25mM HEPES buffer (Sigma-Aldrich), 100 U/ml penicillin with 100 jag/ml 
streptomycin (Sigma-Aldrich) and 0.05mM 2-Mercaptoethanol (Invitrogen, Paisley, 
England).
Media identification was distinguished by its content of fetal calf serum (FCS) (LabTech, 
Ringmer, England): R0 = no FCS; R2 = 2% FCS; R5 = 5% FCS; and R10 = 10% FCS.
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2.2.3 Antigen preparation
2.2.3.1 Purified protein derivative
PPD produced from culture filtrates from virulent strains of M. tuberculosis was obtained 
from Statens Serum Institut (SSI, Copenhagen, Denmark) at a 1 mg/ml solution. Aliquots 
were stored at 2-8°C until required for use in immunological assays.
2.2.3.2 Recombinant proteins
Recombinant proteins to ESAT-6  and Ag85B (Lionex, Braunschweig, Germany) were 
supplied at 1.05 mg/ml and 1.02 mg/ml, respectively. Proteins were made to 1 mg/ml by 
diluting in sterile Phosphate Buffered Saline (PBS) (Severn Biotech Ltd, Worcestershire, 
England) and aliquots were frozen at -20°C until required.
2.2.3.3 Peptides
Overlapping 15mer peptides covering the sequences of Ag85A, CFP10 and ESAT-6  
were manufactured by Peptide Protein Research Ltd, Wickham, England. The sequences 
of the peptides were as shown in figures 2.5-2.7.
2.2.3.3.1 Peptide stocks
Freeze-dried peptides were diluted in dimethyl sulphoxide (DMSO) at 10 mg/ml. 
Aliquots were stored at -80°C.
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P e p t i d e S e q u e n c e
1 MQLVDRVRGAVTGMS
2 RVRGAVT GMS RRLVV
3 VTGMSRRLVVGAVGA
4 RRLVVGAVGAALVSG
5 GAVGAALVS GLVGAV
6 ALVSGLVGAVGGTAT
7 LVGAVGGTATAGAFS
8 GGTATAGAFSRPGLP
9 AGAFSRPGLPVEYLQ
1 0 RPGLPVEYLQVPSPS
11 VEYLQVPSPSMGRDI
12 VPSPSMGRDIKVQFQ
13 MGRDIKVQFQSGGAN
14 KVQFQSGGANSPALY
15 SGGANSPALYLLDGL
1 6 S PALYLLDGLRAQDD
17 LLDGLRAQDDFSGWD
18 RAQDDFSGWDINTPA
19 FSGWDINTPAFEWYD
2 0 INTPAFEWYDQSGLS
2 1 FEWYDQSGLSVVMPV
2 2 QSGLSVVMPVGGQSS
2 3 VVMPVGGQSSFYSDW
2 4 GGQSSFYSDWYQPAC
2 5 FY S DWYQPACGKAGC
2 6 YQPACGKAGCQTYKW
2 7 GKAGCQTYKWETFLT
2 8 QTYKWETFLTSELPG
2 9 ETFLTSELPGWLQAN
3 0 SELPGWLQANRHVKP
3 1 WLQANRHVKPTGSAV
3 2 RHVKPTGSAVVGLSM
3 3 TGSAVVGLSMAASSA
3 4 VGLSMAASSALTLAI
3 5 AASSALTLAIYHPQQ
3 6 LTLAIYHPQQFVYAG
37 YHPQQFVYAGAMSGL
3 8 FVYAGAMSGLLDPSQ
3 9 AMSGLLDPSQAMGPT
4 0 . LDPSQAMGPTLIGLA
41 AMGPTLIGLAMGDAG
42 LIGLAMGDAGGYKAS
43 MGDAGGYKAS DMWGP
44 GYKASDMWGPKEDPA
4 5 DMWGPKEDPAWQRND
4 6 KEDPAWQRNDPLLNV
47 WQRNDPLLNVGKLIA
48 PLLNVGKLIANNTRV
4 9 GKLIANNTRVWVYCG
5 0 NNTRVWVYCGNGKPS
5 1 WVYCGNGKPSDLGGN
5 2 NGKPSDLGGNNLPAK
5 3 DLGGNNLPAKFLEGF
5 4 NLPAKFLEGFVRTSN
5 5 FLEGFVRTSNIKFQD
5 6 VRTSNIKFQDAYNAG
5 7 IKFQDAYNAGGGHNG
5 8 AYNAGGGHNGVFDFP
5 9 GGHNGVFDFPDSGTH
60 VFDFPDSGTHSWEYW
61 DSGTHSWEYWGAQLN
62 SWEYWGAQLNAMKPD
6 3 GAQLNAMKPDLQRAL
64 AMKPDLQRALGATPN
65 LQRALGATPNTGPAP
6 6 GATPNTGPAPQGA
Figure 2.5: Sequences of antigen 85 A peptides
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P e p t i d e S e q u e n c e
1 MTEQQWNFAGIEAAA
2 WNFAGIEAAASAIQG
3 IEAAASAIQ GNVTSI
4 SAIQGNVTSIHSLLD
5 NVTSIHSLLDEGKQS
6 HSLLDEGKQSLTKLA
7 EGKQSLTKLAAAWGG
8 LTKLAAAWGGSGSEA
9 AAWGGSGSEAYQGVQ
10 SGSEAYQGVQQKWDA
11 YQGVQQKWDATATEL
1 2 QKWDATATELNNALQ
1 3 TATELNNALQNLART
14 NNALQNLARTIS EAG
1 5 NLARTISEAGQAMAS
1 6 ISEAGQAMASTEGNV
17 QAMASTEGNVTGMFA
Figure 2.6: Sequences of ESAT-6  peptides.
P e p t i d e S e q u e n c e
1 MAEMKT DAAT LAQEA
2 TDAATLAQEAGNFER
3 LAQEAGNFERISGDL
4 GNFERISGDLKTQID
5 ISGDLKTQIDQVEST
6 KTQIDQVESTAGSLQ
7 QVESTAGSLQGQWRG
8 AGSLQGQWRGAAGTA
9 GQWRGAAGTAAQAAV
10 AAGTAAQAAVVRFQE
11 AQAAVVRFQEAANKQ
12 VRFQEAANKQKQELD
1 3 AANKQKQELDEISTN
14 KQELDEISTNIRQAG
1 5 EISTNIRQAGVQYSR
1 6 IRQAGVQYSRADEEQ
17 VQYSRADEEQQQALS
18 ADEEQQQALSSQMGF
Figure 2.7: Sequences of CFP10 peptides.
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2.2.3.3.2 Peptide pools
Peptides from the individual stocks were diluted in RO medium to give a concentration of 
50 pg/ml for each peptide in the pool. The peptide pools consisted of sequential peptides 
for CFP10 and ESAT-6, with the following peptides in each pool:
CFP10 - pool 1: peptides 1-6 
pool 2: peptides 7-12 
pool 3: peptides 13-18 
ESAT-6 - pool 1: peptides 1-6 
pool 2: peptides 7-12 
pool 3: peptides 13-17
For Ag85A peptides, the pools were made up as shown in table 2.4.
Ag85A peptide pool
A B C D E F G
1 3 5 7 9 11 13
15 17 19 21 23 25 27
29 31 33 35 37 39 41
43 45 47 49 51 53 55
57 59 51 63 65 2 3
6 8 10 12 14 16 18
20 22 24 26 28 30 32
34 36 38 40 42 44 46
48 52 54 56 58 60 62
64 66 50
Table 2.4: Composition of Ag85A peptide pools.
(Numbers denote the peptide sequence as shown in figure 2.5).
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2.2.4 Lymphocyte preparation
2.2.4.1 Isolation of peripheral blood mononuclear cells
Heparinised blood was diluted with approximately an equal volume of RO medium 
before being layered over Ficoll-Paque PLUS (GE Healthcare, Buckinghamshire, 
England). Gradients were centrifuged at 400 g  for 35 minutes at room temperature with 
the centrifuge brake switched off. The buffy coat containing the peripheral blood 
mononuclear cells (PBMC) was aspirated off using a fine-tipped pipette and diluted with 
20 ml of R2 medium. PBMC were washed by spinning at 400 g for 10 minutes.
After removal of the medium, any remaining erythrocytes were lysed by resuspending in 
5 ml filtered ACK lysis buffer (pH 7.2-7.4): 0.5 M ammonium chloride (Sigma), 1.0 mM 
potassium bicarbonate (Sigma), and 0.1 mM EDTA (Sigma). After 5 minutes, 20 ml of 
R2 medium was added and the cells washed by spinning at 400 g for 5 minutes.
The supernatant was removed, and the cell pellet dispersed in R2 medium for cell 
counting.
2.2.4.2 Isolation of lymphocytes from lymphoid tissue
Lymph nodes and spleen were supplied for immunological analysis at necropsy in dry
sterile tubes. Tissues were put into a petri-dish with R0 medium. Any visible fat or
connective tissue was cut away and removed. The lymphoid tissue was cut into small
segments of approximately <5mm size and placed into a medicon device (BD
Biosciences, Oxford, England). R0 medium was added to the medicon before placing the
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lid on and inserting it into a medimachine (BD Biosciences). After approximately 1 
minute, the machine was turned off and the medicon removed. A Pasteur pipette was 
placed into the harvesting port and the single cell suspension was aspirated through the 
50 pm filter contained within the medicon. The cell suspension was layered over Ficoll- 
Paque solution and gradients treated as described for PBMCs in section 2.2.4.1.
2.2.4.3 Depletion of lymphocyte subsets
Cells were depleted by adding magnetic beads coated with antibody (Dynal beads, 
Invitrogen, Paisley, England) against the cell subset to be depleted (CD4+ or CD8+). 
PBMCs were diluted to approximately lx l0 7 cells/ml in PBS containing 2% FCS. Beads 
that had been pre-washed twice with PBS containing 2% FCS were added to cells at a 
ratio of 4 beads to 1 cell. The bead/cell suspension was incubated on a blood tube rotator 
for 30 minutes at 2-8°C.
Depleted cells were harvested by placing the tubes on a magnet (Invitrogen, Paisley, 
England) and leaving for 3 minutes to allow the beads to become fully attracted to the 
magnet. The cell suspension containing the depleted cell subset was then aspirated off 
and used in immunological analysis. Immunophenotyping analysis by flow cytometry 
confirmed successful depletion of cell populations.
2.2.4.4 Cryopreservation of lymphocytes
Cell suspensions were centrifuged at 400 g for 5 minutes. The supernatant was discarded
and the cell pellet resuspended in 1 ml cryopreservation medium (90% fetal calf serum
containing 10% DMSO) per vial to be frozen. Cells were frozen in 1 ml aliquots, each
- 100-
containing between 8xl06-1.2xl07 cells. Vials were placed in an isopropanol freezing 
device and kept at -80°C for at least 24 hours before being transferred to storage in 
liquid nitrogen vapour.
2.2.4.5 Resuscitation of cryopreserved lymphocytes
Cryopreserved cells were removed from storage in liquid nitrogen vapour and placed 
into a 37°C waterbath until thawed. The contents were then transferred to 10 ml R2 
medium and the cells centrifuged at 400 g  for 5 minutes. The supernatant was removed 
and the cell pellet resuspended in a known volume of R2 medium for counting.
2.2.5 Sera preparation
Blood was collected in serum separation tubes (BD Vacutainers) containing silica 
particles that activate clotting. After ensuring the clot has retracted by incubation at 2- 
8°C for up to 2 hours the tubes were centrifuged at 3,000 rpm for 10 minutes. The serum 
was collected and passed through a 0.45 pm filter followed by a 0.2 pm filter before 
being placed into labelled vials and stored at -20°C. Before use, samples of sera were 
heat-inactivated by placing in a 56°C waterbath for 45 minutes.
2.2.6 Quantification of a single cell suspension
Lymphocytes were counted using the trypan blue exclusion method. The cell suspension 
was diluted 1:10 with 0.4% trypan blue solution (Sigma) and mixed by pipetting up and 
down at least 10 times. The suspension was then loaded into a counting grid on a
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disposable counting chamber (KovaSlide, Bio-Stat Ltd, Stockport, England). Cells were 
counted in the large squares in each of the four comers of the slide.
To calculate the number of cells, the mean number of cells for each comer square was 
determined. This was multiplied by 104, to account for the volume of cell suspension 
present in the counting area. The figure was multiplied by 10, to factor in the dilution 
factor of cell suspension with the trypan blue dye solution to give a cell count per ml. To 
determine the total cell count, the result was multiplied by the total volume of cell 
suspension.
2.2.7 Evaluating the frequency of interferon-y secreting cells
The monkey/human IFN-y kit (MabTech, Nacka, Sweden) was used in all ELISPOT 
assays. Sterile polyvinylidene difluoride (PVDF) plates (Millipore, Watford, England) 
were coated with 10 pg/ml of IFN-y antibody (clone GZ-4) diluted in 0.1 M carbonate- 
bicarbonate buffer, pH 9.6 (Sigma-Aldrich) overnight at 4°C.
After incubation the coating antibody was removed and wells washed 6 times with 200 
pl/well sterile PBS solution. Plates were then blocked by the addition of 100 pi per well 
of 0.45 pm-filtered R10 medium for 2 hours at 37°C with 5% CO2.
Antigens and mitogens were diluted in R0 medium and 20 pi added to the appropriate 
wells. Cells were stimulated with antigens at the following final concentrations: PPD -  
10 pg/ml; and 15mer peptides spanning Ag85A, CFP10 and ESAT-6  -  10 pg/ml 
(described in section 2.2.3). The assay also contained a negative and positive control. 
The negative control used medium alone and the positive control consisted of adding
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phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) and ionomycin (CN 
Biosciences, Nottingham, England) at final concentrations of 100 ng/ml and 1 pg/ml, 
respectively.
100 pi cells suspended in R5 medium were then aliquoted into the wells at final 
concentrations of 2x105, lx l0 5 or 5x104 cells/well. All tests were performed at least in 
duplicate, except medium alone where at least 8 replicate wells were used. Plates were 
incubated overnight between 17-20 hours at 37°C in a humidified atmosphere with 5% 
CO2 undisturbed. Following this, plates were washed 6 times with 200 pl/well PBS + 
0.05% Tween-20 (Sigma). 100 pi biotinylated anti-IFN-y antibody (clone 7-B6-1) at 1 
pg/ml diluted in PBS containing 0.5% filtered FCS was added to each well and incubated 
for 2 hours at 37°C.
Plates were washed 6 times with PBS containing 0.1% Tween-20. 100 pi streptavidin- 
ALP (1/1000 dilution made with PBS containing 0.5% filtered FCS) was added per well 
and incubated for 2  hours at room temperature.
Plates were washed 6 times with PBS containing 0.1% Tween-20 and then developed 
using 100 pl/well of 5-Bromo-4-Chloro-Indolyl Phosphate/Nitro Blue Tetrazolium 
(BCIP/NBT) substrate. Plates were left at room temperature for 20-40 minutes to allow 
spots to develop. To terminate the reaction, plates were washed three times with 200 
pl/well of sterile water and dried at room temperature.
Well images were captured with an AID ELISPOT reader system and spots enumerated 
using the companion software (Autoimmun Diagnostika GmbH, Strapberg. Germany). 
Each well was manually checked to ensure consistency of spot counting.
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Data were adjusted to give a value of spot-forming cells per 106 cells. This was done by 
subtracting mean counts seen in the media wells from the value obtained in the antigen 
wells from concentration-matched samples, and then multiplying this result to obtain a 
value equivalent to 106 cells. Where two different cell concentrations were used in the 
assay, each result was multiplied to 106 cells and then a mean value determined from 
both concentrations tested. If the number of IFN-y-secreting cells was determined to be 
too numerous to count, the value per 106 cells was obtained from the lower concentration 
of input cells where spots could be quantified. Where the lowest concentration was also 
too high to count, a value of 250 spots/well was applied.
Where peptides for each antigen were tested in multiple pools, the spot-forming cells per 
106 for each pool were added together to provide a total antigen response.
2.2.8 Measurement of cytokine concentrations after in vitro stimulation
2.2.8.1 Stimulation of blood and PBMC samples
Heparinised blood was diluted 1:10 with R0 medium, or where PBMC preparations were 
used, cells were diluted in RIO medium at a concentration of lx l0 6 cells/ml. Antigens 
were tested at 5-10 pg/ml for PPD and approximately 2xl04 organisms per well for BCG 
(SSI). A negative control sample was cultured with R0 medium and a positive control 
stimulated in the presence of 5-10 pg/ml PHA (Sigma). Typically, 1 ml of blood/PBMC 
preparation was stimulated for each antigen/mitogen preparation using at least 6 wells of 
a 96-well U-shaped plate or in a 5 ml tissue culture tube.
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After incubation the plates or tubes were centrifuged at 400 g for 5 minutes. The 
supernatants were passed through a 0.2 pm filter into sterile tubes and stored at -80°C 
until required for cytokine analysis.
2.2.8.2 Cytokine ELISA assays
2.2.8.2.1 IFN-y ELISA
The human/monkey IFN-y ELISA kit (MabTech) was used for measuring concentrations 
of IFN-y in supernatant samples. Nunc maxi-sorb plates (VWR International Ltd, 
Leicestershire, England) were coated overnight at 4°C with 100 pl/well of 2 pg/ml of 
IFN-y antibody (clone GZ-4) diluted in PBS.
Plates were washed 6 times with 200 pl/well of sterile PBS solution and blocked with 
200 pl/well PBS containing 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich) solution 
for 1 hour at room temperature.
Samples were thawed and vortexed before adding to the plate. 100 pi of each sample was 
added in duplicate wells. As a standard control, a purified human IFN-y was tested in a 
2 -fold serial dilution across each plate starting at a concentration of 8000 pg/ml and 
diluted in incubation buffer: PBS containing 0.05% Tween-20 and 0.1% BSA. Samples 
were incubated overnight at 4°C.
Plates were washed 6 times with PBS containing 0.05% Tween-20 using an automated 
microplate washer (Molecular Devices, Berkshire, England). 100 pl/well of 1 pg/ml
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biotinylated anti-IFN-y antibody (clone 7-B6-1) diluted in incubation buffer was added. 
Plates were incubated for 1 hour at room temperature.
Plates were washed 6  times with 200 pl/well of PBS containing 0.05% Tween-20 and 
100  pl/well of streptavidin (1 /1 0 0 0  dilution in incubation buffer) added to each well. 
This was incubated for 1 hour at room temperature.
Plates were washed a final 6 times with PBS containing 0.05% Tween-20 and 100 pi of 
3,3\5,5’-tetramethylbenzidine (TMB) liquid substrate system (Sigma-Aldrich) added per 
well. This was left to develop at room temperature, typically for 5 minutes. The reaction 
was terminated by the addition of 30 pi 2M sulphuric acid solution (May & Baker Ltd, 
Dagenham. England).
Absorbances were read at 450 nm on a Multiskan EX microplate reader (Thermo 
LabSystems, Basingstoke, England) linked to analysis software (Genesis version 3.05, 
Thermo LabSystems). A standard curve was plotted from the dilutions of the IFN-y 
control for each plate. From the standard curve, the absorbances obtained from the 
samples were evaluated to give the concentrations of IFN-y.
2.2.8.12 IL-10 and IL-12 ELISA
Cytokine ELISA kits specific for monkey IL-10 and IL-12 were used (U-CyTech, 
Utrecht, The Netherlands). Nunc maxi-sorb plates (VWR International Ltd) were coated 
overnight at 4°C with 150 pl/well of coating antibody diluted in PBS. Plates were 
washed 6  times with 200 pl/well sterile PBS solution and blocked with 200 pl/well PBS 
+ 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich) solution for 1 hour at 37°C.
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Samples to be tested were thawed and vortex mixed before adding to the plate. 100 pi of 
each sample was added in duplicate wells. As a standard control, purified monkey IL-10 
and IL-12 was tested in a 2-fold serial dilution across each plate starting at a 
concentration of 30,600 pg/ml and 8,600 pg/ml, respectively. Dilutions were made with 
incubation buffer.
Plates were washed 6  times with 200 pl/well PBS containing 0.05% Tween-20 using an 
automated microplate washer (Molecular Devices). 100 pl/well biotinylated detector 
antibody diluted in incubation buffer was added. Plates were incubated for 1 hour at 
37°C.
Plates were washed 6  times with 200 pl/well PBS containing 0.05% Tween-20 and 100 
pl/well of Streptavidin-HRP polymer (SPP) conjugate added to each well. This was 
incubated for 1 hour at 37°C.
Plates were washed a final 6 times with 200 pl/well PBS containing 0.05% Tween-20 
and 100 pi of 3,3\5,5Metramethylbenzidine (TMB) liquid substrate system added per 
well. This was left to develop at room temperature, typically for 15 minutes. The reaction 
was terminated by addition of 50 pi 2M sulphuric acid solution (May & Baker Ltd, 
Dagenham. England).
Absorbances were read at 450 nm, and analysed as shown for the IFN-y ELISA assay 
(section 2.2.7.2.1).
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2.2.8.2.3 Luminex assay
The luminex assay was used to measure multiple cytokines simultaneously in the same 
sample. The technology works by each cytokine antibody being conjugated to a bead set 
distinguished by its fluorescent intensity. The assay was set up in two parts: (i) 
microsphere binding; and (ii) running of samples and analysis.
2.2.8.2.4 Microsphere binding:
50 pi of test sample was added to each well of a filter plate (Millipore). A standard 
dilution series of a cytokine control mixture was added in parallel to produce standard 
curves for all of the measured cytokines.
Each bead set coated with anti-cytokine antibody (Beadlyte system, Upstate, Dundee, 
UK) was made to a concentration of lx l 05 beads/ml, sonicated, and 25 pi added per 
well. Beadlyte® sets were used for IFN-y, TNF-a, IL-2, IL-6  and IL-lp. The plate was 
covered with foil to protect from direct light and incubated on a plate shaker at room 
temperature for 90 minutes.
Each well was washed twice with 100 pl/well of assay buffer (PBS + 1% BSA + 0.05% 
Tween-20). A vacuum manifold was used to remove fluid via the base of the filter plate. 
25 pl/well of 1 pg/ml reporter antibody (supplied as part of the Beadlyte system) was 
then added per well. Plates were incubated for 90 minutes at room temperature on a plate 
shaker in the dark.
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25 pi of 40 pg/ml Streptavidin-Phycoerythrin was added to each well and incubated for 
90 minutes on a plate shaker at room temperature. To each well, 25 pi stop solution 
(0.2% (vol/vol) formaldehyde in PBS) was added and left for 5 minutes on a plate shaker 
to fully mix. The plate was washed twice with 100 pl/well of assay buffer. Finally, the 
beads were resuspended in 100  pl/well of sheath fluid ready for acquisition on the 
luminex analyser.
*•
2.2.8.2.5 Acauistion o f samvles on the luminex and analysis
Samples were analysed on a luminex-100 machine with StarStation software (Applied 
Cytometry Systems, Sheffield, England). For each sample, results were generated as 
shown in figure 2 .8 .
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Figure 2.8: Overview of Starstation software used for luminex analysis
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2.2.9 Vaccinia-specific antibody ELISA assay
To measure antibodies specific to the modified vaccinia Ankara (MVA) vector, a 
vaccinia-specific ELISA assay was used. MaxiSorp 96-well plates (Nunc Nalgene, 
Herefore. England) were coated with 100 pl/well of 2.5 pg/ml inactivated vaccinia virus 
Lister strain (Autogen Bioclear, England) diluted in carbonate coating buffer (0.015M 
Na2C0 3  + 0.035M NaHC0 3  (Sigma) diluted in 1000 ml purified water). Plates were 
incubated at 2-8°C overnight.
Wells were washed three times with 350 pl/well trizma buffered saline (TBS) (0.14M 
NaCl + 0.002M KC1 + 0.05M Tris + 0.009M Trizma HC1 + 35 ml Brijl solution (Sigma) 
diluted in 20 L of purified water). Each well was blocked by the addition of 250 pi 
diluent buffer (5% skim milk powder (Sigma) diluted in PBS containing 0.01% Tween- 
20 (Sigma)) and left at room temperature for 1 hour.
Wells were washed three times with 350 pl/well TBS. Samples were diluted in duplicate 
four-fold down the plate in diluent buffer starting at 1:25. A control preparation of 
Vaccinia Immunoglobulin (VIG) starting at 8,500 IU/ml was also prepared on each plate. 
The bottom row of the plate was left as a negative control containing diluent buffer only. 
Plates were incubated at room temperature for 2 hours.
Wells were washed three times with 350 pl/well TBS. 100 pl/well of a 1/1250 dilution of 
anti-monkey IgG peroxidase (Insight Biotechnologies, England) was added per well. 
Plates were incubated at room temperature for 2 hours.
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Wells were washed five times with 350 pl/well TBS. To each well 100 pi of 2,2'-azino- 
di[3-ethylbenzthiazolin sulphate] (ABTS) peroxidase substrate system (Insight 
Biotechnologies) was added. Plates were left for 25 minutes to allow the colorimetric 
reaction to develop. 100 pl/well of ABTS stop solution (Insight Biotechnologies) was 
added to terminate the reaction.
Absorbances were read using a VersaMax plate spectrophotometer linked to SOFTmax 
PRO software (Molecular Devices, England) using a wavelength of 405 rim.
To determine the units of VIG per ml the values where curves turn direction were 
ascertained from the SOFTmax PRO software, equating to the mid-point of the curve. 
The value from the test sample was divided by the value obtained for the VIG 
preparation and multiplied by 8,500 (the starting concentration of VIG).
2.2.10 Statistical analysis
Minitab (version 15) was used for all statistical analyses. A significance level of P<0.05 
was used in all analyses.
When comparing groups of animals, the non-parametric Mann-Whitney U-test was used 
as the data were not consistently normally distributed. Where 10 or more points across a 
time-course were assessed using the Mann-Whitney statistical test, the Bonferonni 
correction was used to take into account multiple comparisons, and this lowered the 
threshold at which the p-value becomes signficant.
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To analyse responses over a certain time-period the area under the curve analysis was 
measured using a function on SigmaPlot (version 10) that uses the Trapezium Rule. 
Resultant areas were then compared using the Mann-Whitney test.
In deciphering whether data from two sets were related, the Spearman’s rank correlation 
coefficient (rs) was used as data were not normally distributed.
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3 DETERMINATION OF BASELINE IFN-y RESPONSES
3.1 INTRODUCTION
This chapter provides details on IFN-y responses measured in macaques before entering 
experimental schedules. By monitoring baseline levels, a limit above which responses 
could be designated as “positive” could be ascertained for use in future studies.
3.1.1 Mycobacteria-specific antigens
Having chosen to measure the frequency of cells secreting IFN-y using an ELISPOT 
assay, and the concentration of IFN-y secreted using an ELISA assay, the antigens used 
to stimulate the cells needed to be selected. Mycobacterium components able to stimulate 
T cells can broadly be divided into somatic antigens and secreted antigens. The majority 
of somatic antigens, described as potential ligands for the recognition of the infectious 
agent which include heat shock proteins, are derived from destroyed bacilli during the 
late phase of infection (Ulrichs et al., 1998). In contrast, secreted antigens are produced 
by metabolically active organisms (Ulrichs et a l , 1998) and are largely implicated as 
targets for protective immune responses (Orme & Collins, 1984). The secreted antigens 
are processed and presented primarily in the context of MHC class II, and as the 
infection clears, the immune system then encounters a range of somatic antigens released 
from the degraded bacteria. This results in the stimulation of a broad T cell repertoire 
recognising all classes of antigen (Andersen, 1997). In experimental analysis, responses 
were measured using the following antigens: purified protein derivation (PPD), whole 
bacilli Calmette Guerin (BCG) organisms, antigen 85 (Ag85), 6 kDa early secretory 
antigenic target (ESAT-6) and culture filtrate protein 10 (CFP10).
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3.1.1.1 Purified protein derivative
Purified protein derivative (PPD) is a crude, poorly defined mixture of mycobacterial 
antigens containing both secreted and somatic proteins (Andersen, 1997; van Pinxteren 
et al., 2000b). For in vitro assays in this thesis, PPD was sourced from a commercial 
company, Statens Serum Institut (SSI), who also supply PPD for routine Mantoux testing 
in humans. The PPD used was derived from a culture of M. tuberculosis.
In addition to providing protein antigens for recall of adaptive T-cell responses, 
mycobacterial PPDs also elicit potent early-innate responses (Weir et a l , 2003). Due to 
being a protein lysate, it would be expected to be processed by the exogenous antigen 
presenting pathway resulting in presentation by MHC class II molecules and stimulation 
of CD4+ T cells (Tesfa et a l, 2004). Due to the range of antigens contained in PPD, this 
antigen was used for the detection of responses against M. tuberculosis and BCG. 
Additionally, PPD is widely used as a mycobacteria-specific antigen by the scientific 
community for the detection of immune responses. This means that data can be 
compared between research groups, gives added confidence of its suitability in 
immunological assays, and allows for convenient simultaneous measurement of 
responses to a wide range of mycobacterial antigens.
3.1.1.2 BCG
Whole BCG organisms were derived from vaccine vials supplied by SSI. The BCG used 
in the in vitro assay was the same strain used for animal vaccinations and in human 
clinical trials conducted in Oxford.
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BCG was only used in the whole blood stimulation assay that involved culture for 6  
days, in parallel with human studies (Black et al., 2001; Black et al., 2002). BCG was 
not used as an antigen in the overnight ELISPOT assay due to less time for the 
organisms to undergo phagocytosis which subsequently leads to antigens being 
processed and presented effectively.
3.1.1.3 Antigen 85 complex
The proteins of the antigen 85 (Ag85) complex (Ag85A, Ag85B and Ag85C) are major 
secretion products of M. tuberculosis and M. bovis BCG (Wiker & Harboe, 1992). One 
of the functions of these proteins is to bind to fibronectin (Wiker & Harboe, 1992), 
which may aid intracellular mycobacterial survival and allow mycobacteria to bind to 
host cells aiding dissemination throughout host tissues (Armitige et al., 2000). Others 
have reported that the Ag85 proteins act as enzymes called mycolyltransferases that are 
involved in the cell wall assembly in mycobacteria (Belisle et al., 1997).
As one of the vaccines being tested in non-human primates in this thesis involved an 
MVA boost containing Ag85A, it was important to test responses against this 
mycobacterial protein. The MVA85A vaccine is currently in clinical trials in the UK and 
Africa (McShane et al., 2005). The antigen was also chosen as it is present in all strains 
of BCG as well as being an immunodominant antigen in animal and human studies 
(McShane et al., 2005).
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3.1.1.4 Culture filtrate protein 10 and 6 kDa early secretory antigenic target
Culture filtrate protein 10 (CFP10) and 6 kDa early secretory antigenic target (ESAT-6) 
are both prominent T-cell targets during early TB infection (van Pinxteren et a l, 2000b). 
Their small size may make them more susceptible to proteolytic degradation and 
enhanced processing (Skjot et a l, 2000).
Genes encoding CFP10 and ESAT-6  are transcribed together in M tuberculosis and both 
code for small exported proteins (Berthet et al, 1998). Both genes are contained on the 
region of deletion 1 (RD1) section which is present in M. tuberculosis but absent in BCG 
strains (Behr et a l, 1999). CFP10 and ESAT-6  reside within one operon, indicating that 
they may be expressed and available for immune recognition in the same phase of 
infection (Brock et a l, 2004). It has been speculated that CFP10 and ESAT-6  may have 
a role in bacterial virulence (Skjot et a l, 2000), supported by the fact that they were 
deleted early in the process of attenuation of virulent M. bovis leading to the BCG 
vaccine (Harboe et al, 1996).
Due to these antigens being absent in M. bovis BCG they can be used to differentiate 
between responses to active infection with M. tuberculosis compared to vaccination with 
BCG in IFN-y assays. CFP10 alone has been reported to have a sensitivity of 70% in 
detecting M. tuberculosis infection using protein antigen (Dillon et a l, 2000). ESAT-6  
has shown sensitivities of 65% (Ravn et al, 1999) to 87% (Tesfa et a l, 2004); these 
differences may be due to separate patient populations being tested and also to variations 
in the nature of the antigen as the studies used protein preparations and peptides, 
respectively. When CFP10 and ESAT-6  antigens are combined, sensitivities in detecting
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M. tuberculosis infection increased to 73% (van Pinxteren et a l, 2000b) using proteins 
or 93.1% (Scarpellini et al., 2004) using selected immunogenic peptides.
It is important to note that genes encoding for CFP10 and ESAT-6  are present in 
environmental non-tuberculous mycobacteria (NTM) such as M. kansasii, M. szulgai and 
M marinum (Skjot et al., 2000). Therefore, prior exposure to these mycobacterial strains 
may contribute to CFP10- and ESAT-6 -specific responses.
In this thesis, CFP10 and ESAT-6  antigens were used to determine responses post­
challenge with M. tuberculosis so that responses detected would not be compromised by 
prior vaccination with BCG, i.e. would differentiate M  tuberculosis responses from 
those specific to BCG.
3.1.2 Chapter aims
The aims of the work described in this chapter were to ensure that assays and antigens 
were suitable for monitoring IFN-y immune responses in non-human primates. This was 
achieved by applying the methods and antigens in a large cohort of naive macaques 
involving 49 rhesus macaques and 18 cynomolgus macaques. This included all animals 
that entered the experimental studies described in this thesis, as well as other macaques 
for which samples were available.
Data from these analyses would also allow baseline levels of IFN-y responses in naive 
macaques to be determined. From these results, a cut-off limit could be elucidated to 
help define whether responses increased following subsequent vaccination and infection.
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3.1.3 Chapter methods
Animals for TB work were screened using the PRIMAGAM kit for prior exposure to 
mycobacteria (section 2.2.1). The frequency of antigen-specific IFN-y secreting cells was 
measured using an ELISPOT method (section 2.2.6) and the concentration of IFN-y 
secreted after antigenic stimulation was measured using an ELISA method (section 
2.2.7).
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3.2 RESULTS
3.2.1 Primate IFN-y (PRIMAGAM) test kit for M. tuberculosis
The commercial PRIMAGAM kit was used to determine whether animals had immune 
responses due to previous exposure to mycobacteria. Forty-seven rhesus macaques and 
17 cynomolgus macaques were tested before being assigned to immunological studies. 
All animals screened were negative based on the manufacturer’s guidance of a positive 
result of prior infection being indicated by an absorbance value of >0.05 that of the avian 
PPD- or negative antigen-stimulated samples.
3.2.2 Development of assays to measure IFN-v
3.2.2.1 IFN-y ELISPOT assay
3.2.2.1.1 Suitability o f antisen preparations
In order to measure mycobacterium-specific cytokine responses using the ELISPOT 
assay, cells required stimulation with mycobacterial antigens. Suitable antigens should 
produce low background responses in nai've animals and induce specific responses in 
vaccinated or challenged animals.
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3.2.2.1.1.1 Purified protein derivative
Purified protein derivative (PPD) is a complex mixture of antigens that are contained in 
both M. tuberculosis and M. bovis BCG. Responses to PPD were investigated in PBMCs 
isolated from naive animals (49 rhesus macaques and 18 cynomolgus macaques) using 
the ELISPOT technique (section 2.2.6). All animals showed responses below 200 IFN-y- 
producing cells per 106 PBMCs (<0.04%) in response to stimulation with PPD (figure 
3.1). Animal-to-animal variation was observed, with the median response being 46 
(range 0-131) and 33 (range 0-158) IFN-y-producing cells/106 PBMC in rhesus 
macaques and cynomolgus macaques, respectively.
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3.2.2.1.1.2 Recombinant proteins
Two recombinant proteins were investigated: antigen 85B (Ag85B) and ESAT-6 . Both 
proteins were purified from E. coli expression vectors and were supplied from a 
commercial company (Lionex, Germany).
Responses to these recombinant proteins were assessed in PBMC from naive animals: 33 
rhesus macaques and 6 cynomolgus macaques. Responses were below 300 and 500 IFN- 
y-producing cells per 106 PBMCs after stimulation with rAg85B and rESAT-6 , 
respectively (figure 3.1). The median response to rAg85B was 87 (range 0-275) and 59 
(range 0-192) IFN-y-producing cells/106 PBMC in rhesus macaques and cynomolgus 
macaques, respectively. For rESAT-6 , the median response in rhesus macaques was 97 
(range 0-302) IFN-y-producing cells/106 PBMC, and in cynomolgus macaques was 248 
(range 0-491).
Responses to the two recombinant proteins (rAg85B and rESAT-6) in naive macaques 
were compared with results observed after stimulation with PPD (figure 3.1). The data 
show that the responses to the recombinant proteins were significantly higher and more 
variable in naive animals compared to those observed after stimulation with PPD.
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Figure 3.1: Box-plot comparison of different antigen protein preparations tested in naive 
macaques using an IFN-y ELISPOT assay.
(Each box encompasses 50% of the data. The median value is displayed as a line. The 
upper and lower bars of the box mark the limits of upper and lower quartile of the 
variable population. Whiskers extending from the top and bottom of each box mark the 
10% and 90% limits. Outliers are displayed as individual points. Mann-Whitney 
statistical test, significance level P<0.05).
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The unexpectedly high background responses seen to recombinant proteins in some of 
the animals could have been due to either the purity of the antigen preparation or prior 
exposure of the animals to mycobacterial antigens, possibly as a result of frequent 
tuberculin skin testing to ensure animals remained free from mycobacterial disease. 
Responses to ESAT-6 , which is present in M. tuberculosis but absent in BCG, is 
indicative of TB infection. However, the data from prior testing with the diagnostic 
PRIMAGAM kit using PPD (which also contains ESAT-6) was negative and animals 
showed no clinical signs of infection (e.g. weight loss, coughing). Also, the PPD 
ELISPOT responses were low in these animals, thus providing further evidence of a lack 
of mycobacterial infection and evidence that frequent skin testing is not the reason for 
high baselines in some animals.
To determine if these high background responses were due to the immune status of cells 
isolated from the animals, responses to rESAT-6  and rAg85B were measured in 
cryopreserved PBMC collected from naive rhesus macaques obtained from 3 different 
breeding colonies. Two of the colonies were based in the UK (Dstl and Oxford) and one 
in China. The UK breeding colonies carried out tuberculin testing at a much reduced 
interval (once prior to delivery) than the Chinese colony where animals were tested 
routinely every 6 months.
Additionally, in order to determine if the E. coli expression system used to prepare the 
recombinant Ag85B and ESAT-6  proteins was responsible for the high background 
values, responses to Simian Immunodeficiency Virus (SIV) proteins prepared in a 
baculovirus system (gpl30) and an E. coli system (p27) were included in the assay. The 
SIV proteins were sourced from the AIDS repository held at the National Institute for 
Biological Standards and Controls (NIBSC).
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Results from this experiment showed that the pattern of responses was similar in animals 
from each of the different colonies (figure 3.2). The E. coli derived proteins produced 
consistently high responses whether they were TB proteins or SIV proteins. However, 
the baculovirus-derived protein induced a much lower response equivalent to that seen to 
medium alone.
' 1 Medium
rESAT6 (5pg/ml) - E. coli vector 
rAg85B (5jig/ml) - E. coli vector 
rgp130 (5^g/ml) - baculovirus vector 
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Figure 3.2: Responses to TB and SIV proteins in PBMC from naive rhesus macaques 
obtained from different breeding colonies.
(All results were analysed in the same assay using cells that had been cryopreserved. The 
number in each box refers to the unique identifier for each animal. TB proteins, green 
bars; SIV proteins, blue bars).
- 125 -
3.2.2.1.1.3 Peptide pools
Overlapping 15mer peptides corresponding to gene sequences from M. tuberculosis 
H37Rv for Ag85A (6 6  peptides), ESAT-6  (17 peptides) and CFP10 (18 peptides) were 
manufactured (Peptide Protein Research Ltd, England). Peptides were pooled: 7 pools 
for Ag85A, 3 pools for ESAT-6 , and 3 pools for CFP10.
To compare the peptide pools with proteins, a common antigen (ESAT-6 ) between both 
preparations was used. Direct comparisons were carried out in 37 naive animals; 31 
rhesus macaques and 6  cynomolgus macaques. Results show that the background 
responses were generally lower using peptide pools (figure 3.3). However, there were 
some animals where responses were higher using peptide pools than with the protein. 
Overall, the mean number of IFN-y-producing cells/106 PBMC was 115 after protein 
stimulation, and 44 after stimulation with peptide pools (a 61.7% reduction). When all of 
the results were compared, this reduction was statistically significant (paired t-test, 
P=0.006).
For subsequent experiments, peptide pools were used in addition to PPD.
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Figure 3.3: Comparison of background IFN-y ELISP0T responses to ESAT-6 using 
recombinant protein and peptide pools as antigens in naive macaques.
(Recombinant protein, green bars; peptide pools, blue bars).
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3.2.2.1.2 Macaque species ram e for IFN-yELISPOT antisens in naive animals
Having tested PPD and the peptides pools (Ag85A, CFP10 and ESAT-6), the ranges for 
IFN-y-secreting cells/106 PBMC from rhesus macaques and cynomolgus macaques were 
ascertained for all four antigens (table 3.1). As shown in figure 3.4, most of the antigens 
showed an interquartile range below 100 spots per 106 PBMC (<0.0001%). However, the 
responses to Ag85A were higher and showed greater variability.
Due to the range of responses in the macaque populations, determining a baseline 
response for use in experimental studies could not rely on using an average population 
value for each species. Therefore, responses in individual animals were investigated in 
further detail.
Macaque species
IFN-y-secreting cells/106 PBMC
Median Range
PPD Rhesus (n=49) 46 0-131Cynomolgus (n=18) 33 0-158
Ag85A
peptides
Rhesus (n=48) 96 0-1436
Cynomolgus (n=17) 33 0-386
CFP10
peptides
Rhesus (n=47) 30 0-331
Cynomolgus (n=17) 14 0-90
ESAT-6
peptides
Rhesus (n=47) 68 0-284
Cynomolgus (n=T7) 33 0-93
Table 3.1: Summary of IFN-y responses to mycobacterial PPD and peptide pools in naive 
macaques.
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3.2.2.1.3 Individual range for IFN-yELISPOT antisens in naive macaques
Where baseline responses had been assessed on multiple occasions, the variability in 
response for each individual animal was determined (figures 3.5-3.8). Error bars 
represent 95% confidence intervals (Cl). It should be emphasised that with some of the 
animals baselines were only measured on two occasions whereas, with others, responses 
were tested at up to 14 different time-points. However, there was no apparent difference 
in variation between samples tested twice and those on more occasions.
The background levels after stimulation with Ag85A peptide pools were higher than 
those for the other three antigens: PPD and peptides pools to CFP10 and ESAT-6 . Levels 
and variation were similar between the rhesus macaques and the cynomolgus macaques.
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3.2.2.1.4 Determination o f  a positive IFN-yELISPOT response
Due to the range of variation between individual animals, a cut-off limit for each animal 
was required in order to define a positive IFN-y ELISPOT response. Using the 95% 
confidence intervals for each animal, the upper limit was expressed as a multiplication 
factor of the mean (figure 3.9).
When each antigen was plotted, it became apparent that on no occasions did the upper 
95% confidence interval extend to over 3 times the mean response. Therefore, a positive 
ELISPOT response would be defined in future studies as being over 3 times the 
average baseline level.
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95% confidence interval during baseline screening of macaques.
(Rh; rhesus macaques: Cy; cynomolgus macaques).
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3.2.2.2 Development of the whole blood ELISA assay
The ELISA assay used to measure IFN-y in diluted whole blood supernatants was carried 
out using a commercially-available monkey IFN-y-specific kit.
During the stimulation assay, two antigens were tested: PPD and BCG. In naive samples, 
the background levels of IFN-y secretion was measured after 6 days of stimulation. As 
shown in figure 3.10, only one animal exceeded secretion of 100 pg/ml with the majority 
of animals having undetectable levels of IFN-y. When the groups of animals were 
compared, there was a higher concentration of IFN-y secreted in rhesus blood after 
stimulation with BCG than after stimulation with PPD. However, this difference was not 
observed with cynomolgus macaques.
As the background levels of antigen-specific IFN-y secretion were low, this assay was 
used in subsequent experiments without modification. The cut-off limit in defining a 
positive IFN-y ELISA response was determined to be 100 pg/ml.
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Figure 3.10: Levels of antigen-specific IFN-y secretion measured by ELISA in naive 
macaques.
(Blue error bars denote the mean +/- standard deviation. Green crosses denote values for 
individual animals).
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3.3 DISCUSSION
3.3.1 Screening of animals
Prior to the measurement of any immune responses in non-human primates, all animals 
were screened for any potential M. tuberculosis infection or prior exposure using a 
commercially-available IFN-y based whole blood assay kit (PRIMAGAM). This kit had 
been used to screen a colony of rhesus and cynomolgus macaques during an outbreak of 
M. bovis, and was reported to have a 6 8 % sensitivity (Garcia et al., 2004). However, at 
the Biomedical Primate Research Centre (BPRC) in The Netherlands the PRIMAGAM 
kit was used on 23 experimentally-infected animals (15 cynomolgus macaques and 8 
rhesus macaques) and results from the test were positive for all animals (Vervenne et al., 
2004). It should be noted that in the BPRC study the infection was artificially-induced as 
it was achieved through intratracheal inoculation of 1x105-3x105 cfu of M. tuberculosis, 
which is a large dose and is administered in a way that does not mimic natural infection; 
therefore, all animals would be expected to generate large positive immune responses.
The advantages of using an in vitro assay as compared to the traditional tuberculin skin 
test are: the ability to repeat tests without interfering with the animal’s immune system; 
less time is required to gain results; a larger range of antigens can be included; and the 
procedure is more comfortable and less invasive to the animals. However, it should be 
noted that a negative in vitro immunological test for TB in primates does not necessarily 
indicate that animals are free of M. tuberculosis. As no “gold-standard” exists for 
diagnosis of TB in macaques, the PRIMAGAM test was used to ensure that to the best of 
knowledge no prior exposure had occurred. In addition, animals were also monitored for 
clinical signs of disease (e.g. weight loss, x-ray, bacteriology), with no indicators of TB 
being found in any of the naive animals.
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3.3.2 Development of the IFN-y ELISPOT assay
3.3.2.1 Assessment of baseline responses
With all of the antigens tested, individual animal-to-animal variation was observed. 
Marked inter-subject variability in homeostatic levels of circulating antigen-specific T 
cells (Comin-Anduix et a l, 2006) means that ideally multiple baseline samples should be 
routinely collected as part of an immunisation schedule (Cox et a l, 2006). Although this 
is not always feasible in routine practice (Comin-Anduix et a l, 2006), for non-human 
primate studies the opportunities do exist to sample routinely before experimental studies 
begin. The differences between animals could be caused by different antigenic 
expression levels due to genetically-based characteristics of antigen processing and 
immune responsiveness in the non-human primates, including different cytokine 
secretion profiles or polymorphisms of human leukocyte antigen (HLA) or cytokine 
receptors (Arend et a l, 2000a).
3.3.2.2 Use of PPD as an antigen
IFN-y ELISPOT assay responses to PPD in naive macaques were generally low (<200 
antigen-specific IFN-y-producing cells/106 PBMC). In humans, baseline levels of PPD- 
specific responses have been reported in 3 unvaccinated, tuberculin skin-test negative 
donors of 13.33-30 IFN-y-producing cells/106 PBMC (Helms et a l, 2000). Though the 
same antigen concentration was used, 10 pg/ml, the source of PPD was different in the 
two studies. The cause of the background response to PPD may be through either cross­
stimulation with non-mycobacterial infection or priming of T cells with an opportunistic
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mycobacterial infection, such as M. avium (Helms et a l, 2000). Given that animals were 
all deemed negative by the PRIMAGAM kit this latter explanation is unlikely.
Both the ELISPOT and PRIMAGAM kit use PPD as antigen, but responses were 
detected in ELISPOT when PRIMAGAM results were negative. It could be that 
differences in methodologies might account for differences in response. Both assays 
measure responses after overnight stimuation; however, the PRIMAGAM uses whole 
blood and measures the concentration secreted, whereas the ELISPOT uses PBMC to 
measure the number of cells secreting IFN-y. Importantly, PPD for the PRIMAGAM 
assay was manufactured from M. bovis whereas the PPD used in the ELISPOT assay was 
derived from M. tuberculosis. Variability might be expected as different batches of PPD 
have been reported to have varying protein concentrations and antigenic profiles (Tameni 
et al, 1998). Alternatively, the concentration of PPD is 10 pg/ml in the ELISPOT assay, 
whereas for the PRIMAGAM the concentration is approximately 85 pg/ml (Prionics AG, 
personal communication). Therefore, it is impractical to compare results from 
PRIMAGAM and ELISPOT assay, despite both using PPD as antigen. It was likely that 
due to the high sensitivity of the ELISPOT assay the responses that the assay detected 
were naturally circulating levels of reactive cells.
As background responses to PPD in the ELISPOT assay were low, and due to this 
antigen containing a variety of mycobacterial antigens, PPD was included as an antigen 
for subsequent ELISPOT assays.
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3.3.2.3 Recombinant proteins
Recombinant ESAT-6  and Ag85B proteins were also tested in the IFN-y ELISPOT 
assay. The advantage of using whole protein antigens was that each antigen could be 
tested in fewer wells. Also, as proteins will need to be processed they may further mimic 
the natural environment. However, soluble protein antigens primarily stimulate CD4+ T 
cells (Gomez et a l, 2004) meaning that CD8+ responses could potentially be missed 
(Tesfa et a l, 2004).
High background responses were observed using these protein antigens. Further analysis 
on cryopreserved cells of nai've animals from different breeding colonies appeared to 
show that repeated skin testing was not the cause. Repeated skin testing in humans and 
the induction of false positive results in IFN-y assays is controversial, with some reports 
saying there is no effect (Richeldi et al, 2006) and other studies showing the opposite 
(Vilaplana et al, 2008). However, as all of the proteins (TB and SIV) produced in E. coli 
showed high levels of IFN-y-producing cells, whereas the baculovirus-derived protein 
did not, the expression vector seemed the probable cause of this response in nai’ve 
macaques.
The cause of the increased frequency of IFN-y-producing cells might be due to endotoxin 
contamination of the protein preparations. This lipopolysaccharide (LPS) component of 
the outer cell membrane of E. coli (and other Gram negative organisms) has a large 
number of deleterious biological activities (Fraser, 1982), and is active in nanogram 
amounts (Ozaki et a l, 1989). With their multiple potent effects on biological systems, 
endotoxins represent a possible source of variability in experimental biology and 
pathology (Fumarola, 1981). Therefore, to prevent experimental artefacts in biological
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assays it is crucial to remove or at least significantly reduce LPS levels in protein 
preparations (Salek-Ardakani et a l, 2002). The use of Gram positive organisms, such as 
Bacillus subtilis and various Streptomyces species as host organisms, may help to 
overcome the problem with endotoxin (Fraser, 1982).
Recombinant ESAT-6  has been used in immunological assays after depletion of residual 
endotoxin through an LPS affinity column (Arend et a l, 2000b) or by producing ESAT- 
6  in other vectors, such as Lactococcus lactis (Ewer et a l, 2003). Alternatively, 
polymixin B, a potent antibiotic that binds to and neutralises LPS, has been utilised so 
that E. coli produced recombinant proteins can be used in cytokine assays (Cardoso et 
al, 2007). The proteins in the above example were contaminated with 0.132-0.210 ng/ml 
LPS (Cardoso et al, 2007). The level of endotoxin in the rESAT-6  preparation used in 
the ELISPOT assay in the current study was 456 ng/ml. The endotoxin level of the 
rAg85B protein preparation was not available. Other investigators have also had 
concerns with E. coli preparations and have instead investigated the baculovirus 
expression system (Williams et a l, 1998).
Soluble protein antigens have been used before for different pathogens. In primate 
studies against Leishmania major, soluble Leishmania antigen was used and gave 
background responses of <15 spots/106 cells (Freidag et a l, 2003). In humans, 
recombinant protein of tick-bome encephalitis virus has been used as a neoantigen, with 
background responses of under 300 spots per million cells (Gomez et a l, 2004), though 
the PBMCs were stimulated with protein for 3 days before being transferred to ELISPOT 
plates for assaying.
For future experiments, peptides were assessed in place of recombinant proteins. This
was partly to overcome the problems encountered with the increased background
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responses, but mainly due to peptides being used in parallel human studies conducted in 
Oxford. By using the same antigen preparations, responses would then be comparable 
between human responses and those detected in macaques reported in this thesis.
3.3.2.4 Peptide antigens
Peptides have the advantage over whole protein in that instead of biasing towards CD4+ 
T cells, they are also capable of inducing CD8+ T cell responses (Freidag et a l , 2003). 
As they do not require internal processing an overnight incubation is usually sufficient to 
allow direct binding to MHC molecules on the surface of cells (Mashishi & Gray, 2002), 
with no advantage to using longer incubation times up to 48 h (Kumar et a l , 2001; 
Russell et a l, 2003).
The length of peptides can vary. Peptides of 8-12 amino acids (aa) produce the highest 
levels of CD8+ responses, 20 aa peptides bias more towards the CD4+ subset, and 15 aa 
peptides are effective with both CD4+ and CD8+ T cells (Maecker et a l, 2001). Although 
15 aa peptides should be too long to properly fit into the MHC class I binding groove the 
investigators suggested that: (1) it is possible that 15mers bound to some degree without 
properly fitting into the binding groove; (2 ) the peptides were shortened by extracellular 
proteases; (3) the peptides were actually internalised and processed prior to binding to 
class I MHC; and (4) synthesised intermediates consisting of shorter peptides that 
contaminate the final peptide preparation might be responsible (Maecker et a l, 2001). 
Therefore, length of peptides is determined by which responses are to be detected and 
other practicalities; for example, the use of 15 aa peptides is a balance between testing a 
feasible number of peptides and detecting both CD4+ and CD8+ responses (Maecker et 
al, 2001; Mashishi & Gray, 2002; Mwau et a l, 2002). Additionally, using 15 aa
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peptides has shown over 50% increases in frequencies of IFN-y-producing cells 
compared to 20mers, suggesting that 15mers increase the ability to detect low-level 
responses (Russell et a l, 2003), likely to be due to more efficient presentation via the 
MHC molecule due to the smaller size.
We used pools of 15mer peptides to measure responses to Ag85A, CFP10 and ESAT-6 . 
As both the protein and peptides for ESAT-6  were available it was possible to make a 
direct comparison with the two antigen preparations. A 62% reduction in background 
response was seen using the peptides, most likely due to the absence of endotoxin in the 
peptide preparations. Peptide pools to CFP10 and ESAT-6  have been used by other 
investigators and shown to give similar results as whole proteins in proliferation and 
PBMC-stimulated ELISA assays (Arend et al, 2000b), although in this example peptides 
were 20 aa in length. However, the same observation has also been reported for 15 aa 
peptides using ICS analysis (Maecker et al, 2001). Therefore, the use of peptides can 
mirror responses seen when using protein preparations.
The background responses to the peptide pools for CFP10, ESAT-6  and Ag85A were 
low with <331, <284 and <450 (except one animal, where the baseline response was 
1450) IFN-y-secreting cells/106 PBMC, respectively. When peptides of 9-10 aa in length 
have been used in cancer patients specific for melanoma, cytomegalovirus and Epstein- 
Barr virus, the detection limit has been reported to be 70 IFN-y spots per million PBMC 
(Comin-Anduix et a l, 2006). However, in that study primed antigen-presenting cells 
were added to PBMC so the assay was not conducted in the same way as described for 
the macaque studies. When 20 aa malarial peptides were used, background counts have 
been reported in the range of 10-50 IFN-y spots/106 PBMC in rhesus macaques (Kumar 
et a l, 2001). The background responses with the TB peptides in macaques are higher
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than those reported in the studies described above. The difference with the human study 
could be due to the species, with macaques having intrinsically higher background levels 
of responding cells. Alternatively, differences in peptides may be the cause, possibly due 
to cross-reactive antigenic regions on the peptides causing an increased baseline 
response. There have been examples where peptides have given high background 
responses, but this was due to incomplete dissolving of peptide causing a reaction with 
the avidin component of the detection system (Karlsson et a l, 2004). To overcome this 
phenomenon, we dissolved peptide stocks in DMSO before further diluting them out in 
tissue culture medium. The final DMSO concentration was always kept below 1% to 
avoid cellular toxicity (Russell et al., 2003).
3.3.2.5 Positive controls
For the IFN-y ELISPOT assay we used PMA and ionomycin as a positive control. The 
use of this type of control confirms that the assay was performed correctly (Currier et al., 
2002) by controlling the staining procedure (Mashishi & Gray, 2002). PHA has also been 
used as a mitogen in the ELISPOT assay. As with PMA and ionomycin, the spots after 
stimulation with PHA vary widely in size, intensity and shape; and due to the high spot 
number per well, they can also reach confluence (Currier et al., 2002; Janetzki et al., 
2004). These mitogens typically induce the secretion of cytokine from more than one 
subset of cells, using mechanisms other than antigen recognition (Janetzki et al., 2004). 
After 4 h stimulation with PMA and ionomycin, the frequency of IFN-y-producing cells 
rises from <1% to 12%, reaching 19% by 12 h (Rostaing et al., 1999). Stimulation with 
mitogen indicated that the cells were viable, and if responses were to be quantified the 
input cell number would need to be decreased compared with the rest of the assay plate 
(Mwau et al., 2002).
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Additional controls that are relevant to antigen presentation have been used in human 
studies, including pools of peptides from cytomegalovirus, Epstein Barr and influenza 
virus (CEF pool) recognised by CD8+ T cells and presented by 11 class I HLA-A and 
HLA-B alleles whose cumulative frequencies represent the majority of Caucasian 
individuals (Currier et al., 2002). The CEF pool produced spots that were comparable 
with experimental results, thus providing a standard for spot definition, especially when 
using an automated reader system (Janetzki et al., 2004). However, these peptides are 
human HLA-specific and a non-human primate alternative was not available.
3.3.2.6 Enhancement of the ELISPOT assay
Cells can be cultured and stimulated with antigen prior to analysing them in the 
ELISPOT assay in order to determine lower frequencies of cytokine-secreting cells. 
Seven day culturing has been used to detect low-level responses in multiple sclerosis 
patients (McCutcheon et al., 1997). Others have cultured for ten days to detect longer- 
lived memory T cells in malaria-vaccinated volunteers (Keating et al., 2005) and for pre­
screening of mycobacterial responses before entering vaccine studies (McShane et al., 
2004). For our IFN-y ELISPOT assay we wanted to directly detect ex vivo responses to 
determine as close as possible the in vivo response without altering the kinetics of the 
cell populations by prior incubation and stimulation. Therefore, the overnight assays 
would represent IFN-y production by differentiated T cells (Sirriyah et al., 2004).
After development, plates were counted with an automated ELISPOT reader by the same 
operator. This eliminates discrepancy between individual operators, which has been 
shown to vary considerably (Ryan et al., 2005), especially in wells containing higher
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numbers of spots (Janetzki et al, 2004). Although counting plates using the computer 
settings has proved to be the least variable method of plate counting (Janetzki et al, 
2004), the presence of artefacts and non-inclusion of some of the spots made it necessary 
to revisit each well to confirm results, as also recommended by others (Mwau et al, 
2 0 0 2 ).
3.3.2.7 Defining the cut-off value for the IFN-y ELISPOT
Results gained from the analysis undertaken in naive rhesus and cynomolgus macaques 
showed that baseline responses varied. Therefore, defining a constant cut-off value 
specific for the particular macaque species may obscure positive responses from being 
recorded in animals with low backgrounds or result in false positive results. Instead, an 
individual cut-off for each animal would need to be defined.
Where serial baseline measurements were recorded, mean values and 95% Cl were 
calculated. From these results, it was seen that the upper 95% Cl never exceeded the 
mean baseline value by more than threefold. It was decided that the cut-off value for all 
subsequent experiments would be 3 times the value of the average pre-bleed. This would 
be particularly relevant where responses were low, giving increased confidence that 
responses were “real” and not merely naturally fluctuating baseline levels.
Others who use similar methodologies in human studies have used a cut-off defined of 
being at least twice that of negative control wells and above 5 (Beveridge et a l, 2008) or 
30 (Brookes et a l, 2008) spot-forming units/106 cells. Alternatively, a cut-off of 17 spot- 
forming units/106 PBMC has been applied to ELISPOT studies in human trials 
(Hawkridge et al, 2008).
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3.3.3 Development of the whole blood IFN-y ELISA assay
To eliminate discrepancies between the ELISA and ELISPOT assays, the same antibody 
pairs were used to measure IFN-y. The coating antibody clone GZ-4 and detector 
antibody clone 7-B6-1 have been recommended as being optimal for non-human primate 
IFN-y samples (Lazarevic et al., 2005b; Makitalo et al, 2002).
The ELISA assays used supernatants prepared from whole blood or PBMC. Whole blood 
is deemed to be the best medium in which to study cytokine production (De Groote et 
al, 1992). IFN-y ELISA results are also comparable if blood processing is delayed, 
although sensitivity does decrease after periods as short as 2 h (Doherty et a l, 2005). 
The whole blood assays were carried out soon after collection of samples, thus ensuring 
the minimal effect of any time delay.
As the diluted whole blood ELISA assay is being used in human clinical trials, the assays 
used in macaques were as similar as possible so that results would be comparable. The 
only optimisation carried out was to increase the incubation time of the sample in the 
ELISA assay from two hours at room temperature to overnight at 2-8°C. The presence of 
various binding proteins and other factors in plasma/serum may interfere with antibody 
binding (Prabhakar et a l, 2002) so the time was increased to allow for all of the 
available IFN-y to bind to the detector antibody. This proved not to affect results from 
the recombinant standards giving confidence that the assay was not compromised by 
increasing the time from 2 h at room temperature to overnight at 4 °C (appendix 2, 
section 8 .2 ).
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Background levels of IFN-y production after PPD stimulation in naive macaques was 
always below 100 pg/ml. The same was true when using BCG as an antigen, with the 
exception of one animal where the level was «120 pg/ml. Therefore, a cut-off limit for 
defining a positive IFN-y ELISA response was set at 100 pg/ml. Studies conducted in 
humans have defined a positive responses as being greater than 62 pg/ml (Beveridge et 
a l , 2008; Black et a l , 2001; Weir et a l , 2008).
3.4 CONCLUSION
Using a large cohort of naive macaques, variation in responses was seen in individual 
animals of both species. Cut-off values were used to define a positive response 
(ELISPOT: >3 times the mean pre-bleed values; ELISA: >100 pg/ml), which allows a 
reproducible and standardised criteria to permit IFN-y responses to be measured post­
infection with M. tuberculosis (chapter 4) and after vaccination with BCG and other TB 
vaccines (chapter 5).
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4 IFN-y r e s p o n s e s  d u r in g  at. t u b e r c u l o s i s  i n f e c t i o n
4.1 INTRODUCTION
The dynamics of the immune response were studied in macaques following aerosol 
infection prior to investigating immune responses after vaccination. For newly developed 
TB vaccines, the probability of success could be significantly enhanced through a better 
understanding of the main steps in the pathogenic pathways to bacillary pulmonary TB 
(Wiegeshaus et a l , 1989). Therefore, the main objective of the work described in this 
chapter was to monitor and analyse IFN-y responses post-infection with M. tuberculosis 
to identify the role of IFN-y in the disease process.
4.1.1 Human studies of M. tuberculosis infection
Data on immune responses during the early stages of M. tuberculosis infection in 
humans are rarely available. This is because most reports of immune responses are 
undertaken in patients with advance stages of disease, and also the time since exposure is 
usually not known.
There are two documented studies where the time since exposure was known. One 
involved an accident in a microbiological laboratory where technicians were potentially 
exposed to M. tuberculosis (Leyten et a l , 2006). However, in the two individuals who 
converted to being tuberculin skin test (TST) positive, one was BCG vaccinated. This 
therefore does not reflect a nai’ve individual. The first samples from both individuals 
were taken 4 months after the accidental exposure and both had been treated with an 
antimycobacterial drug. In a second study, a large point-source TB outbreak at a school
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in the UK was described, where the prolonged infectious period of the cases was known 
(Ewer et a l , 2006). This presented a unique opportunity to track M. tuberculosis-specific 
T-cell responses longitudinally in a cohort of contacts recently exposed to the same strain 
of M. tuberculosis (Ewer et a l, 2006). In this study, 11 staff were monitored who did not 
receive antimycobacterial treatment and became TST-positive during the 18 month 
follow-up period; these latently-infected subjects had continual levels of circulating 
RD1-specific IFN-y-secreting cells.
Due to the lack of information on early immune responses after M. tuberculosis infection 
in humans, the non-human primate model provides an unique opportunity to measure 
temporal changes in immune dynamics during the early stages of disease in animals that 
very closely resemble humans in anatomy and physiology.
4.1.2 Aerosol challenge of non-human primates
The ideal challenge route for animal models should mimic the situation in human 
infection. Therefore, the best available option in studying TB infection requires 
aerosolisation of M. tuberculosis. Macaques challenged with a few airborne organisms 
accurately reflects infection in humans under natural conditions (Barclay et a l, 1970). 
Using the aerosol route with very small numbers of bacilli produces a limited, but not 
overwhelming disease (Barclay et a l, 1973).
Many researchers using non-human primates have used bronchoscopes to instill M
tuberculosis into the lung airways in rhesus macaques (Good, 1968; Gormus et a l, 2004;
Langermans et al, 2001; Schmidt, 1972) and cynomolgus macaques (Capuano et al,
2003; Flynn et a l, 2003; Fuller et a l, 2003; Langermans et a l, 2001; Langermans et a l,
2005; Walsh et al, 1996). Instillation of M. tuberculosis via bronchoscope is usually
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performed on one lung, thereby not giving an even distribution of bacilli as occurs via 
delivery through respiratory inhalation. Additionally, using this challenge method, the 
bacilli may not reach into the alveolar macrophages as occurs in natural infection.
As alveolar macrophages are primarily found in the alveoli, to reach these levels deep in 
the lung the bacterial suspension needs to be effectively inhaled. In the early 1970s 
researchers used aerosol infection of rhesus macaques (Anacker et a l , 1972; Barclay et 
a l , 1970; Barclay et a l , 1973; Janicki et a l , 1973), but in-depth immunological analyses 
were not performed in these studies. If the bacteria do not reach the alveolar 
macrophages, then it is likely that other macrophages or dendritic cells (DC) will present 
antigen. DCs are found widely within the bronchopulmonary tree in both humans and 
mice (Sertl et a l , 1986). However, even though aerosolised bacilli will reach the alveolar 
macrophages, DCs still reside in the lung and may still be among the first cells to 
encounter the mycobacteria upon infection (Henderson et a l , 1997). Therefore, 
stimulating both DCs and alveolar macrophages will mimic human infection and allow 
for the induction of relevant cytokine immune responses (Fenton & Vermeulen, 1996; 
Serbina & Flynn, 1999).
Recent reports looking at immune responses in rhesus macaques during the early course 
of infection have shown that IFN-y-secreting cells are detected in PBMC by 2 months 
post-infection (Lewinsohn et a l , 2006), whereas in cynomolgus macaques responses are 
seen 2 weeks after infection (Lin et a l , 2006). However, the rhesus macaques were 
challenged with 1000 cfu of strain H37Rv whereas the cynomolgus macaques received 
25 cfu of Erdman strain; both studies delivered the challenge strain by intratracheal 
instillation. Additionally, different antigens were used to stimulate the cells in the two 
studies, so the results are not directly comparable. To date, a time-course of IFN-y
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production during early TB disease has not been undertaken simultaneously in rhesus 
macaques and cynomolgus macaques.
For macaque experiments at the Centre for Emergency Preparedness and Response 
(CEPR), the dose that the animals received was calculated by the aerobiologist using 
values from the stock suspension used to generate the aerosol, the amount of bacilli 
circulating, and the volume of respiration of the animals. The apparatus used to challenge 
macaques is shown in figure 4.1.
-154-
Henderson equipment contained within a class 
III microbiological safety cabinet. M. 
tuberculosis suspension is aerosolised in a 
nebuliser and then circulated into the airflow.
Control unit controls the humidity 
and the compressed air flow to the 
nebuliser.
......
Macaques housed within an airtight chamber so that changes in air volume can be monitored. 
The computer provides information on lung volumes, respiration rates, and most importantly, 
amount of air inhaled. Aerosolised M. tuberculosis is given through an adapted mask.
Figure 4.1: Equipment used for challenging macaques with aerosolised M. tuberculosis.
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In M. tuberculosis-infected macaques at CEPR, magnetic resonance imaging (MRI) was 
carried out on lungs removed at necropsy, in order to assess the distribution of the 
aerosol-delivered challenge dose. This approach has been carried out previously on 
guinea pigs; the results obtained indicated that lung lesions could be clearly visualised 
and that the application of three-dimensional stacking software could be utilised to give a 
reconstructed view of the whole-organ lesion distribution (Kraft et al., 2004). These 
observations were repeated in the macaque lungs and demonstrated an extremely even 
distribution of lesions throughout both lungs (figure 4.2), thus supporting aerosol 
infection of macaques with M. tuberculosis.
Figure 4.2: MRI image of lungs from a cynomolgus macaque 13 weeks after infection 
with aerosolised M. tuberculosis.
(Animal ID: 9909187. Visible granulomas are seen as white areas, examples shown with 
green arrows, spread throughout both lungs.)
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4.1.3 Study aims
The main aims of the work described in this chapter are:
1) To determine IFN-y responses post-challenge with aerosol-delivered M. 
tuberculosis in two non-human primate species (rhesus macaque and cynomolgus 
macaque).
2) To determine if there are any differences in IFN-y dynamics between the two 
macaque species.
3) To assess whether the frequency of IFN-y-secreting cells correlated with the 
amount of IFN-y secreted.
4) To analyse whether IFN-y measurements provide an indication of outcome or 
disease severity.
4.1.4 Chapter methods
In the challenge experiments, nine rhesus macaques and twelve cynomolgus macaques 
were infected with M. tuberculosis. The estimated mean doses given are shown in table 
4.1.
Estimated retained dose
Rhesus macaques Cynomolgus macaques
1st challenge study 30 cfu
(except D53, 500 cfu)
30 cfu
2nd challenge study 40 cfu
(except D19, 70 cfu)
40 cfu
3rd challenge study 45 cfu
(except D12, 75 cfu)
40 cfu
4th challenge study - 75 cfu
Table 4.1: Challenge dose used in M. tuberculosis infection studies
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Blood samples were taken from these animals before challenge to determine baseline 
levels of IFN-y production, and then at 1, 2, 4, 6 , 8 , 10, and 12 weeks after challenge 
with M. tuberculosis (section 2.1.3.1).
The frequency of antigen-specific IFN-y secreting cells was measured using the 
ELISPOT method (section 2.2.6) and the concentration of IFN-y secreted after antigenic 
stimulation was measured using the ELISA method (section 2.2.7). Other cytokines were 
also measured in some of the M. tuberculosis infected animals using ELISA assays for 
IL-10 and IL-12 (section 22.1.22) and luminex analysis for TNF-a, IL-ip, IL-2 and IL- 
6 (section 2.2.12).
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4.2 RESULTS
4.2.1 Enumeration of IFN-y-secreting cells
4.2.1.1 Frequency of antigen-specific IFN-y-secreting cells post M. tuberculosis 
challenge
Throughout the course of M. tuberculosis infection, the frequency of antigen-specific 
IFN-y-secreting cells was monitored. During the 12-week study period post-challenge, 
four rhesus macaques (D12, D19, D28 and D53) were euthanised before experiment 
completion as they met humane clinical endpoints (e.g. 2 0 % weight loss from maximum 
weight or showing signs of malaise). All cynomolgus macaques survived the duration of 
the study.
Following aerosol challenge with M. tuberculosis, the frequency of IFN-y-secreting cells 
produced after ex vivo stimulation with PPD was measured in rhesus macaques (figure 
4.3) and cynomolgus macaques (figure 4.4). As animals received different doses of M 
tuberculosis, animals were grouped on the graphs according to their estimated dose. In 
both rhesus macaques and cynomolgus macaques, no apparent changes in the frequency 
of IFN-y secreting cells could be related to differences in the dose of challenge. 
However, in the cynomolgus macaques challenged with a higher dose of 75 cfu, PPD- 
specific IFN-y responses initially showed a peak at week 6 compared to week 4 in 
animals challenged with 40 cfu. As only PPD responses were measured at this time- 
point, it is not known whether responses to Ag85A, CFP10 or ESAT-6  peptide were also 
increased at this time.
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Responses to all of the antigens (PPD and peptide pools to Ag85A, CFP10 and ESAT-6) 
were observed in the M tuberculosis-challenged macaques during the 12 week study 
period with all animals making a response to at least one of the antigens tested. Increases 
in IFN-y secreting cells were detected by 4 weeks post-infection, with few responses 
seen before this time-point.
-160-
— D53 (500 cfu)
  D12 (75 cfu)
—»— D19 (70 cfu) 
——  D80 (30 cfu) 
— D31 (30 cfu) 
— C54 (40 cfu)
  D60 (40 cfu)
—r — D42 (40 cfu) 
D28 (40 cfu)
PPD
6 0 0 0
o
4 0 0 0  -
CO
CL
COO
2000 •jo
Q)OCOc 0 J-ioi— P re  0  1 2  3  4  5  6  7  8  9  1 0  11 1 2o
Ag85A
6 0 0 0
4 0 0 0  -
2000 -
P re  0  1 2  3  4  5  6  7  8  9  1 0  11 1 2
CD
E
CFP10 ESAT-6CO
Z  6 0 0 0  - 
LL
6 0 0 0  ■
c  4 0 0 0  - 4 0 0 0  -
c r
LL
2000 - 2000 -
P re  0  1 2  3  4  5  6  7  8 9  1 0  11 1 2 P re  0  1 2  3  4  5  6  7  8  9  1 0  11 1 2
W eek s post-ch allenge
Figure 4.3: Frequency of antigen-specific IFN-y-secreting cells following aerosol 
challenge with M. tuberculosis in rhesus macaques over the defined cut-off value. 
(Cut-off defined as 3 times the mean value of pre-bleed counts. Coloured lines grouped 
according to estimated dose: red, >500 cfu; blue, >70 cfu; and green, <50 cfu).
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Figure 4.4: Frequency of antigen-specific IFN-y-secreting cells following aerosol 
challenge with M. tuberculosis in cynomolgus macaques over the defined cut-off value. 
(Cut-off defined as 3 times the mean value of pre-bleed counts. Coloured lines grouped 
according to estimated dose: blue, >70 cfu; and green, <50 cfu).
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4.2.1.2 Comparison of post-M tuberculosis challenge responses between rhesus
macaques and cynomolgus macaques
To determine whether there were any differences in frequencies of IFN-y secreting cells 
after M. tuberculosis infection between rhesus macaques and cynomolgus macaques, a 
comparison was made between the two species (figure 4.5).
Using the Mann-Whitney statistical test, the differences in frequencies o f IFN-y-secreting 
cells between rhesus macaques and cynomolgus macaques were statistically significant 
(P<0.05) for PPD at 4, 6, and 10 weeks post-infection. For the peptide pools, significant 
differences were observed at 4, 6, 8 and 10 weeks post-infection. Results are summarised 
in table 4.2 and show that there are statistically significantly lower frequencies of 
antigen-specific IFN-y-secreting cells in the cynomolgus macaques as compared to the 
rhesus macaques.
Mann-Whitney 
statistical p-value
Weeks post M. tuberculosis infection
1 week 2 weeks 4 weeks 6 weeks 8 weeks 10weeks
12
weeks
PPD 0.6588 0.1098 0.0302 0.0049 0.0820 0.0046 0.0651
Ag85A 1 .0 0 0 0 0.2893 0.0081 0.0081 0.0164 0.0230 0.1709
CFP10 0.1939 0.7285 0.0116 0.0149 0.0234 0.0094 0.0234
ESAT-6 0.3538 0.1658 0.0077 0.0262 0.0234 0.0157 0.1425
Table 4.2: Statistical analysis comparing responses in rhesus macaques against those 
detected in cynomolgus macaques for the different antigen preparations tested.
(Mann-Whitney test, green boxes show significant values where P<0.05).
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Figure 4.5: Comparison of median frequencies of IFN-y secreting cells post-M 
tuberculosis challenge in rhesus macaques and cynomolgus macaques.
(Red lines, rhesus macaques; green lines, cynomolgus macaques. Error bars denote 
interquartile range of samples).
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4.2.1.3 Comparison between rapid progressors and 12 week survivors
From the nine rhesus macaques challenged with M. tuberculosis, four animals were 
terminated before the end of the planned 12 week study period. These animals were 
necropsied at week 5 (animal D19), week 6  (D28 and D12) and week 7 (D53) post­
infection. As these animals met humane clinical endpoints it was clear that they had a 
more rapid progression to disease than those that survived the 12-week post-challenge 
study endpoint.
The frequency of IFN-y-secreting cells between the 12-week survivors and the rapid 
progressors were plotted and compared (figure 4.6). Statistical analysis (table 4.3) 
showed that there were no significant differences between the frequencies of IFN-y- 
secreting cells in animals that succumbed to rapid clinical disease and those that survived 
the 12 week study period.
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Figure 4.6: Comparison of median frequencies of IFN-y-secreting cells in animals which 
survived the 12-week study period and those which were necropsied prior to the end of 
the study.
(12 week survivors, green lines; rapid progressors, red lines. Error bars denote 
interquartile range of samples).
Mann-Whitney 
statistical p-value
Week 1 Week 2 Week 4 Week 6
PPD 0.9025 1 .0 0 0 0 0.5403 0.8465
Ag85A 0.5403 * 0.7133 0.0814
CFP10 * * 0.7133 0.5613
ESAT-6 * 0.5403 0.9025 0.5613
Table 4.3: Statistical test results comparing 12-week survivors against rapid disease 
progressors.
(Mann-Whitney test, significance confirmed if P<0.05; *, insufficient data to perform 
Mann-Whitney statistical test).
-166-
4.2.1.4 Responses to individual peptide pools post-M tuberculosis challenge
Previous results for CFP10, ESAT-6  and Ag85A are shown as summed responses from 
multiple peptide pools for each of the antigens. For Ag85A the peptides are divided into 
7 pools, and for CFP10 and ESAT-6  they are divided into 3 pools each.
The responses to each of the peptide pools of each of the antigens were plotted, in order 
to get an indication of whether any of the pools contained promiscuous epitopes 
recognised by several of the infected macaques (figures 4.7, 4.8 and 4.9). In addition, it 
may also indicate whether the immune response targets different parts of the antigen 
during the 12-13 week infection period.
CFP10 peptide pools 2 and 3 were dominant in both the rhesus macaques and 
cynomolgus macaques, with the exceptions of animals D12, 109181 and 1163 where 
peptide pool 1 gave the highest responses. For ESAT-6 , pool 1 gave the highest 
frequencies of IFN-y-secreting cells in 7 of the 9 rhesus macaques (78%) and pool 3 gave 
the largest responses in 6 of the 9 cynomolgus macaques (67%).
Unlike the CFP10 and ESAT-6  peptide pools, where sequential peptides are in each of 
the pools (e.g. peptides 1-5 are in pool 1, 6-10 in pool 2, and 11-15 in pool 3), peptides 
for Ag85A are dispersed non-sequentially (e.g. pool A contains peptides 1,6, 15, 20, 29, 
34, 43, 48, 57 and 64). This method was chosen to emulate the work carried out in 
human clinical trials, where epitope screening is more efficient if peptides are not 
sequential. Results show that pools A, D and E are the most immunogenic in the rhesus 
macaques and cynomolgus macaques. Interestingly, pool D of Ag85A induced a 
response in all of the animals except in one cynomolgus macaque (9909013).
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Each animal displayed a similar profile of antigen-recognition throughout the duration of 
the experiment post-challenge. Where a peptide pool gave a high response, this 
continued throughout the period of study. Likewise, pools which gave low responses 
appeared to do so at each time point tested.
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Figure 4.7: Responses by rhesus and cynomolgus macaques to CFP10 peptide pools
post-challenge with M. tuberculosis.
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Figure 4.8: Responses by rhesus and cynomolgus macaques to ESAT-6 peptide pools
post-challenge with M. tuberculosis.
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Figure 4.9: Responses by rhesus and cynomolgus macaques to Ag85A peptide pools
post-challenge with M. tuberculosis.
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4.2.1.5 Local IFN-y responses in M. tuberculosis-challQnQQd macaques
At the end of the experimental studies all animals were euthanised and necropsies 
performed, unless they showed advanced symptoms beforehand in which case they were 
terminated and necropsied for ethical reasons as soon as possible.
During post-mortem examination, samples were taken from the spleen, hilar lymph 
nodes and axillary lymph nodes for analysis of IFN-y-secreting cells. Results from the 
rhesus macaques and cynomolgus macaques are shown in figures 4.10 and 4.11, 
respectively.
Rhesus macaques had similar frequencies of IFN-y-secreting cells in the PBMC, spleen 
and hilar lymph node. Lower responses were detected in the axillary lymph nodes.
In the nine cynomolgus macaques the same observations were seen as with the rhesus 
macaques, with frequencies in the axillary lymph nodes being lower than that of the 
other tissues.
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Figure 4.10: Frequencies of IFN-y-secreting cells in local tissues taken at post-mortem of 
M. tuberculosis challenged rhesus macaques.
(Dashed line indicates a reference value of 2000 IFN-y-secreting cells/106 PBMC; ND, 
not done).
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Figure 4.11: Frequencies of IFN-y-secreting cells in local tissues taken at post-mortem of 
M  tuberculosis challenged cynomolgus macaques.
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done; *, Ag85A responses not measured).
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Statistical correlation analyses was performed to determine whether local responses 
corresponded to severity of disease. The lesion:lung volume ratios were used to compare 
disease severity in the macaque models. This is a ratio of the volumes of the lesions 
compared to the total lung volume, and was measured by special software analysis of 
MRI scans (performed by Dr R. Basaraba). Data from 9 rhesus macaques and 9 
cynomolgus macaques were compared, as lesion:lung volume ratios from animals in the 
4th challenge study (0111231, 0201011 and 0201191) were not available.
In rhesus macaques, higher frequencies of Ag85A- and ESAT-6 -specific IFN-y secreting 
cells in the spleen correlated with increased lesiondung volume ratios (figure 4.12). In 
the cynomolgus macaques, however, no antigen-specific responses in the PBMC 
correlated with disease severity in the lungs (figure 4.13).
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Figure 4.12: Comparison of disease severity with frequencies of IFN-y-producing cells at 
local sites sampled at post-mortem in rhesus macaques.
(P-values represent significance levels of Spearman’s rank correlation analysis).
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Figure 4.13: Comparison of disease severity with frequencies of IFN-y-producing cells at 
local sites sampled at post-mortem in cynomolgus macaques.
(No values were significantly correlated using Spearman’s rank correlation analysis).
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4.2.1.6 Responding T-cell subsets of IFN-y-secreting cells
At post-mortem, an increased volume of blood collection meant that more PBMC were 
available, thus allowing the depletion of CD4+ and CD8+ T-cell subsets to be carried out. 
By removing these subsets, their contribution to the IFN-y response could be assessed. In 
each assay the same input number of cells were assayed in the ELISPOT experiments; 
therefore, data were not adjusted to take into account the relevant contribution of 
removed cells compared to unaltered PBMC preparations.
Results are shown as the percentage of response in the depleted populations compared to 
those detected in untreated PBMCs (figure 4.14). Responses were not measured in all of 
the M. tuberculosis-challenge animals, due to variations in cell yield and practical 
considerations. In most animals, the CD8-depleted preparations gave responses greater 
or equal to undepleted PBMC, indicating that removing the CD8+ population did not 
contribute to the frequencies of IFN-y-secreting cells. In contrast, when CD4+ cells were 
removed, many of the responses declined thereby confirming that the primary cell subset 
producing IFN-y at this time was CD4+ T cells.
Although most animals showed mainly CD4+ IFN-y responses, there were two animals 
(rhesus macaque D19 and cynomolgus macaque 2151) that showed a bias towards CD8+ 
IFN-y production. This was to all of the peptides tested in both animals, although in 
animal 2151 only one peptide preparation was used. However, the PPD-induced IFN-y 
responses did not show such bias towards CD8+ cells.
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4.2.1.7 Frequencies of IFN-y-secreting cells across 12 weeks post-infection
When looking at responses post-challenge (figures 4.3 and 4.4), data from individual 
animals were displayed according to antigen stimulation. In some antigen-specific 
responses, a decline in response was observed at weeks 6 -8 . To investigate this further, 
responses from each individual animal that survived the 12-week post-challenge study 
period were plotted individually (figure 4.15), thus excluding the 4 rhesus macaques 
which met humane clinical endpoints mid-study.
Intriguingly, in the majority of both the rhesus and cynomolgus macaques there was a 
decline in response at weeks 6-8  post-challenge with M. tuberculosis. When there was a 
decline in response it was seen with all of the antigens tested, suggesting that this was a 
generic response not limited to certain antigen preparations.
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4.2.2 Concentrations of IFN-y produced in peripheral cells from M. tuberculosis-
challenged macaques
4.2.2.1 Responses after 6 days of diluted whole blood stimulation
In line with human studies (Black et al, 2001; Black et al, 2003; Black et a l , 2002), the 
amount of IFN-y secreted after 1:10 diluted whole blood had been stimulated for 6 days 
with PPD or BCG was measured. This assay was carried out in samples taken from 
animals in the first challenge study. Results for both antigens are shown in figure 4.16, 
with all animals showing responses above the cut-off value of 100  pg/ml for this assay.
IFN-y was first detected in the supernatants 6  weeks after challenge with M. tuberculosis. 
The amount of IFN-y secreted in the rhesus macaques was similar with both antigens 
tested: PPD and BCG. However, in the cynomolgus macaques, 2 of the animals secreted 
more IFN-y in response to simulation with PPD than with BCG.
There was a significant correlation in the IFN-y concentrations secreted after stimulation 
with PPD and BCG (Spearman’s rank correlation: rhesus macaques, rs=0.842, P0.001; 
cynomolgus macaques, rs=0.859, P0.001). As both antigens gave comparable profiles, 
and PPD is used for stimulation in the ELISPOT assay, for future experiments only PPD 
responses were monitored in the whole blood ELISA assay.
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Figure 4.16: Concentrations of IFN-y secreted after 6 days incubation of diluted whole 
blood in rhesus macaques and cynomolgus macaques challenged with M  tuberculosis. 
(PPD-stimulated, red line; BCG-stimulated, green line).
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As PPD antigen was used to measure both the concentration of IFN-y secreted and the 
frequency of IFN-y-secreting cells, a comparison was made between the two assays. 
Results are shown in figure 4.17. The data show that the two responses are not 
comparable, as the peaks in the frequency of IFN-y-secreting cells do not often occur at 
the same times as the peaks in the concentration of IFN-y secreted. Statistical analysis 
confirmed that the two assays were not correlated (Spearman’s rank correlation 
coefficient: rhesus macaques, rs=0.375, P=0.125; cynomolgus macaques, rs=0.372, 
P=0.106).
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Figure 4.17: Comparison between the frequency of PPD-specific IFN-y-secreting and the 
amount of IFN-y secreted in diluted blood after 6 days of stimulation with PPD. 
(Frequency of cells, blue line; concentration secreted, green line).
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4.2.2.2 Responses after 24 hours of diluted whole blood stimulation
To determine whether the differences in response seen between the frequency of IFN-y- 
secreting cells and the amount of secreted IFN-y in 6 day whole blood supernatants was 
due to the length of stimulation, a different approach was taken with a group of M 
/w&ercw/asA-challenged macaques. As the increased stimulation of 6 days in the whole 
blood assay may allow an amplification of responding cells, or the ability for more cell 
subsets to contribute to IFN-y secretion, the time of stimulation in both assays was made 
identical. Diluted whole blood was stimulated overnight, in parallel with the IFN-y 
ELISPOT assay, and concentrations of IFN-y in the supernatants assessed by ELISA.
Results from these experiments are shown in figure 4.18. Responses in both assays start 
being detected at 4 weeks post-challenge with M. tuberculosis. It was noticed that there 
were comparable trends in the data, and this was confirmed by the data being statistically 
correlated (Spearman’s rank correlation coefficient: rhesus macaques, rs=0.764, P=0.001; 
cynomolgus macaques, rs=0.831, P<0.001). However, the sample size (n=3 from each 
macaque species) remains small.
Therefore, results between the ELISPOT and whole blood ELISA assay are comparable 
when both are incubated overnight.
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4.2.2.3 Responses after 3 days of PBMC stimulation
To align data with other non-human primate studies where this analysis has been carried 
out in rhesus macaques and cynomolgus macaques (Langermans et a l, 2001; 
Langermans et al., 2005), and to stimulate a known number of cells, PBMC were used 
instead of whole blood. Additionally, the period of stimulation was 3 days.
Concentrations of IFN-y secreted in the 3 day PBMC stimulation assay were compared 
with the frequencies of IFN-y-secreting cells (see figure 4.19). Although there were some 
time-points where a high concentration of IFN-y was secreted with a high frequency of 
IFN-y-secreting cells, generally, results between the two assays did not produce high 
levels of correlation (Spearman’s rank correlation: rhesus macaques, rs=0.750; 
cynomolgus macques, rs=0.458).
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The levels of IFN-y secreted in PBMC stimulated for 3 days were used in two of the 
challenge studies, thereby providing data from six rhesus macaques and six cynomolgus 
macaques. The amount of IFN-y secreted into the supernatants of these animals is shown 
in figure 4.20.
Secretion of IFN-y was detected 4 weeks post-challenge with M. tuberculosis in both the 
rhesus macaques and the cynomolgus macaques. Two rhesus macaques (D19 and D12) 
were challenged with >50 cfu M. tuberculosis. However, no apparent difference in the 
concentration of IFN-y secreted was observed with these higher doses. Apart from two 
rhesus macaques (C54 and D60) secreting higher levels of IFN-y (>10,000 pg/ml), the 
other rhesus macaques secreted concentrations similar to those detected in the 
cynomolgus macaques (<1 0 ,0 0 0  pg/ml).
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Three of the rhesus macaques (D19, D12 and D28) studied had to be euthanised before 
the 12-week follow-up period due to rapid progression of M. tuberculosis infection. To 
determine whether these animals showed differences in concentrations of IFN-y secreted 
they were compared with 12-week survivors (figure 4.21). These results show that there 
were no differences in IFN-y secretion between animals which rapidly progressed to 
disease and those which survived until 12 weeks post-M tuberculosis infection.
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Figure 4.21: Comparison of IFN-y secreted in 3 day, PPD-stimulated PBMC 
supernatants between animals with rapid disease progression and 12-week survivors. 
(Rapid progressors, red lines; 12-week survivors, green lines).
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4.2.2.4 Comparison of IFN-y secretion in rhesus macaques and cynomolgus macaques
Different conditions (e.g. incubation times and sample preparations) were tested, so 
differences between concentrations of IFN-y secreted in rhesus macaques and 
cynomolgus macaques were compared for all experiments.
Results show a difference in the 3 day PBMC supernatants 6 weeks post-challenge 
between the two species, but at all the other time-points and in all o f the other sample 
preparations no statistically significant differences were observed (table 4.4).
Therefore, after challenge with M. tuberculosis rhesus macaques and cynomolgus 
macaques produce similar amounts of IFN-y after stimulation with PPD. This is in direct 
contrast to the differences observed in the frequency of IFN-y-secreting cells, where 
cynomolgus macaques had significantly fewer antigen-specific IFN-y-producing cells 
compared to rhesus macaques (shown previously in table 4.2).
Mann-Whitney 
statistical p-value
Weeks post M. tuberculosis challenge
2 4 6 8 10 12
24hr whole blood * 0.1489 0.1904 0.0809 0.0809 0.0809
3 day PBMC 0.3153 0.1282 0.0081 0.3711 * 0.7656
6 day whole blood 0.6625 1.0000 1.0000 0.7728 0.2453 0.1489
Table 4.4: Statistical significance values when IFN-y secreted from rhesus macaques and 
cynomolgus macaques is compared in the different experimental conditions.
(Mann-Whitney statistical test, significant level is P<0.05; *, insufficient data to perform 
statistical analysis).
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4.2.2.5 Detection of multiple cytokines using luminex analysis
Supernatants from the 3 day PBMC stimulation were used in a multiplex assay (luminex) 
to detect multiple cytokines simultaneously in the same sample. In addition to IFN-y, 
four other cytokines were tested: TNF-a, IL-lp, IL-2 and IL-6 . Due to their importance 
in contributing to the kinetics of IFN-y production, IL-10 and IL-12 were also monitored 
using an ELISA assay, as luminex reagents specific for non-human primates were not 
available for these cytokines.
To ensure that the luminex assay gave consistent results, IFN-y results were compared 
with those obtained by ELISA. Results are shown in figure 4.22. These show that both 
assays were significantly correlated (Spearman’s rank correlation coefficient: rhesus 
macaques, rs=0.900, PO.OOl; cynomolgus macaques, rs=0.961, PO.OOl). However, 
equations from the fitted lines show that luminex concentrations are approximately 2 0  
times less than those of the ELISA assay. Therefore, although trends are correlated, the 
actual concentrations differ.
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Figure 4.22: Comparison of IFN-y concentrations in the ELISA and luminex assays 
using 3 day PBMC supernatants post M. tuberculosis-challenge.
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Secretion profiles of TNF-a, IL-lp, IL-2, IL-6 , IL-10 and IL-12 in 3 day, PPD- 
stimulated PBMC supernatants are shown in figure 4.23.
IL-10 and IL-12 were quantified by ELISA assays. IL-10 was detected in one rhesus 
macaque (C54; 12 weeks post-challenge), and in two cynomolgus macaques (1111 and 
2151; 8 and 6 weeks post-challenge, respectively). In the remaining animals it was either 
not detected or gave results below baseline values. Concentrations of IL-12 never 
exceeded those observed prior to infection. However, the results show that the responses 
prior to challenge were subsequently diminished during M. tuberculosis infection.
The remaining cytokines were quantified using luminex analysis. Secretion of TNF-a 
was observed in all three rhesus macaques and all five cynomolgus macaques, with peak 
production varying but generally being at around weeks 6-8  post-infection. IL-2 
production was seen 6 -8  weeks after infection with M. tuberculosis in most of the 
challenged macques. However, IL-2 was not produced in rhesus macaque D60 or 
cynomolgus macaque 109181. IL-6  was detected in all of the rhesus macaques, from 
week 4 post-infection in D42 but 8 weeks after challenge in animals C54 and D60. In the 
cynomolgus macaques, only two of the five animals (40%) responded at weeks 4 (1163) 
and 8 (109203). The other three animals had levels similar to those observed prior to 
infection. Detection of IL-ip was seen in all three rhesus macaques studied, with levels 
peaking at weeks 6 (D42) and 8 (C54 and D60). In the cynomolgus macaques only 
animals 1163 and 109203 produced IL-lp which was also detected first at weeks 6 and 
8 , respectively.
-195-
Rhesus macaques Cynomolgus macaques
IL-10
— • —  1 0 9 1 8 1  
1 0 9 2 0 3  
1111 
1 1 6 3  
2 1 5 1
IL-12
3 0 0
2 5 0
200
150
100
10 12P re  2 4 6 8
2 5 0
200
150
100
50
0
P re 10 12
T N F -a
IL-2
05
CL
C(1)ocooa)c
o>.O
30 0
25 0
200
150
100
P re  2 4 6 8 10 12
0 » ■ » 
P re  2 4 6 8 10 12
3 5 0
3 0 0
2 5 0
200
1 50
100
50
0
P re 10 12
10 12
3 5 0 0
3 0 0 0
2 5 0 0
2000
1 5 0 0
1000
5 0 0
0
3 5 0 0
3 0 0 0
2 5 0 0
2000
15 0 0
1000
5 0 0
0
2000
15 0 0
1000
5 0 0
P re  2 4 6 8 10 12
2 5 0 0
2000
1 5 0 0
1000
5 0 0
P re  2 4 10 126 8
W e e k s  p o s t M. tuberculosis  c h a lle n g e  
Figure 4.23: Secretion profiles o f multiple cytokines in 3 day, PPD-stimulated PBMC 
supernatants after M. tuberculosis challenge.
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4.3 DISCUSSION
4.3.1 Frequencies of IFN-y-secreting cells post-challenge with M. tuberculosis
4.3.1.1 Responses in peripheral blood mononuclear cells
4.3.1.1.1 Antisen-svecific responses
For all of the antigens tested (PPD and peptides to Ag85A, CFP10 and ESAT-6 ), 
responses were first detected 4 weeks post-challenge. This has previously been reported 
in other studies of M tuberculosis infection using cynomolgus macaques (Lin et al., 
2006) and rhesus macaques (Gormus et al., 2004). This is also in line with M. bovis 
infection in cattle (Dean et a l, 2005) and corresponds to specific protective immunity 
taking up to 3 weeks to become sufficient to control growth of M. tuberculosis (Toossi, 
2000).
During peaks of response, the median frequencies of PPD-specific IFN-y producing cells 
were approximately 3000 and 1000 IFN-y-producing cells/106 PBMC in rhesus and 
cynomolgus macaques, respectively. In human studies levels ranged from 146-692 IFN-y 
producing cells/106 PBMC (Abramo et al., 2006; Leyten et al., 2006; Nicol et al., 2005). 
Thus, documented levels of PPD-specific IFN-y-secreting cells in humans appear closer 
to the responses seen in the cynomolgus macaques than the rhesus macaques.
The median frequencies of IFN-y-secreting cells to CFP10 and ESAT-6  were 
approximately 1500 and 2000 per 106 PBMC in rhesus macaques, respectively, and 300 
per 106 PBMC for both antigens in the cynomolgus macaques. Human IFN-y-secreting 
cell responses to CFP10 peptides ranged from 39-469/106 PBMC (Ewer et al., 2006; 
Leyten et al., 2006) and ESAT-6  peptides ranged from 18-390/106 PBMC (Ewer et al.,
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2006; Leyten et al., 2006; Pathan et al., 2001). These levels are in line with the responses 
seen in the cynomolgus macaques as compared to the higher frequencies observed in the 
rhesus macaques.
However, although the data obtained from human studies appear to be more comparable 
to the levels detected in cynomolgus macaques rather than the rhesus macaques, caution 
in extrapolating similarities must be exercised. Firstly, responses in the non-human 
primates were measured for 12 weeks post-infection, whereas in the human studies 
infection would have lasted considerably longer. In most of the human studies patients 
were hospitalised or were confirmed as having TB by smear-positive culture, therefore 
these results do not reflect the early stages of disease progression. Secondly, the 
infectious dose of M. tuberculosis the animals received was known (approximately 40 
cfu), and was given at a single time-point, whereas it has been estimated that the human 
infectious dose is 1-5 tubercle bacilli (Balasubramanian et al., 1994b). In human 
infection, re-exposure is a distinct possibility or relapse of a previous infection may have 
occurred. Additionally, the strain of M. tuberculosis used in the macaques was known 
and would be different from that circulating in human populations. Different strains of 
M. tuberculosis have been shown to cause differences in immune response and virulence 
in mouse (Dunn & North, 1995) and rabbit (Manabe et al., 2003) models of infection.
4.3.1.1.2 Comparison o f IFN-y-secretins cell frequencies in rhesus macaques and 
cvnomolsus macaques post-challense with M. tuberculosis
As the estimated dose of M. tuberculosis did not affect the levels of IFN-y secreting cells 
detected, results from all of the infected rhesus macaques and cynomolgus macaques 
were directly compared after M. tuberculosis infection. The data showed that rhesus
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macaques have significantly higher frequencies of antigen-specific IFN-y-secreting cells 
than cynomolgus macaques during early infection with M. tuberculosis.
After M. tuberculosis challenge, a range of frequencies of IFN-y-secreting cells was 
detected in the animals. This heterogeneity of data has been reported in cynomolgus 
macaques before, due to the genetic diversity of non-human primates giving degrees of 
animal-to-animal variation (Lin et al., 2006). Animal-to-animal variation has also been 
seen in the cattle model through the course of M. bovis infection (Dean et al., 2005). 
Therefore, due to the outbred nature of the macaques it is not surprising that there is 
variation seen in the levels of IFN-y-secreting cells.
4.3.1.1.3 Effect o f IFN-y-secreting cell frequencies on rapid disease progression
When responses in four rhesus macaques that were euthanised due to meeting humane 
endpoints (caused by rapid disease progression) were compared to the animals which 
survived to 12 weeks post-infection, no significant differences in frequency of IFN-y- 
secreting cells were found for any of the antigens tested.
Three of the four animals that met humane endpoints received higher doses of M. 
tuberculosis (D53, 500 cfu; D12, 75 cfu; D19, 70 cfu), whereas the other rhesus 
macaques received 30-40 cfu. Therefore, a higher dose had an impact on the severity of 
disease, but not on IFN-y production. When different doses of M. bovis have been used 
to infect calves, varying from 1,000 to 1 cfu, there were no difference in the time taken to 
achieve a positive IFN-y response or levels of IFN-y responses (Dean et al., 2005). This 
observation is similar with the IFN-y responses seen in M. tuberculosis-challenged 
macaques.
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4.3.1.1.4 Responses to individual peptides vost-M. tuberculosis challenge
Responses from individual peptide pools were analysed to determine whether any pools 
contained consistently recognised epitopes or whether the target of the immune response 
changed through the course of early infection.
Results from the CFP10 peptide pools show that pools 2 and 3 are the most frequently 
detected in macaque infection. In human infection CFPIO71-85 has been identified as 
having multiple epitopes (Shams et a l, 2004). The equivalent peptide is number 13 in 
our peptide set. Thus, although the whole peptide is in pool 3, due to the overlapping 
nature of the peptide sequences some of the sequence overlaps into pool 2. Thus, it is 
possible that this same region is also immunogenic in macaque infection.
For ESAT-6, pool 1 was the most dominant in rhesus macaques and pool 3 in 
cynomolgus macaques. Results from human studies show strikingly similar results to 
those of the macaques, with the beginning and end of the ESAT-6 sequence being the 
most immunogenic (Pathan et al., 2001; Ulrichs et al., 2000).
Responses to Ag85A peptide pools are more difficult to interpret as pools are not made 
up of sequential peptides. However, an interesting observation was that peptide pool D 
was responsive in all but one of the 18 macaques. It has been reported that the amino 
acid region from 61-80 gives the strongest proliferative response in TB patients (Launois 
et al., 1994). This 20mer peptide is represented by peptides 12-15 using 15mers, which 
are found in pools A, D, E and G. Although pool D is highly immunogenic, it would be 
speculative to suggest that this is due to this specific peptide region and further work 
would have to be done to clarify responses in more detail.
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4.3.1.1.5 Decline in IFN-y-secreting cells at 6-8 weeks post-infection
An unexpected observation was the decline in responses in most animals 6 -8  weeks post­
challenge with M. tuberculosis. As this phenomenon was seen in animals from different 
challenge experiments, it is unlikely that this could be an experimental artefact.
It has been reported by other researchers that antigen-specific T lymphocytes are 
sequestered at the site of disease, thus making responses appear anergic in the peripheral 
circulation. Evidence for this includes IFN-y levels in pleural fluid being 65-fold higher 
than in plasma in TB patients (Hirsch et al., 2001). Also, more PPD-specific IFN-y- 
secreting cells have been detected in the lung compartment of patients with TB as 
compared with responses in the blood (Breen et al., 2006).
Alternatively, an increase in Th2 cytokines may account for a decrease in Thl cytokine, 
including IFN-y, activity. In one study, decreased IFN-y production was associated with 
increased IL-4 production (Smith et al., 2002). However, the long stimulation period (7 
days) may have allowed the immune profile to shift from the in vivo situation. Another 
report showed that in mice challenged with M. tuberculosis by tail vein, a peak of IFN-y- 
secreting cells was followed by a peak of IL-4-producing cells (Orme et al., 1993b). 
Therefore, there is increasing evidence that both Thl and Th2 arms of the immune 
system may be involved in the response to M. tuberculosis, and this may be particularly 
evident in those patients with more extensive disease (Wilsher et al., 1999). However, 
not all researchers agree with the Th2 contribution to mycobacterial immunity. Using 
mRNA expression of PBMC from TB patients, expression of Thl cytokines (IFN-y and 
IL-2) was diminished, but no change in mRNA expression was detected for the Th2 
cytokines (IL-4, IL-10, and IL-13), thus showing no association between Thl and Th2
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responses at the level of systemic T cells (Zhang et a l, 1995). Therefore, the impact of 
Th2 cytokines on Thl cytokine responses remains controversial in TB immunity.
Apoptosis of IFN-y-secreting cells may also cause reductions in frequencies of IFN-y- 
secreting cells (Hirsch et a l, 1999). Continuous exposure to M. tuberculosis-infected 
antigen-presenting cells may cause programmed cell death of M. tuberculosis-specific 
effector cells resulting in the inability to restimulate central memory cells and to prime 
naive precursors (Goletti et al, 2006), especially during chronic infection (Lazarevic et 
al, 2005a). Apoptosis in macrophages may benefit the immune response by releasing 
apoptotic vesicles that carry mycobacterial antigens to MHC class I and CD 1-restricted T 
cells (Schaible et a l, 2003). Additionally, apoptosis reduces mycobacterial growth, as 
seen by a 60-70% loss in viability of intracellular BCG of apoptotic cells in vitro 
(Molloy et a l, 1994). Ironically, IFN-y may be involved in the mediation of apoptosis as 
although it is immunoprotective in the sense that it increases the ability of macrophages 
to contain mycobacteria, it also contributes to apoptosis in responsive T cells (Hirsch et 
al, 2001). Thus, IFN-y is essential to a regulatory mechanism that eliminates activated 
CD4+ T cells and maintains CD4+ T cell homeostasis during an immune response 
(Dalton et a l, 2000). In the macaques studied, there was no detectable loss in 
lymphocytes (including CD3+, CD4+, and CD8+), granulocytes or monocytes 
(appendices 3-8, sections 8.3-8.8). The observation of no changes in the number of CD4+ 
and CD8+ T-lymphocytes has also been observed in the rhesus macaques and 
cynomolgus macaques post-M tuberculosis challenge by others (Langermans et a l,
2 0 0 1 ), therey proving little evidence of apoptosis in the macaque model.
Anergy of effector cells may also cause fewer cells to produce IFN-y after antigenic 
stimulation. Anergy generally follows activation of individual T cells (Yamamoto et a l,
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2007), so after the peak of IFN-y response cells may become unresponsive. However, 
proliferation results show that the PBMC are still capable of expanding in vitro when 
IFN-y responses are decreased (appendices 9-10, sections 8.9-8.10), thus arguing against 
anergy causing a depression in immune function. This proliferation in the absence of 
IFN-y production has also been reported by others (Launois et a l , 1994; Onwubalili et 
a l , 1985; Surcel et a l , 1994), providing evidence that the cells are capable of 
multiplying after antigenic stimulation, and so are unlikely to be anergic.
Activated regulatory T cells are also known to suppress IFN-y production (Becker et a l , 
2007; Roberts et a l , 2007). Regulatory T cells have been seen at sites of infection in the 
spleen and lung in mice, and been shown to prevent eradication of tubercle bacilli by 
suppressing an otherwise efficient CD4+ T cell response (Kursar et a l , 2007). Their role 
during M. tuberculosis infection is not clear. It is possible that they are programmed by 
specific microbial stimuli, thus ensuring survival of tubercle bacilli (Kursar et a l , 2007). 
Conversely, suppression of the immune response could serve as a means of maintaining 
a constant antigenic pool providing a continuous supply of antigen-specific T cells to 
defend against reinfection, or as a means of curtailing active pathology (Kursar et a l , 
2007).
Alternatively, the reduction in response may be due to cycling bacterial antigen levels 
(Murray, 1999) causing bursts and reductions in the immune response (Lazarevic et a l, 
2005a). Additionally, antigen-presenting cells, such as dendritic cells, may have less 
ability to present antigens during ongoing disease (Aleman et a l, 2007) affecting the 
immune response. Due to the study period only being 12-weeks post-challenge, further 
cycling of responses may become evident during the progression of TB disease.
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4.3.1.1.6 Responding T cell subsets
The majority of IFN-y was secreted by CD4+ cells, as depletion of this subset reduced 
responses and enrichment (by depletion of CD8+ cells) increased proportions of IFN-y- 
secreting cells. It is expected that CD4+ T cells are the principal cells involved in the 
immune response to mycobacteria, as bacterial antigens can find their way into the class 
II MHC processing pathway and are subsequently presented to CD4+ T cells (Murray,
1999). For PPD-specific responses, only CD4+ cells were stimulated to produce IFN-y. 
This has also been reported by others who demonstrated that PPD was able to stimulate 
CD4+ lymphocytes, but not CD8+ T lymphocytes (Barry et al., 2003).
In a single rhesus macaque and a single cynomolgus macaque, there was evidence of 
peptide-specific CD8+ IFN-y secretion. The contribution of CD8+ T cells to IFN-y 
production is affected by several factors. When they are killing infected cells, as 
measured by the secretion of perforin, their ability to produce cytokines is compromised 
(Sad et al., 1996). However, when CD8+ T cells are stimulated with higher numbers of 
APC their ability to produce cytokines is greatly increased, probably because of repeated 
stimulation and/or stimulation of a greater proportion of CD8+ T cells (Sad et al., 1996). 
These observations have been confirmed by levels of T-cell receptor (TCR) occupancy 
affecting cytotoxic T lymphocyte (CTL) responses. IFN-y production required a 
substantial level of TCR occupancy, whereas cytotoxicity was elicited by triggering 
fewer TCRs (Valitutti et al., 1996). Although these observations were made in vitro, 
these features probably occur in vivo whereby they provide a regulatory mechanism. 
When infection levels are high the CD8+ T cells contribute to the cytokine response to 
attempt to bring M. tuberculosis infection under control, with CD8+ T cells contributing 
equally to IFN-y production (Lazarevic et al., 2005a). However, once the infection levels
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have been reduced their cytokine production is not necessary, but their cytolytic function 
is still needed to clear residually infected cells.
4.3.1.2 Responses in local lymphoid tissues
As lung material was not available (due to requirements for MRI scanning analysis and 
histology), the hilar lymph nodes represented the second site of disease. In this study, 
responses in the hilar lymph nodes in macaques were generally lower than those seen in 
PBMC. This is in contrast to studies in cynomolgus macaques where, during early 
infection, responses were broader and stronger in the hilar lymph nodes than in PBMC 
(Lin et al., 2006). The difference may be due to those investigators using a different 
route of challenge, as they achieved infection by instilling M. tuberculosis via a 
bronchoscope. Alternatively, the cynomolgus macaques in the report by Lin et al. were 
euthanised 3-6 weeks post-infection, whereas in this study the cynomolgus macaques 
were assessed later in infection at 12 weeks post-M tuberculosis challenge.
Responses in the axillary lymph nodes were measured in order to determine levels at a 
site more distant from infection. Although, as expected, responses were much lower it 
was still apparent that some antigen-specific responses were being detected. This may be 
due to the axillary lymph node trapping some antigen-presenting cells that passed by or 
escaped from the hilar lymph node.
The spleen is able to trap antigen-specific lymphocytes that escape the lymphatic system 
and enter the systemic circulation (Chackerian et al., 2002). This may in turn account for 
the spleen also being a site of secondary M. tuberculosis infection as it traps infected 
cells which then multiply and spread the infection to this organ. In both rhesus and 
cynomolgus macaques, antigen-specific IFN-y-secreting cells were detected in the
-205-
spleen. This is in contrast to a study in 4 rhesus monkeys where dissemination of M 
tuberculosis to the spleen was not detected 12 weeks post-challenge (Lewinsohn et al.,
2006). However, these animals were challenged by instillation of bacteria via 
bronchoscope using a higher dose (1000 cfu) and a different strain (H37Rv) of M 
tuberculosis.
Analysis was performed to determine whether frequencies of IFN-y-secreting cells in 
PBMC and lymphoid tissue correlated with disease severity. Spleen responses in rhesus 
macaques increased alongside the severity of infection as determined by the extent of 
lung involvement measured using the lesion:lung volume ratio. In the rhesus macaques, 
there was a strong correlation between responses in the spleen when using Ag85A and 
ESAT-6  peptides. No correlation was observed in the cynomolgus macaques. However, 
in the cynomolgus macaques only one animal had a high lesion:lung volume ratio and 
increased IFN-y frequencies, so the data were less evenly distributed. Looking at bacteria 
load in the spleen results showed detectable M. tuberculosis infection in 7 spleens from 9 
rhesus macaques, but in the cynomolgus macaques infection was observed in only 2  
spleens from 9 animals (appendix 11, section 8.11). Haematogenous spread has been 
reported for M. tuberculosis infection in rhesus macaques by others after 10 (Anacker et 
al., 1972) and 13 (Barclay et al., 1970) weeks post-infection. Where the two species have 
previously been compared, there was miliary spread to the spleen in the rhesus macaques 
but not in the cynomolgus macaques 9 weeks post-infection (Langermans et a l , 2001). 
Therefore, in the cynomolgus macaques the infection does not spread into the spleen.
Surprisingly, in neither species did responses in the hilar lymph nodes correlate with
disease severity. As this is the draining lymph node from the primary site of infection in
the lungs, it would be expected to show a strong correlation. When bacteriology was
performed on the hilar lymph nodes, there was a high bacterial load in these tissues
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(appendix 12, section 8.12). Thus, it may be that the infection in the lymph nodes had 
overwhelmed the capacity of this tissue to generate a sufficient protective immune 
response. This has been seen in guinea pigs aerosolly infected with M. tuberculosis 
where the lymph node architecture had been destroyed (Kraft et a l , 2004).
4.3.2 Concentrations of IFN-y secreted from circulating cells post-infection with 
M. tuberculosis
4.3.2.1 Whole blood stimulation
IFN-y levels in whole blood stimulated for 6 days were detected in supernatants 6 weeks 
after M. tuberculosis challenge. In whole blood stimulated for 5 days, IFN-y was 
detected in household contacts when they sero-converted to disease (Whalen et a l ,
2006). This is similar to our assay, where disease was clearly evident by analysis of chest 
X-rays at 4 weeks post-infection (appendix 13, section 8.13). When responses in 6 -day 
whole blood supernatants were compared to the overnight ELISPOT results, little 
correlation was seen between the two readouts. The main differences in the assays were 
the time of stimulation (overnight for ELISPOT, 6 days for whole blood stimulation) and 
the cell preparation used (PBMC for ELISPOT, whole blood for stimulation assay). 
Additionally, the ELISA only measures secreted cytokine present in the supernatant, 
whereas the ELISPOT assay captures it as soon as it is produced preventing its uptake by 
other cells. Another factor is that by using whole blood, the number of cells used are not 
pre-determined. However, immunophenotyping results (appendices 3-8, sections 8.3-8.8 ) 
showed no major alterations in numbers of circulating immune cells. Other investigators 
have also found that IFN-y production does not correlate with parameters such as whole 
blood counts or granulocyte numbers (Sahiratmadja et a l , 2007b).
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To determine whether the difference in responses was due to stimulation times, diluted 
whole blood was incubated overnight in agreement with the ELISPOT assay. The results 
showed a positive correlation, which has also been shown by others who stimulated 
whole blood overnight (Goletti et a l , 2005). This indicates that with the 6  day 
supernatants a different response was being detected due to the longer period of 
stimulation. This may be due to increased CD8+ contributions due to the prolonged 
incubation allowing optimal antigen uptake and presentation (Serbina & Flynn, 1999). 
Alternatively, compared with effector memory cells, central memory cells need a longer 
period of stimulation to produce effector cytokines (Sallusto et a l , 1999). The 
contribution of central memory cells may thus relate to differences in IFN-y secretion.
4.3.2.2 PBMC stimulation
PBMC’s were stimulated for 3 days with PPD, as used by macaque studies (Langermans 
et a l, 2001; Langermans et al, 2005). Responses started four weeks post-challenge, in 
line with reports on cynomolgus macaques (Langermans et a l, 2005). There was not a 
close correlation between the amount of IFN-y secreted and the frequencies of IFN-y- 
producing cells. Mean macaque responses were between 5000-7500 pg/ml. In human 
patients, PBMC responses after 3-4 days of stimulation with heat-killed M. tuberculosis 
were 327 (far advanced disease)-1,639 pg/ml (moderately advanced disease) (Sodhi et 
al, 1997). However, results cannot be directly compared with macaque data due to 
differences in antigen preparation and the history of clinical disease is not fully known.
4.3.2.3 Comparison of rhesus macaques and cynomolgus macaques
When responses from the different stimulation studies were compared, there were no 
consistent differences in the amount of IFN-y secreted between the two macaque species.
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This is an interesting observation, as previously the frequency of IFN-y cells after M 
tuberculosis infection have been shown to be higher in rhesus macaques as compared to 
cynomolgus macaques. Therefore, it could be postulated that cynomolgus macaques may 
have less cells secreting IFN-y, but each cell secretes cytokine more efficiently, thus 
maintaining the same concentrations of IFN-y released.
4.3.2.4 Measurement of other cytokines
To determine whether other cytokines had an effect on IFN-y secretion, luminex analysis 
was carried out to simultaneously measure multiple cytokines in a single sample. To 
ensure that this assay gave similar results to the standard ELISA assay, a comparison of 
the two assays was made using IFN-y. A strong correlation between the two assays was 
found, although the actual concentrations reported were 2 0 -fold lower for the luminex. 
Therefore, although trends were comparable, concentrations were not.
From the luminex results, TNF-a production peaked at weeks 6 -8 , coinciding with the
peaks in secretion of IFN-y. TNF-a affects the expression of many chemokines, and
therefore plays a significant role in granuloma formation (Algood et al., 2004) and is a
critical cytokine that is essential for early control of primary infection (Botha & Ryffel,
2003). IL-2 production also peaked at weeks 6 -8  alongside IFN-y secretion in both
rhesus macaques and cynomolgus macaques. This observation has also been noted in
CD3+ T cells in patients with active pulmonary TB (Winkler et al., 2005), in serum
cytokine levels (Berktas et al., 2004; Dlugovitzky et al, 1997), and in bronchoalveolar
fluid (Casarini et al, 1999). IL-6  was produced in all three rhesus macaques studied
post-challenge with M. tuberculosis and in 2 of the 5 cynomolgus macaques. However,
production of IL-6  was not related to levels of IFN-y secreted. Other investigators have
found that IL-6  production is enhanced with IFN-y secretion (Orme et a l, 1993b; Verbon
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et al., 1999). However, IL-6  can also differentiate activated regulatory T cells into IL-17- 
producing cells (Xu et al., 2007). Therefore, due to its range of functions in early 
infection its effects may not be influenced by IFN-y. IL-ip was produced by all three 
rhesus macaques and two of the five cynomolgus macaques tested. Mice lacking the 
receptor for this cytokine have been shown to be more susceptible to pulmonary TB 
infection and for a decreased ability of splenocytes to produce IFN-y (Juffermans et al.,
2000). The peaks of IL-ip levels coincided with IFN-y secretion in the macaques, 
therefore suggesting that secretion levels between these two cytokines are related.
In addition to those cytokines being measured via luminex, IL-10 and IL-12 
concentrations were measured by ELISA assay, due to non-human primate reagents not 
being available at the time for analysis in the luminex assay. IL-10 concentrations were 
measured due to the ability of this cytokine to reduce IFN-y secretion (Gong et al., 
1996). IL-10 was only detected in one out of three rhesus macaques and above 
background in two out of five cynomolgus macaques at 6 and 8 weeks post-infection. 
This is the same point at which the frequencies of IFN-y-secreting cells decline in most 
animals. Therefore, although this observation was only observed in a minority of 
animals, it could be speculated that IL-10 may potentially play a role in down-regulation 
of IFN-y-producing cells. IL-12 levels in the supernatants were difficult to assess as the 
sample at pre-bleed was high in all of the animals. Therefore, post-challenge results 
rarely exceeded those detected at baseline. However, this observation could be due to the 
sequestration of IL-12 secreting cells to the site of disease in the lungs. Other 
investigators have reported that IL-12 secretion is compartmentalised in the lung 
(Morosini et al., 2003), thus detection in PBMC proves difficult.
-2 1 0 -
4.4 CONCLUSION
This is the first time that rhesus macaques and cynomolgus macaques responses have 
been simultaneously monitored after aerosol M. tuberculosis infection. After challenge, 
the IFN-y responses showed differences between the two macaque species, with rhesus 
macaques having more cells secreting IFN-y after mycobacteria-antigen stimulation, yet 
both species secreting the same concentration of IFN-y. Analysis of the responses during 
the early time-points after challenge have shown that levels IFN-y did not provide a 
marker for rapid disease progression.
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5 IFN-y RESPONSES AFTER IMMUNISATION WITH BCG AND 
BCG/MVA85A
5.1 INTRODUCTION
Having analysed IFN-y responses during early disease progression in M. tuberculosis 
infection, the next aim was to analyse responses after vaccination. In addition to 
measuring the dynamics of IFN-y production after vaccinating macaques, responses after 
challenge of vaccinated animals with M. tuberculosis were also assessed to determine 
whether IFN-y measurements could be used as correlates of protection following TB 
vaccination. A correlate of protection may not necessarily be part of the mechanism of 
protection, so looking at protective vaccination responses may be critical. For example, a 
new vaccine may induce protective immunity without engaging the pathways 
contributing to protection against naturally acquired M. tuberculosis (Ellner et a l , 2000). 
The ideal scenerio is to find a surrogate marker of protection for M. tuberculosis, where 
many populations and different settings are generalised to be protected (Sadoff & Wittes,
2007).
5.1.1 Vaccination of macaques against TB
Rhesus macaques were used to test the current human vaccine, BCG, as early as in 1955 
(Schmidt, 1972). Up until the mid-1970’s several researchers working on simian TB 
reported the protective effects of BCG vaccination on M. tuberculosis infection in rhesus 
macaques. Thereafter, reports in 2001 and 2002 (Langermans et a l , 2001; Shen et a l ,
2002) have assessed BCG-induced protection in rhesus macaques. All of these reports
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are summarised in table 5.1. In summary, these reports show that in 8 of the 9 studies 
BCG conferred some protection against TB disease in rhesus macaques.
As well as different routes of vaccination, different strains of BCG were also used in the 
non-human primate studies by the different researchers (Good, 1968; Ribi et al., 1971). It 
was generally observed that BCG did not completely protect the rhesus macaques by 
giving sterilising immunity, but instead resulted in a lesser extent of pathological disease. 
Due to many of these studies being carried out before modem immunological techniques 
had been widely introduced, the primarily readouts were pathology scores, clinical signs 
and occasionally basic immunology assessments (antibody production or proliferation 
assays).
Author ref Route of BCG administration Protected against M.tuberculosis?
(Good, 1968) Intravenous
Yes (apart from 
Kikuth’s isoniazid- 
resistant strain)
(Barclay et al., 1970) Intravenous Yes
(Ribi et al., 1971) Intravenous Yes
(Anacker et al., 1972) Intramuscular or intravenous Yes
(Schmidt, 1972) Intratracheal, intracutaneous or intravenous Yes
(Barclay et al., 1973) Aerosol or intravenous Yes
(Janicki et al., 1973) Intravenous and intracutaneous Yes
(Langermans et al., 
2001) Intradermally No
(Shen et al., 2002) Intravenous Yes
Table 5.1: Summary of papers on BCG vaccination conferring protection against M  
tuberculosis challenge in rhesus macaques.
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Following the 1970s there has been very little published work on tuberculosis research in 
non-human primates. More recently, however, work has begun again in macaque studies 
of infection and vaccination against M. tuberculosis. BCG vaccination has been assessed 
in rhesus macaques for expansion of lymphocyte subsets (Lai et al., 2003), though 
animals were not challenged with virulent M. tuberculosis. The contribution of y5 T cells 
has also been assessed in a rhesus macaque model during BCG vaccination and after M. 
tuberculosis-infection (Shen et al., 2002), showing the potential importance of this cell 
phenotype for the clearance of mycobacteria.
Following the early work in rhesus macaques, recent experiments have begun to use the 
cynomolgus macaque model. Vaccines tested in cynomolgus macaques include heat- 
shock protein (HSP) 65 combined with human IL-12 DNA within a haemagglutinating 
virus of Japan (HVJ)-liposome (Kita et al., 2005; Okada et al., 2007) and a recombinant 
BCG expressing the 72f fusion gene (Kita et al., 2005) -  all giving survival equal or 
better than BCG alone.
Only one study has compared immune responses in rhesus macaques and cynomolgus 
macaques directly using both BCG vaccine and M. tuberculosis infection (Langermans et 
al., 2001). However, this study used a large dose of 3,000 cfu delivered via intratracheal 
instillation to achieve disease in both species, which is unrepresentative of natural human 
infection. Unlike earlier studies performed decades before, the rhesus macaques failed to 
achieve any substantial protection in this study, although this may have been due to the 
treatment of the macaques with anti-mycobacterial antibiotics to clear any residual BCG 
bacteria (Langermans et al., 2001). The only IFN-y readout presented was concentration 
of IFN-y secreted at a single time-point post-vaccination with BCG.
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5.1.2 Modified vaccinia Ankara virus expressing Ag85A as a booster vaccine
In addition to BCG vaccination, the BCG and MVA85A prime-boost regime was tested 
in macaques to determine responses to a novel TB vaccine that is undergoing human 
clinical trials. MVA85A has entered phase II clinical trials in South Africa (Sander & 
McShane, 2007), where it has been shown to be safe and immunogenic (Hawkridge et 
al., 2008). This vaccine has also shown great promise in trials conducted in West Africa 
(Brookes et al., 2008) and the UK (McShane et al., 2004). Due to there being no pre­
defined immunological correlates of protection against M. tuberculosis, determining 
whether the significantly enhanced immune responses observed after MVA85A boost are 
accompanied by an improvement in protective efficacy is a key question (Pathan et al.,
2007). To evaluate this in humans would be expensive and time consuming, as vaccinees 
would need to be followed for many years to determine whether there was a correlation 
between their IFN-y response and their subsequent susceptibility to TB infection. 
Therefore, by using the macaque model, a controlled infection could be delivered post­
vaccination to determine the efficacy of a vaccine in an animal model that very closely 
resembles human infection.
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5.1.3 Chapter aims
The main aims of this chapter are:
1) To determine IFN-y responses after vaccination with BCG in non-human 
primates.
2) To assess IFN-y responses after BCG vaccination followed by responses after 
MVA85A, a novel TB vaccine currently undergoing human clinical trials.
3) To monitor responses after vaccinated and non-vaccinated macaques are 
challenged with M tuberculosis and determine whether IFN-y measurements 
are indicative of survival.
4) To compare data on responses obtained in macaques with data generated in 
human clinical trials.
5.1.4 Chapter methods
In a pilot study, 2 rhesus macaques and 2 cynomolgus macaques were vaccinated with 
BCG and responses monitored for 74 weeks (section 2.1.3.2). A larger study of rhesus 
macaques were analysed after BCG vaccination and BCG/MVA85A immunisation, after 
which animals were challenged via aerosol with M. tuberculosis to determine protective 
efficacies (section 2.1.3.3).
The frequency of antigen-specific IFN-y secreting cells was measured using the 
ELISPOT method (section 2.2.6) and the concentration of IFN-y secreted after antigenic 
stimulation was measured using the ELISA method (section 2.2.7). Anti-vector 
antibodies to MVA85A vaccination were measured in sera samples using an anti­
vaccinia ELISA assay (section 2.2.9).
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5.2 RESULTS
5.2.1 IFN-y responses post-vaccination with BCG
5.2.1.1 Comparison between rhesus macaques and cynomolgus macaques
5.2.1.1.1 Frequency o f IFN-y secreting cells
In a preliminary experiment, two rhesus and two cynomolgus macaques were vaccinated 
with BCG vaccine. The frequencies of PPD-specific IFN-y-secreting cells were measured 
over the 74 week post-BCG vaccination period (figure 5.1). Rhesus macaques show 
PPD-specific responses peaking at around 350 IFN-y-secreting cells at week 4 in animal 
1040 and week 8 in animal 1252. Responses were detected throughout the 74 weeks 
post-vaccination. In contrast, the BCG-vaccinated cynomolgus macaques displayed 
lower frequencies of PPD-specific IFN-y-secreting cells. In animal 9911021, all 
responses were below the cut-off value. In animal 1007 no responses were detected at 
pre-bleed, so using a cut-off of 3 times the pre-bleed value was zero. When mean 
responses were plotted (figure 5.2), the frequencies of PPD-specific IFN-y-secreting cells 
were consistently lower in cynomolgus macaques than in rhesus macaques.
-217-
Rhesus macaques
CO
E
ECO
T’o
is
o  CL
U— CD
o  o
400
300
200
100
0
1040
r i y  i i I t  ^  r
Q. cO
0- O) 400 -[ 
Q- c
4— '4 3O 0
>% o  300 -O Q)E w
1252
200  -
100 -
■15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75
Weeks post-BCG vaccination
Cynomolgus macaques
400 
300 
200 
100 
0
CD
E
E
CD
T’ o
i s
o  0 -
4— CDo o 0 2T
A 0Q  O
o "0 b
o 0 
0 w3cr
0
-
1 0 0 7
J-------1---------1---------1--------- nn n n n fl 1 n n fl n n n „ ,n  0 - ~  r ~ ~ t D - r — -
-15 -10 -5 0 10 15 20 25 30 35 40 45 50 55 60 65 70 75
400
300
200
100
0
9911021
-15 -10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75
Weeks post-BCG vaccination
Figure 5.1: Frequencies of PPD-specific IFN-y-secreting cells post-BCG vaccination in
macaques.
(Rhesus macaques, green bars; cynomolgus macaques, yellow bars. Animal 
identification number is shown in top right comer of each graph. Blue line indicates cut­
off of 3 times the mean pre-bleed level).
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Figure 5.2: Mean frequencies of PPD-specific IFN-y-secreting cells in macaques. 
(Rhesus macaques, green line; cynomolgus macaques, yellow line).
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With a distinct difference between the frequencies of PPD-specific IFN-y-secreting cells 
in the two macaque species, data from human clinical studies conducted in Oxford were 
used to determine which, if  either, more closely resembled the responses detected in 
humans.
As shown in figure 5.3, the responses from rhesus macaques more closely follow those 
seen in humans than do the levels observed in the cynomolgus macaques. The 
frequencies of PPD-specific IFN-y-secreting cells in both the humans and the rhesus 
macaques peaked at 8 weeks post-vaccination with BCG. In contrast, the lower 
frequencies of antigen-specific IFN-y-secreting cells detected in the cynomolgus 
macaques did not resemble the responses seen in human studies.
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Figure 5.3: Median frequencies of PPD-specific IFN-y-secreting cells post-vaccination 
with BCG in macaques and human volunteers.
(Rhesus macaques, green line; cynomolgus macaques, yellow line; and human 
volunteers, blue line).
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5.2.1.1.2 Concentration ofIFN-y secreted
In addition to measuring the frequencies of IFN-y-secreting cells after BCG vaccination 
in the rhesus macaques and cynomolgus macaques, the concentration of PPD- and BCG- 
specific IFN-y release after stimulation of diluted whole blood for 6 days was also 
measured.
As with the frequencies of IFN-y-secreting cells, the concentration of IFN-y released was 
lower in cynomolgus macaques than in rhesus macaques after BCG vaccination (figure 
5.4). Peak responses were detected 6 weeks post-BCG vaccination in the two rhesus 
macaques, and at weeks 6 and 10 in the cynomolgus macaques. However, in the 
cynomolgus macaque, levels in animal 1007 remained mainly below the cut-off value set 
for the assay. When samples were initially measured, the peak response in animal 1252 
was over the limit of detection of the assay (3000 pg/ml). Therefore, the supernatant was 
diluted 1:5 and re-analysed. The diluted sample gave a value which was still over the 
limit of detection (3874 pg/ml). Therefore, the actual concentration is estimated from this 
value as no further supernatant was available for re-testing.
Responses to PPD antigen were generally higher than with BCG in the rhesus macaques, 
whereas the reverse was true for the cynomolgus macaques. When the responses to the 
PPD and BCG antigens were compared using the Spearman’s rank correlation statistical 
test there was a significant correlation between antigens in both rhesus macaques 
(rs=0.746, P0.001) and cynomolgus macaques (rs=0.654, P=0.001). As PPD is used as 
an antigen in the ELISPOT assay, for future work only responses against this antigen 
were subsequently tested.
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Figure 5.4: Concentration of IFN-y secreted in PPD-stimulated and BCG-stimulated 6- 
day diluted whole blood supernatants in rhesus macaques and cynomolgus macaques. 
(PPD stimulated, green line; BCG stimulated, blue line. Animal identification numbers 
are displayed in the top right comer of each graph. Reference line indicates cut-off level; 
100 pg/ml).
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5.2.1.2 Frequencies of IFN-y-secreting cells in BCG-vaccinated rhesus macaques
The observation of responses in rhesus macaques being similar to human responses was 
followed up in an increased sample size of rhesus macaques. Twelve rhesus macaques 
were vaccinated intradermally in the upper arm with BCG vaccine and the frequencies of 
IFN-y-secreting cells in response to stimulation with PPD and Ag85A peptide pools were 
measured. In parallel, responses in four unvaccinated rhesus macaques were measured 
simultaneously as a control. Samples were measured every 2 weeks after BCG 
vaccination up to 12 weeks (section 2.1.3.3).
As shown in figure 5.5, significant differences in levels of PPD-specific IFN-y secreting 
cells between BCG-vaccinated and unvaccinated rhesus macaques were seen from 4 
weeks post-vaccination with PPD antigen. However, few Ag85A-specific IFN-y- 
secreting cells were detected in BCG-vaccinated animals. Responses in the unvaccinated 
control animals remained low to both the PPD and the Ag85A peptide pool antigens.
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Figure 5.5: Frequencies of PPD-specific and Ag85A-specific IFN-y-secreting cells above
cut-off in rhesus macaques vaccinated with BCG and unvaccinated controls (BCG
vaccinated, blue lines; unvaccinated, green lines. Cut-off defined as 3 times the mean
pre-bleed value. * = significant difference [Mann-Whitney statistical value P<0.05]).
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To determine whether the profiles o f PPD-specific IFN-y-secreting cells in the twelve 
BCG-vaccinated rhesus macaques were similar to human responses, data were compared 
with those from a human clinical trial conducted in Oxford where eight volunteers were 
vaccinated with the same volume and strain of BCG with responses similar in both 
studies. When median results were plotted (figure 5.6) the rhesus macaques and human 
studies showed comparable frequencies of PPD-specific reactivity. However, it is not 
known whether the peak frequencies o f IFN-y-secreting cells in the rhesus macaque 
group at 6 weeks post-vaccination is mirrored by humans as levels were not measured at 
this time-point in the latter. No significant differences between rhesus macaques and 
human responses were observed post-BCG vaccination (Table 5.2).
Mann-Whitney 
statistical p-value
Weeks post-BCG vaccination
2 4 8 12
Rhesus macaques 
vs. Humans 0.3749 0.2170 0.8471 0.8471
Table 5.2: Mann-Whitney statistical analysis of frequencies of IFN-y-secreting cells in 
rhesus macaques and humans after vaccination with BCG.
(Significance, P<0.05).
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Figure 5.6: Median values of IFN-y-secreting cells in BCG-vaccinated rhesus macaques 
and human volunteers.
(Rhesus macaques, blue line; human volunteers, green line. Error bars indicate 
interquartile range of samples).
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5.2.1.3 Concentrations of IFN-y secreted in diluted whole blood supernatants from
BCG-vaccinated rhesus macaques
The concentration of IFN-y secreted in diluted whole blood after 6 -day stimulation with 
PPD was measured in the BCG-vaccinated rhesus macaques.
As shown in figure 5.7, PPD-specific IFN-y production was seen after vaccination with 
BCG in 7 of the 12 animals above cut-off levels (animals K59, K50, K44, K61, K65, 
K79 and K8 6 ). None of the unvaccinated controls showed any PPD-specific IFN-y 
secretion above cut-off levels during the 12 week time-course. Using area under the 
curve analysis, a significant difference (P=0.0064) was found between BCG-vaccinated 
and unvaccinated rhesus macaques (figure 5.8).
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Figure 5.7: Concentrations of IFN-y secreted in diluted whole blood supernatants from 
rhesus macaques vaccinated with BCG compared to unvaccinated controls.
(BCG vaccinated, blue lines; unvaccinated, green lines. Reference line indicates cut-off; 
100 pg/ml).
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Figure 5.8: Area under the curve analysis showing differences in amount of IFN-y 
secreted between BCG-vaccinated and unvaccinated rhesus macaques.
(Analysis carried out using a Mann-Whitney statistical test. Significance, P<0.05).
-229-
As the concentration of IFN-y secreted in response to stimulation with PPD was 
measured alongside the frequencies of PPD-specific IFN-y-secreting cells, a statistical 
analysis was carried out to determine if the two measurements were significantly 
correlated.
Using the Spearman’s rank correlation test, there was no significant correlation between 
the two assays (rs=0.425). As seen from figure 5.9, high levels of IFN-y were secreted in 
the ELISA assay when only moderate frequencies of IFN-y-secreting cells were detected 
in the ELISPOT assay. In addition, there were also times where the ELISA assay failed 
to detect any IFN-y secretion yet the ELISPOT assay showed that frequencies of IFN-y- 
secreting cells were detected.
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Figure 5.9: Comparison of PPD-specific responses in concentrations of IFN-y secreted 
after stimulation of diluted whole blood with the frequencies o f IFN-y-secreting cells 
detected in PBMC after vaccination of rhesus macaques with BCG.
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5.2.2 Responses after immunisation of BCG-vaccinated animals with MVA85A
Of the twelve animals vaccinated with BCG, six animals were immunised using the 
MVA85A vaccine. IFN-y responses were monitored in these animals over an 8 week 
period after immunisation with MVA85A.
5.2.2.1 Frequencies of IFN-y secreting cells post-MVA85A immunisation
Post-MVA85A immunisation, the frequency of PPD- and Ag85A-specific IFN-y- 
secreting cells increased in 5/6 and 6 /6  of the animals, respectively (figure 5.11). One 
animal (K20) showed no boosting of IFN-y-secreting cells with PPD.
Responses peaked one week after MVA85A immunisation in most of the animals. 
Animal K79 proved an exception as Ag85A-specific responses peaked 2 weeks post- 
MVA85A immunisation and PPD-specific responses increased until week 6 . Animal 
K65 showed much higher frequencies of PPD- and Ag85A-specific IFN-y secreting cells 
following MVA85A immunisation in comparison to the other five MVA85A-immunised 
animals.
Six weeks after MVA85A immunisation there were no significant differences in 
frequency of antigen-specific IFN-y-secreting cells detected between the MVA85A- 
immunised animals and those that had not been MVA85A-immunised.
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Figure 5.10: Frequencies of PPD-specific and Ag85A-specific IFN-y-secreting cells post- 
MVA85A immunisation in rhesus macaques previously vaccinated with BCG compared 
with unboosted controls.
(MVA85A-immunised, red lines; BCG-vaccinated only, blue lines. Numbers beginning 
with ‘K ’ refer to animal identification. * = significant difference [Mann-Whitney 
statistical test, P<0.05]).
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Responses from the MVA85A-immunised rhesus macaques were compared with data 
where MVA85A had been used in clinical trials to boost BCG-vaccination responses in 
human volunteers (Oxford trial T009, Helen McShane, personal communication). 
However, the rhesus macaques received 5x l08 pfu whereas the human volunteers 
received lx l0 8 pfu MVA85A (Beveridge et al., 2008). When the median responses 
between the rhesus macaques were compared with data from the human studies (figure 
5.11), the kinetics of response were extremely similar. Both groups showed peaks at 1 
week post-MVA85 A boost with a decline thereafter.
Statistical analysis of the results showed no significant differences between peak 
responses 1 week post-MVA85A immunisation in rhesus macaques as compared with 
humans (table 5.3). With PPD, there were no statistically significant differences in 
response during the 8 weeks post-MVA85A immunisation between rhesus macaques and 
humans. However, with the Ag85A peptides there were significant differences after the 
initial response at week 1, with human volunteers maintaining a higher number of 
Ag85A-specific IFN-y-secreting cells despite receiving a lower dose of MVA85A. When 
the area under the curve was measured post-MVA85A vaccination in humans and rhesus, 
there was no statistical difference with either antigen tested over the 8 week study period 
(figure 5.12).
Mann-Whitney 
statistical p-value
Rhesus macaques vs. humans
PPD Summed Ag85A peptides
Week 1 0.3254 0.2061
Week 2 0.2061 0.0131
Week 4 0.2061 0.0009
Week 8 0.4824 0.0009
Table 5.3: Comparison of frequencies of IFN-y-secreting cells post-MVA85A 
immunisation in rhesus macaques and human clinical trials.
(Mann-Whitney statistical test; significance level, P<0.05).
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Figure 5.11: Comparison of mean frequencies of PPD-specific and Ag85A-specific IFN- 
y-secreting cells post-MVA85A immunisation of rhesus macaques and human 
volunteers.
(Rhesus macaques, green line; human volunteers, red line. Error bars denote interquartile 
range of samples).
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Figure 5.12: Area under curve analysis after MVA85A immunisation comparing 
responses in humans and rhesus macaques using PPD and Ag85A peptides.
(Mann-Whitney statistical test, significance level P<0.05).
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5.2.2.2 Concentration of IFN-y secreted after immunisation of BCG-vaccinated rhesus
macaques with MVA85A
The concentration of IFN-y secreted in PPD-stimulated 6-day diluted whole blood 
supernatants was measured in BCG-vaccinated animals immunised with MVA85A and 
in BCG-only controls. As shown in figure 5.13, half of the animals that received 
MVA85A showed a peak response 1 week post-immunisation (K69, K86, K65), 
indicating that the boost was successful. The remaining three MVA85A-immunised 
animals (K20, K79, K61) failed to show any increase in PPD-specific IFN-y production 
and were therefore not boosted.
Graphical analysis showed a trend in differences between the BCG/MVA85A- 
immunised and BCG-only animals post-MVA85A boost. However, using the Mann- 
Whitney statistical test at each timepoint (table 5.4) or by analysing areas under the curve 
(figure 5.14), the differences were non-significant (P>0.05) confirming that the 
MVA85A had not resulted in a boosted immune response.
Mann-Whitney 
statistical p-value
Weeks post-MYA85A boost
0 1 2 4 6 8
MVA85A 
immunised vs. 
BCG-only
0.4320 0.0538 0.0741 0.0741 0.2840 0.0633
Table 5.4: Comparison of concentrations of IFN-y secreted in animals immunised with 
MVA85A compared to BCG-only controls.
(Mann-Whitney statistical test; significance level, P<0.05).
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Figure 5.13: Concentration of PPD-specific IFN-y secretion in rhesus macaques 
immunised with MVA85A compared with BCG-only controls.
(BCG/MVA85A-immunised, red lines; BCG-only, blue lines. Numbers beginning with 
4K’ corresponds to individual animal identification numbers).
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Figure 5.14: Area under the curve analysis showing differences in amount of IFN-y 
secreted between BCG-vaccinated and BCG/MVA85A-immunised rhesus macaques. 
(Mann-Whitney statisitical test; significance, P<0.05).
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To determine whether the levels of IFN-y secreted in 6-day diluted whole blood 
supernatants were comparable to frequencies o f IFN-y-secreting cells in PBMC, results 
from the two assays using PPD as antigen were compared.
As shown in figure 5.15, there was a significant correlation between the two data sets 
(r=0.664, p<0.001) using the Spearman’s rank correlation statistical test. As the 
frequencies o f PPD-specific IFN-y-secreting cells increased, so did the level of PPD- 
specific IFN-y secretion in whole blood samples.
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Figure 5.15: Comparison of PPD-specific responses in concentrations of IFN-y secreted 
after stimulation of diluted whole blood with the frequencies of IFN-y-secreting cells 
detected in PBMC after BCG/MVA85A immunisation.
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5.2.2.3 Anti-vaccinia antibody responses after boosting with MVA85A
Due to not all animals showing large IFN-y responses to PPD and Ag85A antigens, an 
anti-vaccinia antibody ELISA was used to determine whether animals had produced an 
anti-vector response. As shown in figure 5.16, all of the animals immunised with 
MVA85A exhibited an increase in anti-vaccinia antibody levels compared with BCG- 
only and unvaccinated control groups. This provided confirmation that all animals had 
received the MVA85A vaccine.
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Figure 5.16: Anti-vaccinia antibody responses in rhesus macaques immunised with 
MVA85A compared to BCG-vaccinated only and unvaccinated controls.
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5.2.3 Responses after challenge of vaccinated animals with M. tuberculosis
Sixteen rhesus macaques were challenged by the aerosol route with M. tuberculosis 
(estimated dose, 50 cfu), with animals divided into three groups:
• 6 animals received BCG (21 weeks prior to challenge).
• 6  animals received BCG, and 12 weeks afterwards were immunised with 
MVA85A (9 weeks prior to challenge).
• 4 animals were unvaccinated.
5.2.3.1 Frequencies of IFN-y-secreting cells in vaccinated animals after challenge with 
M. tuberculosis
As with the post-vaccination phase, the frequencies of IFN-y-secreting cells after 
stimulation with PPD and Ag85A peptides were measured for up to 1 year post­
challenge (figure 5.17). Using PPD as antigen, responses started to rise 6 weeks after 
infection, whereas using Ag85A peptides the response increased in some of the animals 
4 weeks post-challenge.
Using Ag85A peptide pools there was no statistical difference in response between the 
vaccinated and unvaccinated groups. By using PPD as antigen there were some 
differences between the vaccinated and unvaccinated groups of rhesus macaques when 
measured at individual time-points. However, when a statistical correction test was 
applied (Bonferroni correction) to take into account multiple comparisons, the difference 
became insignificant (table 5.5). Statistical analysis was only carried out during the 24 
weeks after M. tuberculosis challenge as after this point group sizes decreased due to 
animals meeting humane end-points.
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PPD
Mann-Whitney 
statistical p-value
Weeks post-M tuberculosis challenge
1 2 4 6 8 10 12 16 20 24
BCG vs. 
BCG/MVA85A 0.0051 0.1282 0.0927 0.1282
'7'A ’-A ^
0.0051
. - 'A
0.0131 0 .0 1 2 2 1.0000 1.000 0.1052
BCG vs. 
unvaccinated 0.1356 0.0700 0.6698 0 .0142 0.2410
* 0.1752 0.8465 0.2472 1.0000
BCG/MVA85A
vs.
unvaccinated
0 .0 1 4 2 0 .0252 0.0700
A A A
0.0142 0.1098 * 0.0814 0.6985 0.6985 0.2453
Ag85A peptides
Mann-Whitney 
statistical p-value
Weeks pos1:-M tuberculosis challenge
1 2 4 6 8 10 12 16 20 24
BCG vs. 
BCG/MVA85A 0.8102 0.9362 0.3785 0.2298 0.5752 0.0927 1.0000 1.0000 0.2472 0.4875
BCG vs. 
unvaccinated 0.9151 0.4555 0.6698 0.2410 0.4555 0.6171 0.5613 0.5613 1.0000 0.4875
BCG/MVA85A
vs.
unvaccinated
0.5224 1.0000 0.2410 0.7491 0.9151 0.4047 0.0814 0.6985 1.00000 1.0000
Table 5.5: Differences in frequencies o f PPD- and Ag85A-specific IFN-y-secreting cells 
after challenge with M. tuberculosis between vaccinated and non-vaccinated groups of 
rhesus macaques.
(Mann-Whitney statistical test; significance level, P<0.05. * = unable to perform 
statistical test. Light green shading indicates where individual Mann-Whitney statistical 
test is significant, but differences were not significant when a Bonferonni correction was 
applied, P<0.005).
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Figure 5.17: Frequencies of PPD- and Ag85A-specific IFN-y-secreting cells after 
challenge of vaccinated and unvaccinated rhesus macaques with M. tuberculosis.
(BCG-vaccinated, blue lines; BCG/MVA85A-vaccinated, red lines; and unvaccinated, 
green lines).
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After challenge of animals with M. tuberculosis the responses occurred in peaks; the first 
beginning between 0 -1 0  weeks post-infection and then 10-16 weeks after challenge. 
During the first period, the BCG/MVA85A immunised animals seemed to have the 
highest responses, and then during the second period the BCG-vaccinated and 
unvaccinated animals prevailed as frequencies of IFN-y-secreting cells increased in these 
groups.
To determine whether these observations were statistically significant, areas under the 
curves were measured during these periods. Results confirm that 0-10 weeks post­
challenge the frequencies of PPD-specific IFN-y-secreting cells were significantly 
greater (P<0.05) in the BCG/MVA85A-immunised group than in the BCG-vaccinated or 
unvaccinated groups of animals (figure 5.18). 10-16 weeks post-infection the responses 
in the BCG/MVA85A group declined and responses in the other two groups increased, 
although these differences did not reach statistical significance (P>0.05). In contrast to 
the PPD-specific results, no differences were observed when Ag85A peptides were used 
as antigen.
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Figure 5.18: Comparison of area under the curve analysis to determine differences in 
frequency of IFN-y-secreting cells at different stages post-M tuberculosis challenge. 
(Mann-Whitney statistical test: * = P<0.05).
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In addition to measuring the frequencies of IFN-y-secreting cells after stimulation with 
the antigens present in the vaccine (PPD and Ag85A), M. tuberculosis-specific peptide 
antigens were also used: CFP10 and ESAT-6 .
Responses to at least one of these antigens was detected in all animals 4 weeks post­
challenge (figure 5.19). The kinetics of responses were similar with both antigens, with 
peaks at similar times and frequencies of IFN-y-secreting cells comparable for each 
animal.
To determine whether the response was affected by prior vaccination, statistical analyses 
were undertaken at each time-point until 28 weeks post-M tuberculosis challenge. At 
this point animal numbers had declined to such an extent that statistical analysis became 
less relevant. The only significant difference (P<0.05) observed was between the BCG 
and BCG/MVA85A vaccinated animals 8 weeks post-infection using CFP10 peptides to 
stimulate cells, where the MVA85A-immunised animals had higher responses. At all 
other time-points there were no differences between the groups of vaccinated and 
unvaccinated animals.
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Figure 5.19: Frequencies of CFP10- and ESAT-6-specific IFN-y-secreting cells after 
aerosol M. tuberculosis challenge of vaccinated and unvaccinated rhesus macaques. 
(BCG-vaccinated, blue lines; BCG-MVA85A vaccinated, red lines; and unvaccinated, 
green lines).
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5.2.3.2 Concentration of IFN-y secreted in vaccinated animals after challenge with M.
tuberculosis
The amount o f IFN-y secreted in 6 day PPD-stimulated diluted whole blood samples was 
measured in the vaccinated and non-vaccinated rhesus macaques after infection with M. 
tuberculosis.
IFN-y secretion was detected in all animals 4 weeks post-M tuberculosis challenge 
(figure 5.20). Individual animals varied with the time of their peak response and the 
concentration of IFN-y detected, with animal K20 showing large concentrations of IFN-y 
produced at weeks 12 and 16 post-challenge.
To determine whether there were any significant differences in responses between the 
vaccinated and unvaccinated groups, a statistical analysis of the data was carried out 
(table 5.6). No significant differences (P<0.05) between the groups were found at any of 
the time-points tested.
Mann-Whitney 
statistical p-value
Weeks post-M tuberculosis challenge
2 4 6 8 10 12 16 2 0 24
BCG vs. 
BCG/MVA85A 0.4712 0.6889 1.0000 0.9362 0.8102 0.1437 0.3329 0.1052 0.1052
BCG vs. 
unvaccinated 0.3938 0.1098 0.7491 0.5940 1.0000 0.0814 0.8465 0.8170 0.1052
BCG/MVA85A 
vs. unvaccinated 0.5940 0.3374 0.9151 0.5940 0.8676 1.0000 0.6985 1.0000 0.2453
Table 5.6: Statistical analysis of the differences between vaccinated and non-vaccinated 
groups of rhesus macaques in concentrations of PPD-specific IFN-y secretion after 
challenge with M. tuberculosis.
(Mann-Whitney statistical test; significance level P<0.05).
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Figure 5.20: Concentrations of IFN-y secreted in 6 day PPD-stimulated diluted whole 
blood supernatants in vaccinated and unvaccinated rhesus macaques after M  
tuberculosis challenge.
(BCG-vaccinated, blue lines; BCG-MVA85A vaccinated, red lines; and unvaccinated, 
green lines).
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As the concentration of IFN-y secreted and frequency of IFN-y-secreting cells after PPD 
stimulation were measured at the same time-points, the data were compared to see if any 
correlation was observed (figure 5.21). Data used covered the 24 weeks post-challenge; 
no correlation was seen when comparing these data sets (Spearman’s rank correlation 
test; rs=0.146, P=0.119). When performed on the separate vaccinated/non-vaccinated 
groups, no correlation was seen in the BCG-vaccinated, BCG/MVA85A-immunised or 
unvaccinated groups, with rs=0.115 (P=0.435), rs=0.187 (P=0.241) and rs=0.131 
(P=0.524), respectively.
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Figure 5.21: Comparison of concentration of IFN-y secreted and frequency of IFN-y- 
secreting cells after stimulation with PPD in vaccinated and unvaccinated rhesus 
macaques post-M tuberculosis challenge.
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5.2.4 Specificity of the Ag85A responses after vaccination and post-M tuberculosis
infection
As Ag85A peptide responses were detected after MVA85A immunisation and after M 
tuberculosis challenge, the specificity of which peptide pools were immunogenic was 
studied.
Figure 5.22 shows the responses to the 7 peptide pools of Ag85A after MVA85A 
boosting and after M tuberculosis challenge. The specificity of the response at 1 and 2 
weeks after MVA85A immunisation was similar for each animal, though different 
between animals. Post-M tuberculosis infection though, the specificity differs as the 
dominant pool(s) change. However, there are instances of the same peptide pool giving 
strong frequencies of IFN-y-secreting cells post-MVA85A and post-challenge, such as 
peptide pool B in animals K20 and K79.
As the peak responses were 1 week after MVA85A immunisation, and 6 weeks post-M 
tuberculosis infection in most animals, these time-points were looked at in greater detail. 
As shown in figure 5.23, the dominant responses to the peptide pools changed in most of 
the animals after MVA85A-boost and after M tuberculosis infection. However, one 
animal (K79) did show similar responses, with the exception of losing the peptide pool C 
response after infection.
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Figure 5.22: Frequencies of IFN-y-secreting cells after stimulation with the individual 
Ag85A peptide pools after MVA85A immunisation and M. tuberculosis challenge. 
(MVA85A boost given at week 12; M. tuberculosis challenge delivered at week 21).
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Figure 5.23: Proportion of the total Ag85A response to the individual peptide pools of 
Ag85A 1 week post-MVA85A immunisation and 6 weeks post-M tuberculosis 
infection.
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5.2.5 Measurements of IFN-y and relation to survival post-M tuberculosis
infection
As some animals reached humane clinical endpoints prior to the end of the study, IFN-y 
measurements were analysed to see if  they showed any differences. Figure 5.24 shows 
where each animal was euthanised due to reaching humane endpoints.
Weeks post-M tuberculosis challenge:
0 5 10 15 20 25 30 35 40 45 50
Unvaccinated K54 K47 K62 K32
BCG K44 K52 K80 K50 K59 K43
BCG/MVA K69 K61 K86K79 K20 K65
TShort-term survivors End of study
Figure 5.24: Diagrammatic overview of animals euthanised during the experimental 
study.
Animals were split into two groups of 8, those that were euthanised at 16 weeks or less 
post-challenge (short-term survivors) and those that survived for over 16 weeks (longer- 
term survivors), as shown in table 5.7. It was assumed that meeting the humane clinical 
endpoint within 16 weeks was due to more rapid disease progression in these animals.
Short-term survivors Longer-termsurvivors
K54 K62
K47 K20
K44 K32
K69 K80
K61 K65
K86 K43
K52 K50
K79 K59
Table 5.7: Animals present in short-term and longer-term survival groups.
-254-
5.2.5.1 IFN-y responses during vaccination in relation to survival post M. tuberculosis
challenge
5.2.5.1.1 Frequency o f IFN-y-secreting cells during vaccination
To determine whether the frequency of PPD- or Ag85A-specific IFN-y secreting cells 
provided a correlate of protection against M. tuberculosis infection, data during the 
vaccination period were analysed in comparison with survival times post-challenge 
(figure 5.25).
No trends were observed between the frequency of PPD- or Ag85A-specific IFN-y 
secreting cells during vaccination and survival post-M tuberculosis challenge. The 
results show that the BCG/MVA85A-immunised group had the highest median PPD- 
specific responses and survived longer. However, as this observation was made on a 
group consisting of only two animals error bars could not be assigned. In this group, one 
animal (K65) had 4555 IFN-y secreting cells/106 PBMC and the other (K20) only 218; 
therefore a considerable range was seen between these animals.
Another way to interpret the data was to determine whether the peak response post­
vaccination correlated with length of survival post-M tuberculosis challenge. Using this 
method, it was shown that the in the BCG-vaccinated group the PPD-specific responses 
were significantly correlated (Pearson correlation coefficient, r=-0.922, P=0.009)) with 
survival time (Figure 5.26). Animals boosted with MVA85A did not show any statistical 
correlation between peak response and time post-infection.
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Figure 5.25: Median frequencies o f IFN-y-secreting cells after stimulation with PPD and 
Ag85A peptides in BCG-vaccinated and BCG/MVA85A-vaccinated rhesus macaques in 
relation to their period of survival after M. tuberculosis infection.
(Error bars denote interquartile range for group sizes consisting of 4 animals).
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(a) BCG vaccination
IFN-y secreting cells/10 PBMC 
Pearson correlation 
coefficient
Animal
ID
Survival
(days)
K44 527
K52 117 466
K80 350 222
K50 350 351
K59 350 273
K43 350 204
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(b) BCG vaccination with MVA85A boost
Animal
ID
Survival
(days)
IFN-y secreting cells/106 PBMC
PPD Pearson correlation coefficient
Ag85A Pearson correlation 
coefficient
K69 68 885
r=0.764
(P=0.077)
2910
r=-0.281
(P=0.590)
K61 85 368 2561
K86 86 1642 7276
K79 90 750 474
K20 199 114 204
K65 350 4320 21850
Figure 5.26: Peak vaccination responses compared to survival post-M tuberculosis 
challenge.
(Results displayed are values above pre-vaccination levels).
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5.2.5.1.2 Concentration o f  IFN-y secretion during vaccination
To determine whether the concentration of PPD-specific IFN-y secreted in 6 day diluted 
whole blood supernatants related to survival, data after BCG and BCG/MVA85A 
vaccination were plotted (figure 5.27). Results show that the BCG/MVA85A-immunised 
animal with the highest secretion of IFN-y survived for over 200 days. However, there 
was no overall trend with the concentration of IFN-y post-immunisation and survival, as 
animals with low concentrations of IFN-y also were in the longer survival groups.
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Figure 5.27: Concentration of IFN-y secreted in diluted whole blood after stimulation 
with PPD for 6 days in BCG-vaccinated and BCG/MVA85A-vaccinated rhesus 
macaques in relation to their period of survival after M. tuberculosis infection.
(Long-term survivors, green lines; shorter-term survivors, red lines. BCG-vaccinated, 
solid lines; BCG/MVA85A-vaccinated, dashed lines).
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5.2.5.2 IFN-y responses post-challenge in relation to survival post M. tuberculosis
challenge
5.2.5.2.1 Frequency o f IFN-y-secreting cells vost-challense
To determine whether there were any trends between the frequency of antigen-specific 
IFN-y-secreting cells after M. tuberculosis challenge and the survival of animals, results 
using PPD and Ag85A were compared. As shown in figure 5.28, there was no obvious 
indication of a relationship between the number of cells able to secrete IFN-y after PPD 
or Ag85A stimulation and survival time.
Post-challenge responses were measured against CFP10 and ESAT-6 antigens, as well as 
PPD and Ag85A. To determine whether there was a difference between responses to 
these antigens after M. tuberculosis infection a statistical analysis was carried out on the 
data in the 10 weeks following challenge. As shown in table 5.8, there were sporadic 
differences between responses to Ag85A, CFP10 and PPD at 2, 4 and 10 weeks post­
infection, respectively. Due to no consistency in the same antigen or time-point showing 
a significant difference it is difficult to ascertain a definite correlation between frequency 
of IFN-y-secreting cells and survival periods of animals.
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Figure 5.28: Median frequencies of PPD- and Ag85A-specific IFN-y-secreting cells in 
long-term survivors (>16 weeks post-infection) and shorter-term survivors (<16 weeks 
post-infection).
(Error bars indicated interquartile range where groups sizes consisted of n=4).
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Mann-whitney 
statistical p- 
value
Weeks post-M tuberculosis challenge
-1 1 2 4 6 8 10
PPD 0.2131 0.7972 0.1383 0.7073 0.8279 0.0855 0.0027
Ag85A 0.3184 0.5635 0.0313 0.2271 0.7132 0.7929 0.4777
CFP10 0.0742 ND 0.8748 0.0406 ND 0.1278 ND
ESAT-6 0.2076 ND 0.4622 0.7929 ND 0.7929 ND
Table 5.8: Statistical analysis of frequencies of antigen-specific IFN-y-secreting cells 
after challenge with M. tuberculosis in animals which survived for a short time (<16 
weeks post-infection) and those which survived longer (>16 weeks post-infection). 
(Mann-Whitney statistical test; significance, P<0.05. ND = not done).
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5.2.5.2.2 Concentration o f  IFN-y secreted post-challense
To determine whether the concentration of IFN-y secreted in 6 day PPD-stimulated 
diluted whole blood supernatants related to prolonged survival of animals, this 
measurement was compared in long-term survivors versus shorter-term survivors. As 
shown in figure 5.29, the animals which were euthanised <16 weeks post-M tuberculosis 
had concentrations of IFN-y less than 4200 pg/ml post-infection, whereas most of the 
animals which survived over 16 weeks post-challenge had greater concentrations of IFN- 
y secreted.
To determine if there were any statistically significant differences in concentrations of 
IFN-y secreted and prolonged survival, each time-point post-infection was analysed. As 
shown in figure 5.30, the difference at 6 weeks post-infection approached significance 
(P=0.0520). However, at 8 weeks post-infection the difference was statistically 
significant (P=0.0136), with animals that survived longer secreting higher concentrations 
of IFN-y.
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Figure 5.29: Concentration of PPD-specific IFN-y secreted in blood from long-term 
survivors (>16 weeks post-infection) and shorter-term survivors (<16 weeks post­
infection).
(Long-term survivors, green lines; shorter-term survivors, red lines).
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Figure 5.30: Differences in concentrations of IFN-y secreted in 6 day PPD-stimulated 
diluted whole blood supernatants post-M tuberculosis challenge in long-term survivors 
versus shorter-term survivors.
(Mann-Whitney statistical test: Significance level, P<0.05)
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5.3 DISCUSSION
5.3.1 IFN-y responses after BCG vaccination
5.3.1.1 Comparison of rhesus macaques and cynomolgus macaques
5.3.1.1.1 Frequency o f IFN-y secreting cells in rhesus macaques and cvnomolsus 
macaques
In a pilot study using two rhesus macaques and two cynomolgus macaques, IFN-y 
responses were monitored for over 70 weeks post-vaccination. The frequency of PPD- 
specific IFN-y-secreting cells was higher in the rhesus macaques than in the cynomolgus 
macaques. However, given that the cynomolgus macaques only had one baseline 
measurement, it is difficult to determine whether the responses seen post-BCG were 
induced by the vaccine or represented natural fluctuations in background responses. As 
shown previously (figure 3.5), frequencies of PPD-reactive IFN-y-secreting cells 
fluctuated by similar amounts during baseline screening of nai've animals. However, in 
the rhesus macaques baseline frequencies were assessed at four intervals so there could 
be greater confidence in the responses seen after BCG-vaccination.
Responses in macaques were detected for 70 weeks post-vaccination. In human studies 
where infants were BCG-vaccinated at 0-2 months of age, PPD-specific responses 
persisted for at least 1 year after immunisation (Marchant et a l, 1999). However, in 
other human studies, BCG-induced IFN-y-secreting cell responses became 
indistinguishable from background after 24 weeks (Pathan et a l , 2007). These 
differences may be due to the latter study using subjects who were older, or due to 
differences in study populations with the earlier study using subjects in Africa and the 
latter using volunteers in the UK. In the guinea pig model, intradermal vaccination with
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BCG showed that low levels of organisms persisted for at least 6 months after 
immunisation (Horwitz & Harth, 2003). Therefore, it could be speculated that the 
continued response in the rhesus macaques for over 70 weeks is due to these 
mycobacteria continuing to prime the immune response. However, no bacteria were 
detected in tissue samples collected from animals at necropsy (appendix 14, section 
8.14), although this could be due to low levels or to the bacilli being at sites not 
measured (e.g. at the site of vaccination in the arm). Alternatively, it could be that BCG 
vaccination activated memory T cells that were detected long after the BCG organisms 
had cleared (Marchant et al., 1999).
5.3.1.1.2 Concentration o f IFN-y secretion post-BCG vaccination in rhesus macaques 
and cynomolgus macaques
In the rhesus macaques, peak production of IFN-y was observed 6 weeks post­
vaccination. In human studies, investigators have found peak IFN-y production 8 weeks 
after immunisation (Nabeshima et a l, 2005). However, in this study concentrations were 
only measured 0, 2, 4, 8, and 52 weeks post-vaccination, so the week 6 time-point was 
not assessed. Following BCG-vaccination, the cynomolgus macaques produced lower 
concentrations of IFN-y. The observation of cynomolgus macaques producing less IFN-y 
post-BCG vaccination compared to rhesus macaques has also been reported by others 
(Langermans et al., 2001).
5.3.1.2 IFN-y responses in a larger cohort of rhesus macaques vaccinated with BCG
The rhesus macaques were immunised with the same BCG vaccine preparation as used 
in the human clinical trials conducted in Oxford, thereby allowing data to be compared. 
This is an important factor, as it has been shown that different strains of BCG (e.g.
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Japanese BCG, strain 172 and Danish BCG, strain 1331) can affect the immune response 
(Davids et al., 2006; Wedlock et al., 2007).
5.3.1.2.1 Frequency o f IFN-y secretins cells in BCG-vaccinated rhesus macaques
After PPD-stimulation, the peak frequencies of circulating IFN-y-secreting cells were 
seen 4-8 weeks post-vaccination. When rhesus macaques were vaccinated with BCG 
intravenously and via bronchial inoculation, PPD-specific IFN-y-producing cells were 
detected in PBMC 3-4 weeks post-vaccination (Lai et al., 2003). Due to the different 
vaccination routes, it could be that delivery by intradermal injection takes longer for the 
immune response to be established. In parallel to the ELISPOT analysis, intracellular 
cytokine staining (ICS) was also carried out. However, few PPD-specific increases in 
CD3+, CD4+ or CD8+ T-cell subsets were seen (appendix 15, section 8.15). This was 
likely due to the ELISPOT assay being more sensitive than ICS analysis.
Few responses to Ag85A peptides were observed in rhesus macaques following BCG 
vaccination, similar to data from human studies (McShane et al., 2004; Pathan et al., 
2007). However, responses to Ag85A peptides have been identified in CD8+ T-cells 
using BCG-stimulated human cells (Smith et al., 2000). These responses were detected 
by boosting responses ex vivo with BCG and so measures a different parameter to that 
which was studied in the rhesus macaques where cell populations were not expanded.
5.3.1.2.2 Concentration o f IFN-y secreted from 6 day whole blood supernatants in 
BCG-vaccinated rhesus macaques
BCG-immunised rhesus macaques produced significant concentrations of IFN-y after 
PPD-stimulation over the 12 weeks post-vaccination. Responses were detected at 2
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weeks post-vaccination, whereas in humans no reactivity was found before 4 weeks post­
vaccination (Ravn et a l , 1997). The human studies used stimulation of PBMC for 5 days 
with short-term culture filtrate; 8 weeks post-BCG vaccination the concentration of IFN- 
y was 396 pg/ml in 10 non-sensitised donors (Ravn et a l , 1997). This is similar to the 
levels observed in the BCG-vaccinated rhesus macaques.
5.3.2 IFN-y responses after MVA85A immunisation of BCG-vaccinated rhesus 
macaques
Of the 12 rhesus macaques vaccinated with BCG, 6 were immunised with the MVA85A 
vaccine. MVA85A immunisation was carried out 12 weeks after the BCG vaccination. 
This time-point was chosen as it needed to be long enough to allow the priming 
immunisation with BCG to induce antigen-specific T cells (McShane & Hill, 2005) and 
not interfere with the initial vaccination response induced by the BCG.
5.3.2.1 Frequency of IFN-y-secreting cells post-MVA85A boosting
One week after MVA85A immunisation of BCG-vaccinated rhesus macaques, the 
frequencies of antigen-specific IFN-y-secreting cells sharply increased, as seen in 
humans (Brookes et ah, 2008; Hawkridge et al, 2008; McShane et a l, 2004; Pathan et 
al, 2007). However, not all of the animals showed an increase in IFN-y-secreting cells, a 
situation again similar to the human studies where one of the 17 volunteers failed to 
boost IFN-y responses (McShane et al, 2004).
Comparing responses of MVA85A-immunised versus BCG-only animals, there was a
statistically significant difference in the frequency of PPD-specific IFN-y-secreting cells
until 2 weeks post-immunisation using PPD antigen and until 4 weeks using Ag85A
peptides. In human studies, responses were statistically significantly higher in MVA85A-
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boosted subjects for at least 24 weeks (McShane et al., 2004) and 52 weeks (Beveridge 
et al., 2008; Hawkridge et al., 2008) following vaccination. Median responses in the 
boosted animals were consistently higher than their unboosted counterparts despite not 
reaching statistical significance.
When the MVA85A-immunised responses in the rhesus macaques were directly 
compared with data from human clinical trials, the median human responses were higher 
than the median responses seen in the rhesus macaques. Statistical analysis showed that 
when using PPD as antigen, there were no differences in response between rhesus 
macaques and humans throughout the 8 weeks post-MVA85A. With Ag85A peptides, 
there was no difference in the peak response 1 week post-boost, but there were 
differences at weeks 2, 4 and 8. The reason for the higher level of responses in humans, 
despite the macaques receiving a higher dose (5x108 pfu) of MVA85A compared to 
concentrations used in human clinical trials (lx l08 pfu, Oxford trial T009), could be due 
to continual restimulation with environmental mycobacteria encountered by the 
population. It is unlikely that the rhesus macaques would encounter similar levels as air 
into the rooms is continually filtered, water is sterilised, and there is little contact with 
other subjects apart from the animal handlers. However, as the animal handlers wear 
personal protective equipment, this further reduces potential sources of exposure to 
environmental mycobacteria to the rhesus macaques.
Using ICS analysis, PPD-stimulated cells showed an increase in CD3+ T cells expressing 
IFN-y in animals K65 and K86 (appendix 17, section 8.17), the two animals with the 
highest frequency of IFN-y-secreted cells detected by ELISPOT. When the T-cells were 
sub-divided, increases in IFN-y expression were found in CD4+ T-cells but not CD8+. 
This is similar to human studies where all of the responses seen following vaccination
-270-
with BCG and MVA85A were diminished after depletion of CD4+ T cells (McShane et 
al., 2004). The lack of CD8+ T-cell responses may be due to experimental design relating 
to the use of PPD in the ICS assay, whereas using live BCG in a restimulation assay, as 
used by others (Smith et al., 2000), may have yielded some CD8+ responses.
Using DNA vaccination with poxvirus boosting in malaria studies, the peak ex vivo 
response was at 7 days after the heterologous vaccination for each participant. When this 
was compared with their corresponding cultured ELISPOT response at 6 months post­
vaccination, there was a significant correlation between the two assays (Keating et al.,
2005). This suggested that the magnitude of ex vivo responses has an impact on the 
development of a long-term memory population of T cells. Using MVA85A as a vaccine 
boost, if the same is true then the high frequencies of IFN-y-secreting cells detected 1 
week post-boost in the rhesus macaques may indicate the establishment of longer-term 
memory immunity. However, as the responses declined rapidly this may mean that there 
was insufficient time for optimum development of memory immune cells.
5.3.2.2 Concentration of IFN-y secreted post-MVA85A immunisation
Secretion of IFN-y was elevated post-MVA85A immunisation in three of the six animals 
following PPD stimulation -  which were also the animals with the highest frequencies of 
PPD-specific IFN-y-secreting cells. Increased secretion of IFN-y has also been observed 
after MVA85A boosting of BCG responses in mice (Romano et al., 2006). When the 
concentration of IFN-y secreted was compared with the frequency of cells secreting IFN- 
y after MYA85A immunisation of rhesus macaques, a significant correlation was 
observed. A similar correlation was not found in humans (Beveridge et al., 2008).
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5.3.2.3 Anti-vaccinia antibodies after MVA85A boosting
All of the MVA85A-immunised animals showed vaccinia-specific responses, whereas 
the BCG-only and unvaccinated animals did not show any specific increases in antibody 
levels. This confirmed that all animals had made an immunological response to the 
vector; so although not all animals showed strong IFN-y responses, this was not due to 
failure of vector delivery. However, as insert-specific responses were not measured they 
could have been a failure in antigen 85 A presentation to the immune response.
5.3.3 IFN-v responses after M. tuberculosis challenge of vaccinated rhesus 
macaques
5.3.3.1 Frequency of IFN-y-secreting cells after M. tuberculosis challenge of vaccinated 
animals
The increase in frequencies of PPD-specific IFN-y-secreting cells occurred sooner after 
M tuberculosis infection in the BCG/MVA85A-immunised rhesus macaques than either 
the BCG-vaccinated animals or the unvaccinated group. In BCG-vaccinated rhesus 
macaques, the ability of CD4+, CD8+ and y8 T cells to mount faster and stronger recall 
responses were considered to be important mechanisms underlying the immune 
protection against mycobacterial infection (Lai et al., 2003). In mice vaccinated with 
BCG and protected from M tuberculosis infection, an early increase at 2 weeks post­
challenge of IFN-y in lungs compared to nai’ve animals was seen (Goter-Robinson et al., 
2006; Rodgers et al., 2006). These differences diminished as the nai've mice mounted 
their own immune response to infection. The early vaccine-induced cytokine responses 
in immunised animals limited bacterial growth during the early stages of infection which 
resulted in a decreased bacterial burden during the chronic stage of the infection (Goter- 
Robinson et al., 2006). Therefore, by decreasing bacterial growth during early stages of
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infection, these vaccine-induced cytokine responses to mycobacteria may enhance 
survival of vaccinated animals .
Increases in IFN-y+ T-cell populations (CD3+, CD4+ and CD8+) measured by 
intracellular cytokine staining showed that most of the responses post-M tuberculosis 
challenge were CD4+-specific (appendix 18, section 8.18). However, antigen-specific 
CD8+ T cells were identified in 2 MVA85A-boosted animals (K20 and K86). This may 
indicate that MVA85A enhances the cytotoxic T-lymphocyte (CTL) response in some of 
the poxvirus-boosted animals, although further work would be needed to confirm this.
5.3.3.2 Concentration of IFN-y secreted after M. tuberculosis challenge of vaccinated 
animals
There were no significant differences in concentrations of IFN-y secreted between the 
vaccinated groups of animals and the unvaccinated group. This observation has also been 
reported in mice, where BCG-vaccinated and unvaccinated animals produced similar 
concentrations of IFN-y post-infection (Elias et a l, 2005), even though the BCG- 
vaccinated group had some protection from disease. In human studies, despite 
differences in initial IFN-y levels in BCG-vaccinated and unvaccinated household 
contacts, after becoming infected with M. tuberculosis final levels of IFN-y were also 
similar (Whalen et a l , 2006).
5.3.3.3 Specificity of the peptide responses during vaccination and after M tuberculosis 
infection
To see if the same peptides reacted after MVA85A-immunisation and after M.
tuberculosis challenge, individual responses to the Ag85A peptide pools were analysed.
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In 5/6 animals the response varied between those seen after MVA85A-immunisation and 
those detected after infection, showing that the specificity of response changed.
After MVA85A-immunisation of rhesus macaques, the response detected to the peptide 
pools was similar in specificity for each animal at each of the time-points. However, each 
individual macaque showed its own immunodominant peptide pool recognition, with 
different pools being immunogenic in different animals. This is similar to humans where, 
after MVA85A-boosting, mapping the specificity of the response to Ag85A by IFN-y 
ELISPOT revealed that different epitope targeting patterns were observed in each of the 
2 subjects tested (Beveridge et a l , 2007). Also similar to the rhesus macaques, the 
responses in humans decreased but the epitope specificity displayed at week 1 post- 
MVA85A boosting was maintained at week 24 (Beveridge et a l , 2007).
5.3.4 IFN-v as a correlate of protection
5.3.4.1 Survival of vaccine groups
Throughout the analysis so far, differences in IFN-y responses have been analysed in
light of the vaccination protocols for the groups of animals. Importantly, BCG-
vaccinated animals were found to be significantly protected from M. tuberculosis
infection compared to unvaccinated controls (appendix 19, section 8.19). This is in line
with earlier studies (Anacker et a l , 1972; Barclay et a l , 1970; Barclay et a l , 1973;
Good, 1968; Janicki et al, 1973; Ribi et al, 1971; Schmidt, 1972) and more recent work
where BCG-vaccinated rhesus macaques remained clinically healthy during a 2.5-month
period of follow-up after M. tuberculosis challenge (Shen et a l, 2002). However, a study
comparing BCG vaccination efficacy in rhesus macaques and cynomolgus macaques
found no significant protection in rhesus macaques (Langermans et al., 2001). This
difference may be due to a large dose of 3,000 cfu M. tuberculosis being delivered via
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intratracheal instillation in the latter study compared to 50 cfu delivered by aerosol in 
this study. Also, in the Langermans et al study, BCG was removed with chemotherapy 
after 8 weeks (Langermans et a l , 2001). As BCG is known to persist for over 6 months 
in guinea pigs (Horwitz & Harth, 2003), perhaps there was insufficient priming of the 
immune response or that a continual BCG presence was required for protection.
Using the rhesus macaque model, MVA85A immunisation abolished protection above
that of BCG alone from M. tuberculosis infection in this study (appendix 19, section
8.19). This is in contrast to another study in rhesus macaques performed at the
Biomedical Primate Research Centre (BPRC), The Netherlands (Verreck-FAW et a l ,
“New primary and booster vaccination strategies display significant protection in a
rhesus monkey model for tuberculosis”, poster presented at Tuberculosis: from lab
research to field trials conference, 2007). In the BPRC study, BCG/MVA85A-vaccinated
animals showed protection by overall pathology scores, lung pathology, chest X-ray
scores at autopsy, body weight and C-reactive protein levels. Although this thesis reports
a different measure of outcome, i.e. survival, the BPRC study lasted for up to 18 weeks
post-challenge and no BCG/MVA85A-immunised animals were reported to have
reached clinical end-points. As 4 of the 6 BCG/MVA85A-immunised animals in the
studies described in this thesis reached end-points before 18 weeks, it is apparent that
animals in the BPRC study survived longer. The differences in this study include the
period between BCG and MVA85A boost (9 weeks compared to 12 weeks in this thesis)
and a difference in challenge (1,000 cfu delivered by intratracheal instillation compared
to 50 cfu delivered by aerosol in this thesis). It could be speculated that housing
conditions of the primates varied; for example, both colonies allow their macaques
outdoors during certain periods prior to experimental study, which may mean they are
exposed to different strains and levels of environmental mycobacteria. Alternatively, it
may be that differences in animal genetics contributed to the differences in response. One
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comparison between studies would be to look at differences in IFN-y responses, 
especially 1 week post-MVA85A boost. However, in the BPRC study the assay failed at 
this timepoint (Verreck-FAW, personal communication) preventing this comparison 
from being made.
Protection against M. tuberculosis using MVA85A boosting of BCG vaccination has 
showed mixed results in mice. A decrease in bacterial load in the spleen and lung 6 
weeks after aerosol M. tuberculosis challenge has been observed (Goonetilleke et al., 
2003). Others, however, have shown that MVA85A did not result in a significant 
enhancement in survival as boosted animals had a median survival time of 18.5 weeks 
compared to 19 weeks when given BCG alone (Romano et a l , 2006). As well as using 
different outcomes to measure success, the route of M tuberculosis infection was i.v. in 
the latter study compared to aerosol delivery in the former, thus likely contributing to 
differences seen between the two studies.
In the guinea pig model, protection was seen after poxvirus boosting of BCG responses
(Williams et a l , 2005a). The differences between the guinea pig studies showing
protection and the study in mice (Romano et a l , 2006) and rhesus macaques that did not
show protection could be due to several factors. Firstly, the guinea pig studies included a
boost with Ag85A contained within a fowlpox virus vector (FP85A) in addition to
MVA85A (Williams et a l , 2005a). Also, there were differences in time between BCG
vaccination and MVA85A boosting: 9 weeks in the rhesus macaques, 8 months in the
mouse study (Romano et al, 2006), and 1 month in the guinea pig experiments
(Williams et al, 2005a). However, in humans a difference in boosting interval did not
significantly affect the peak vaccine immune responses (Pathan et a l, 2007). Challenge
routes also varied, with intravenous challenge being used in the mice (Romano et a l,
2006) but aerosol infection in the rhesus macaques and guinea pigs (Williams et a l,
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2005a). It has also been hypothesised that after boosting, the cytokine secretion pattern in 
guinea pigs may be different due to immunological differences between animal species 
(Wakeham et al., 1998). Recent advances in cytokine work in guinea pigs, including the 
analysis of cytokine mRNA profiles in-situ (Ly et al., 2008) and the development of 
monoclonal antibodies for IFN-y (Schafer et al., 2007), will allow this hypothesis to be 
tested out in the future.
5.3.4.2 Survival and post-M tuberculosis infection responses
5.3.4.2.1 Frequency o f IFN- y-secreting cells and rapid disease vrosression o f animals 
during M. tuberculosis infection
No consistent difference could be found between those animals that survived >16 weeks 
post-infection and those that did not in terms of the frequency of circulating antigen- 
specific IFN-y-secreting cells post M. tuberculosis challenge. This has also been recently 
reported in the mouse model of BCG-vaccination and M. tuberculosis infection, where 
frequencies of Ag85A-specific IFN-y-secreting T cells did not correlate with protection, 
but instead reflected the load of M. tuberculosis infection (Mittrucker et al., 2007).
5.3.4.2.2 Concentration o f IFN-y secreted and rapid disease progression o f animals 
during M. tuberculosis infection
Data from experimental animals and patients with pulmonary tuberculosis and their 
household contacts indicate that M. tuberculosis-sX3ra\AdXQ& whole-blood production of 
IFN-y, although imperfect, is the best available correlate of protection (Ellner et al., 
2000; Kaufmann, 2006b).
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When the concentration of IFN-y was measured in PPD-stimulated diluted whole blood 
supernatants, differences were observed between 6-8 weeks post-infection. In the 
animals that survived >16 weeks post-M tuberculosis challenge, significantly higher 
concentrations of IFN-y were secreted. However, the significance disappeared when only 
vaccinated animals were analysed (appendix 20, section 8.20). Therefore, the ability of 
rhesus macaques to secrete IFN-y after M. tuberculosis infection indicates a good 
prognosis, but does not correlate with vaccine-induced protection. Others have shown 
that the magnitude of the BCG-attributable increase in IFN-y responsiveness to PPD, 
from before vaccination to 1 year after vaccination, correlates better with the known 
levels of protection induced by immunisation with BCG than does the absolute value of 
the IFN-y response (Black et al., 2002). The study described in humans (Black et al., 
2002) measured responses in populations using large numbers of individuals (n=613), 
whereas responses in macaques used in this thesis consisted of smaller group sizes and 
responses were determined on an individual animal basis. Also, as the majority of the 
rhesus macaques had no IFN-y detected in supernatants prior to vaccination, a similar 
analysis could not be undertaken in the macaque model.
The finding in the rhesus macaques that the concentration of IFN-y secreted in PPD- 
stimulated whole blood supernatants 6-8 weeks post-challenge correlated with an 
increased survival time could be due to the 6-day incubation period of this assay, rather 
than the overnight stimulation of the ELISPOT assay. This extended period may have 
allowed memory responses to be differentiated from effector responses.
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5.4 CONCLUSION
When analysed alongside data generated from human clinical trials, it has been found 
that IFN-y responses after BCG-vaccination are comparable with data in rhesus 
macaques. Using a novel ‘booster’ vaccine of MVA85A, kinetics of responses were 
similar but magnitudes of IFN-y secreting cells were lower in rhesus macaques compared 
to humans, despite a higher vaccine dose being administered. Vaccinated animals were 
challenged via aerosol with M. tuberculosis, with this being the first study where IFN-y 
measurements have been undertaken throughout such a time-course. It was found that 
BCG-vaccinated rhesus macaques were significantly protected against disease as 
measured by survival against aerosol M. tuberculosis challenge, but MVA85A-boosted 
animals were not. In the animals that showed signs of protection there were no 
differences in IFN-y responses compared to those that were not protected.
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6 GENERAL DISCUSSION
6.1 ANSWERING THE HYPOTHESIS
The hypothesis this thesis set out to test was:
“IFN-y measurements in a non-human primate experimental model of tuberculosis 
provide an accurate measure of protective efficacy against M. tuberculosis
infection”.
Three questions were addressed:
1) Were there any differences in IFN-y production in two macaque species: 
rhesus macaques and cynomolgus macaques?
2) Was IFN-y production in macaques similar to that observed in human 
clinical trials?
3) Were IFN-y measurements (frequency of IFN-y secreting cells or 
concentration of IFN-y secreted) in macaques correlated with protection 
against M. tuberculosis infection?
The findings from these questions are summarised and discussed below.
6.1.1 Differences in IFN-y responses between two macaque species
During BCG vaccination it was shown that rhesus macaques have higher frequencies of 
PPD-specific IFN-y secreting cells and increased concentrations of IFN-y secreted after 
PPD-stimulation of diluted whole blood compared to cynomolgus macaques. During M. 
tuberculosis infection, the frequencies of IFN-y-secreting cells were also higher in rhesus 
macaques compared to levels detected in cynomolgus macaques. However, similar 
concentrations of IFN-y were observed in the PPD-stimulated cell supernatants in both
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species of macaques after M tuberculosis challenge. Therefore, the trend was that IFN-y 
responses were higher in rhesus macaques compared to cynomolgus macaques 
during BCG vaccination and M. tuberculosis infection, especially with respect to the 
number of antigen-specific cells secreting this cytokine.
The analysis of TB-specific IFN-y responses in two macaque species has only once been 
reported in the literature (Langermans et a l , 2001). However, their study only assessed 
IFN-y production at one time point, 13 weeks after BCG vaccination, showing that 
rhesus macaques produced more than twice the amount of PPD-specific IFN-y compared 
to cynomolgus macaques (Langermans et a l , 2001). The challenge experiments reported 
by Langermans et al also used a large dose of 3,000 cfu M. tuberculosis delivered via 
intratracheal instillation compared to the aerosol delivery of a small number (30-75 cfu) 
of M. tuberculosis bacilli in the studies conducted at the Health Protection Agency 
(HPA) and reported in this thesis. This is the first time that a simultaneous comparison of 
IFN-y responses between two macaque species after aerosol M. tuberculosis infection 
has been reported.
One possible explanation for differences between the macaque species could be that the 
antibodies used in the IFN-y ELISPOT and ELISA assays have a higher affinity to rhesus 
macaque IFN-y than cynomolgus macaque IFN-y. The same antibody clones were used 
for both the ELISPOT and ELISA assays. The combination of monoclonal antibodies 
GZ-4 for capture and 7-B6-1 for detection used in this thesis have also been shown by 
other researchers to result in the detection of the highest levels of monkey IFN-y 
(Makitalo et a l, 2002). However, the IFN-y molecule is identical in rhesus macaques and 
cynomolgus macaques (Tatsumi & Sata, 1997; Villinger et a l, 1995), discounting the
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argument of different antibody affinities contributing to the differences seen between the 
two macaque species.
6.1.2 Comparison of IFN-y responses in macaques and humans
To date, there have been no publications directly comparing TB vaccination responses in 
humans and macaques using the same assays, time-points and vaccine preparations. In 
the studies reported in this thesis, data from macaques immunised with BCG and 
MVA85A were compared with results generated in human clinical trials conducted in 
Oxford.
In a pilot study using two rhesus macaques and two cynomolgus macaques vaccinated 
with BCG, the rhesus macaques showed frequencies of PPD-specific IFN-y-secreting 
cells similar to humans. The cynomolgus macaques, on the other hand, had much lower 
responses.
Using a larger cohort of 12 rhesus macaques, the frequency of PPD-specific and Ag85A- 
specific IFN-y-secreting cells followed the same trends in both macaques and humans 
after BCG vaccination. After MVA85A-immunisation, the kinetics of the response were 
similar but the magnitude was lower in rhesus macaques compared to responses in 
human studies. One week after MVA85A-immunisation, the responses to PPD and 
Ag85A were not significantly different between the two species, but beyond week 1, the 
Ag85A responses were statistically higher in humans than rhesus macaques. With 
Ag85A being the antigen for the MVA85A vaccine, this observation showed a distinct 
difference between the species.
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The finding that rhesus macaques showed different IFN-y responses to Ag85A peptides 
post-MVA85A-immunisation to humans is extremely important in the calibration of the 
model to assess TB vaccines. As the rhesus macaque IFN-y immune response mimicked 
the kinetics of human responses, the role of these animals in the testing of novel TB 
vaccines remains relevant. However, due to the magnitude of IFN-y responses being 
lower, care has to be exercised in interpretation of results. Because only one in 10 
infected individuals develop TB in their lifetime, large numbers of individuals will be 
required to demonstrate efficacy of any new vaccine in phase III clinical trials (Sander & 
McShane, 2007). However, macaques can be challenged in a controlled manner. 
Therefore, a balance needs to be assessed over risks and benefits in order to maximise 
the usefulness of non-human primate studies.
6.1.3 IFN-v as a correlate of protection
6.1.3.1 IFN-y responses during vaccination
During BCG vaccination, the animals with the lowest peak frequencies of PPD-specific 
IFN-y secreting cells were also statistically significantly likely to survive longer post-M 
tuberculosis challenge. This indicates an inverse relationship between the number of 
cells secreting IFN-y and survival. However, this observation was made using only 6 
animals, so should be followed up using a larger cohort of animals.
After MVA85A boosting of BCG primed animals, the rhesus macaque (animal K65) that 
had the most PPD- and Ag85A-specific IFN-y secreting cells and the highest 
concentration of PPD-specific IFN-y secreted in 6 day diluted whole blood supernatant 
survived for a year post-M tuberculosis challenge, there was no evidence of a trend of 
increased IFN-y responses in animals that survived for periods beyond 16 weeks post­
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challenge than those which met humane clinical endpoints before 16 weeks. Therefore, it 
was concluded that the frequency of Ag85A- or PPD-specific IFN-y-secreting cells or the 
concentration of IFN-y secreted in 6-day PPD-stimulated diluted whole blood induced 
after MVA85A vaccination did not correlate with protection.
There is certainly a minimum requirement for IFN-y to protect against M tuberculosis 
disease (Rook et al., 2006), which can be enhanced by booster vaccines that increase 
IFN-y levels (Goonetilleke et al., 2003; Tanghe et al., 2001). However, other studies 
show that a plateau of protective effect is rapidly reached, where further enhancement of 
IFN-y production is not helpful (Leal et a l, 2001; Skinner et al., 2003). Therefore, the 
plateau of response may possibly only have been breached by one animal, K65, resulting 
in enhanced survival. However, further studies would be needed to confirm this 
hypothesis.
Others have found that increasing the IFN-y response does not necessarily increase 
survival (Fonseca et al., 2007; Majlessi et al., 2006; Pardini et al., 2006; Young et al., 
2002). However, as seen with the MVA85A vector in the rhesus macaque studies, these 
observations suggest that IFN-y on its own does not correlate with protection in these 
models, meaning that further work is needed to determine what represents a correlate of 
protection against TB disease.
6.1.3.2 IFN-y responses after M. tuberculosis challenge of vaccinated animals
Despite the early PPD-specific IFN-y responses after M. tuberculosis challenge in the
BCG/MVA85A-vaccinated animals in the present study, compared to BCG-only or
unvaccinated control animals, this vaccination approach did not afford significant
protection against M. tuberculosis. The ability of M. tuberculosis to limit activation of
-284-
macrophages by IFN-y suggests that the amount of IFN-y produced by T cells may be 
less predictive of outcome than the ability of the cells to respond to this cytokine (Flynn 
& Chan, 2001a). The presence of a functional IFN-y receptor is essential for the recovery 
of mice from BCG infection (Kamijo et a l , 1993).
6.1.4 Conclusion
This thesis has documented IFN-y responses following M tuberculosis infection and 
after vaccination with BCG and the novel ‘booster’ vaccine, MVA85A. The results have 
shown that IFN-y responses in rhesus macaques during vaccination are similar in kinetics 
to those observed in humans. However, the magnitude of IFN-y secreting cells post- 
MVA85A boost were lower in rhesus macaques compared to human responses. Work 
has also proved that IFN-y is an important marker showing that immunity has been 
generated. However, neither the frequency of IFN-y-secreting cells nor the concentration 
of IFN-y secreted in a vaccination regime was indicative of protection. As the data 
reported in this thesis discount the hypothesis that IFN-y alone is a correlate of protection 
against M. tuberculosis infection, this leaves the elusive immune mechanism still to be 
discovered. However, it remains possible that IFN-y is just one component of many that 
may make a protective biosignature, as proposed by others (Beveridge et a l , 2008).
6.2 IMPROVEMENTS AND LIMITATIONS
A main limitation to these studies is the measurement of IFN-y responses in peripheral 
blood, as the disease site in TB is mainly in the lungs. Although peripheral T cells and 
monocytes can be influenced by pulmonary pathology, as they travel through the lung 
many times each day, the evaluation of their function may provide rather indirect 
information on what happens at the site of disease (Vanham et a l, 1997). Using BCG- 
MVA85A vaccination in mice, Ag85A-specific T cell responses in the lung lymph nodes
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(LLN) were found to correlate better with protection in the lung than splenic immune 
responses (Goonetilleke et a l, 2003). This observation has also been reported using 
Ag85A contained in an adenovirus vector where responses in the lung correlated better 
with survival than splenic responses (Forbes et a l, 2008). These data suggest that the 
frequency of antigen-specific IFN-y-secreting T cells in the vicinity of the lung may 
constitute a better indicator of protection in lung than systemic responses against 
pulmonary TB. It may be that the lymphocytes resident in the LLN can effectively 
control M. tuberculosis infection limiting its spread systemically.
The readouts from the IFN-y assays used in this thesis were the frequencies of antigen- 
specific IFN-y cells and the concentration of IFN-y secreted. Although the levels of the 
cytokine secreted may be important, receptors for the cytokine are also required. Ratios 
of cytokine:cytokine receptor may be more predictive of disease outcome then the 
measurement of the cytokine alone (McDermott, 2001). Other investigators have 
measured IFN-y-induced responses, which assess the integrity of the IFN-yR signalling 
pathway using monokine induced by gamma interferon (MIF) (Abramo et a l, 2006). 
This method would, therefore, test the functioning of IFN-y, instead of purely its 
production, and thus may be a more suitable measure of IFN-y function.
Looking at the actual cytokine network in vivo may also prove beneficial in assessing 
responses during M tuberculosis infection (Verbon et a l, 1999). After prolonged 
stimulation, such as with a chronic infection, elevated cytokine levels may be evident 
without additional stimulus (Morosini et al, 2003). As such, circulating levels of IFN-y 
in the plasma have been shown to correlate with disease severity (Sahiratmadja et a l, 
2007a). These elevated levels may be generated following prolonged stimulation, as 
would be expected in M tuberculosis infection.
-286-
Work described in this thesis was routinely carried out using unfractionated PBMC or 
whole blood. Therefore, the T-cell subsets involved in immunity were not routinely 
assessed. A vaccine-induced CD8+ T cell response may provide an important role in 
protective immunity (Behar et a l , 2007). Another important cell subset is CD 1-restricted 
T cells. Lipid antigens which are abundantly expressed by mycobacteria are highly 
specific for CD1 molecule activation (Behar & Porcelli, 2007). The primate model of M 
tuberculosis infection may prove an excellent approach for studying these responses as 
rodent models lack group 1 CD 1-restricted T cells that function primarily in the adaptive 
immune response (Behar & Porcelli, 2007). Assays to monitor the contribution of 
individual cell types in the production of IFN-y may therefore identify differences in 
vaccination approaches and establish the ideal repertoire of cells required for protection 
against M tuberculosis infection.
In this thesis, the focus was to address solely IFN-y responses. However, the requirement 
of a balance of Thl and Th2 cytokines, governed by IFN-y, IL-10 and IL-4 to prevent 
tissue destruction, has been suggested by a model used to predict cell-mediated immune 
regulatory mechanisms during human TB (Wigginton & Kirschner, 2001). Although the 
measurements of IL-lp, IL-2, IL-6, IL-10, IL-12 and TNF-a were undertaken in the M. 
tuberculosis challenged macaques, levels were only determined over a 12 week time- 
course of animals that did not succumb to rapid disease progression. Looking at a larger 
range of cytokines may yield more answers about the immune response, and why some 
vaccines fail to protect against M tuberculosis challenge. Implementing multiplex 
analysis, such as using luminex assays, during the vaccination stage would assist in 
further defining vaccine-induced immune responses.
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6.3 FUTURE WORK
6.3.1 Cytokines beyond IFN-v
6.3.1.1 Thl cytokines
Although IFN-y is a major cytokine necessary for the control of M tuberculosis 
infection, obviously there are others involved. IL-12 is critical in the development of a 
Thl response and the production of IFN-y, but additionally TNF can synergise with IFN- 
y to activate macrophages (Collins & Kaufmann, 2001). Therefore, future studies that 
assess cytokines that induce or work alongside IFN-y may yield further evidence on 
potential correlates of protection.
Measuring another cytokine such as IL-2 may prove beneficial in measuring the quality 
of IFN-y-secreting cells instead of the quantity. In studies of human responses following 
vaccination with tetanus or hepatitis B virus two types of Thl cells were examined; those 
that produce IFN-y and IL-2, and those that produced only IL-2 (De Rosa et al., 2004). 
The IFN-y- and IL-2-producing Thl cells were found to be short-lived in vitro and in 
vivo. In contrast, the Thl cells that only produce IL-2 efficiently developed into long­
term memory cells (De Rosa et al., 2004). Using polyfunctional T cell analysis by flow 
cytometry, in human studies the Ag85A-specific IFN-y-secreting cells in BCG/MVA85A 
vaccinated volunteers were also shown to secrete IL-2/TNF-a/MIP-lp (Beveridge et al.,
2007) and IL-2/TNF-a/IL-17 (Hawkridge et al., 2008). Therefore, it is possible that the 
IFN-y-secreting cells detected in the rhesus macaques following MVA85A-boosting 
were also secreting these cytokines and so were contributing to the immune response by 
more than solely the secretion of IFN-y.
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6.3.1.2 Th2 cytokines
Th2 cytokines have been detected in TB patients during the chronic stage of disease. The 
late appearance of Th2 cells does not necessarily imply a pathogenic role, but may 
suggest that they participate in down-regulation of the protective Thl response to avoid 
exaggerated pathologic consequences (Kaufmann & Andersen, 1998). Blood monocytes 
and lung granuloma macrophages from patients with active tuberculosis express TGF-p, 
a Th2 cytokine, and excessive activity of this cytokine may underlie depressed T cell 
responses (Toossi et al., 1995). Mean titres of Thl cytokines (IFN-y and IL-2) in mild 
and moderate TB patients appeared higher than in those with advanced disease, whereas 
moderate and advanced patients showed the higher levels of a Th2 cytokine (IL-4) in 
comparison to mild cases (Dlugovitzky et a l, 1997). A Th2 immune component of a TB 
vaccine may therefore prove advantageous in preventing potential immunopathology 
caused by an excess of pro-inflammatory cytokines.
6.3.1.3 Thl7 cells
A new class of T-helper cell that complements the Thl and Th2 subsets has been
proposed, named Thl 7 due to its secretion of IL-17. The production of IL-17 during M.
tuberculosis infection is primarily by y8 T cells after stimulation with IL-23 (Lockhart et
al., 2006). Evidence suggests that IL-17 is central to lymphocyte migration to the lung
(Kolls & Linden, 2004), including after BCG vaccination (Khader et al., 2007).
Therefore, directing T lymphocytes to the lung by activating the IL-17-producing Thl 7
cells could improve the protective potential of novel vaccine candidates (Kaufmann,
2006b). It has been suggested that IL-17 is not involved in protection against M
tuberculosis, but instead regulates inflammation (Khader & Cooper, 2008). Due to IFN-y
affecting the production of IL-17 (Cruz et al., 2006), levels of these two cytokines may
be critical to the inflammatory outcome of any mycobacterial infection (Khader &
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Cooper, 2008). Increased levels of IL-17 were found when boosting BCG vaccination 
responses with MVA85A in mice, but no protection was observed against a virulent M. 
tuberculosis infection (Romano et al., 2006). However, challenge was performed 
intravenously, so the cells in the lung were not preferentially targeted during infection. In 
the future investigating the effect of IL-17 on immune responses in protected vs. non­
protected macaques, especially after aerosol M tuberculosis challenge, may be useful.
6.3.2 Involvement of regulatory T-cells
TB disease may be accompanied by (a) the wrong type of regulatory T cell activity, 
compromising essential effector mechanisms, or (b) insufficient regulatory activity, 
which therefore results in pulmonary immunopathology (Doherty & Rook, 2006).
In a study to determine whether regulatory T cells affected the immune response induced 
by BCG vaccination, cells were inactivated using anti-CD25 antibody (Quinn et al., 
2008). Although this resulted in increased numbers of IL-2 producing CD4+ cells after 
BCG vaccination and an accelerated response after M. tuberculosis challenge, the level 
of protection remained unaltered compared to control mice (Quinn et al., 2008). These 
results suggest that regulatory T cells do not affect the efficacy of BCG vaccination.
When BCG responses in humans were boosted with MVA85A, the immunoregulatory 
cytokine transforming growth factor beta 1 (TGF-p 1) was downregulated (Fletcher et al.,
2008). This may allow for the induction of increased effector responses, such as those 
elevated frequencies of IFN-y-secreted cells observed in the rhesus macaques in this 
thesis; especially as the effect was observed 7 days post-MVA85A boost.
In infection the role of regulatory T cells may be more apparent as M tuberculosis may
exploit the inflammatory process to cause immunopathology and cavitation that
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characterise the disease and facilitate further transmission by coughing (Doherty & 
Rook, 2006). If this is the case, then perhaps in the lungs at least, there is too little 
regulatory T-cell activity (Doherty & Rook, 2006). In TB patients, regulatory T cells 
have been successfully isolated from PBMC at higher levels compared to those from 
healthy individuals with latent TB or uninfected controls (Hougardy et al., 2007). It has 
been shown in mice that, after aerosol M tuberculosis infection, regulatory T cells 
accumulated in the lung and pulmonary lymph nodes and suppressed the immune 
response that controls M. tuberculosis growth, thus having a negative effect on the 
control of TB disease (Scott-Browne et al., 2007). Therefore, a balance is required where 
regulatory T cells are required to prevent destructive inflammatory processes, but at the 
same time not suppress protective immune responses.
6.3.3 Other antigens
Future work could include looking at other antigenic components of M tuberculosis in 
order to stimulate a broader range of immune responses. In the macaques, only responses 
to PPD and selected peptides were measured. Whereas PPD predominantly induces a 
CD4+ ap T-cell response, there is little or no increase in y8 T cells (Fenton & Vermeulen, 
1996; Tsukaguchi et al, 1995). However, BCG also contains lipid antigens, which can 
induce immune responses (Watanabe et a l, 2006). Vaccination with BCG has been 
shown to induce y5 T-cells in cynomolgus macaques (Cairo et a l, 2007), rhesus 
macaques (Shen et a l, 2002), pigs (Lee et a l, 2004) and humans (Hoft et a l, 1998). y8 T 
cells can constitute 5% of T cells in lymphoid organs and 1-5% of circulating blood 
lymphocytes; they are also preferentially expanded by live mycobacteria suggesting they 
may play a role in the primary immune response to infection (Orme et a l, 1993a). 
Additionally, y8 T cells secrete IFN-y before ap T cells, so may contribute to early 
control of infection by production of this cytokine (Vanham et a l, 1997). yS T cells have
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also been shown to increase after M. tuberculosis infection of macaques (Shen et al., 
2002).
6.3.4 Antibody induction
Anti-vector antibodies were measured in this thesis, showing an interesting observation 
that the MVA85A-boosted animal with the lowest anti-vector antibodies (K65) was also 
the only animal that survived for a year post-challenge (appendix 21, section 8.21). This 
animal also had the highest IFN-y responses. Due to being only a single animal, it is 
difficult to ascertain the significance of this finding. However, future work may look into 
antibody responses of the insert protein to determine whether responses are biased 
towards the vector or the TB protein, and to analyse the importance of the overall 
humoral response with respect to survival. When MVA vectors containing 
cytomegalovirus proteins have been assessed in rhesus macaques, both antibody and 
cellular responses were observed concomitantly (Yue et al., 2008); thus, it is possible 
that this observation will also be seen in MVA85A-boosted macaques.
6.3.5 Mycobacteria-killing assays
Antigen-specific IFN-y T cell responses are useful for confirming the induction of the 
pattern of cellular immunity associated with protection. These will be employed in the 
initial phase I/II human studies of vaccines, but it has been shown in studies conducted in 
this thesis and by others (Britton & Palendira, 2003) that increased IFN-y production and 
protection do not always correlate in experimental models of TB. IFN-y alone is not 
sufficient to activate human infected macrophages to kill M tuberculosis, and a more 
global in vitro mycobacterial killing assay may measure the effect of the multiple factors 
needed to control the infection (Britton & Palendira, 2003). IFN-y production has been
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shown not to correlate with mycobacterial inhibition (Hoft et al, 2002), highlighting that 
this cytokine alone is not solely responsible for killing or stasis of mycobacteria.
6.3.6 Material available for the future assessment of immune parameters
The storage of material (PBMC, tissue lymphocytes, sera, saliva and stimulated blood 
supernatants) generated during this project will permit some of the suggested analyses to 
be undertaken. Where samples are not available, then future studies undertaken in non­
human primates may make provisions to ensure that the appropriate samples are 
available. One such example would be to assess immune responses in the lungs, the 
primary site of infection. In studies documented in this thesis, lungs were fixed in 
formaldehyde for magnetic resonance imaging (MRI) scanning and histology, or used to 
assess bacterial load. Therefore, future studies will need to address the benefits of 
immunological analysis in addition to work carried by other disciplines where samples 
are limited to ensure that the maximum information continues to be gained from the 
macaques.
Of utmost important is the fact that material is stored from animals that have been shown 
to be protective, and from those that were not. This will allow future studies to 
discriminate between the two groups, and therefore should greatly aid interpretation of 
results in the hunt for a correlate of protection.
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8 APPENDICES
8.1 APPENDIX 1: Challenge doses
The following tables show the doses of M. tuberculosis delivered to the macaques 
estimated from the circulating concentration of bacilli and the inhaled volume of the 
animals.
Challenge studies:
Estimated dose (cfu retained)
1st challenge 
study
2 nd challenge 
study
3rd challenge 
study
4th challenge 
study
Rhesus
macaques
D53 500 D19 70 D12 75
D80 30 C54 40 D42 45
D31 30 D60 40 D28 45
Cynomolgus
macaques
9909187 30 109181 40 1163 40 0111231 75
9909013 30 109027 40 1111 40 0201011 75
4313 30 109203 40 2151 40 0201191 75
Vaccine efficacy study:
Estimated dose
K44 K50
50 cfu
K20 K61
K79 K59
K43 K69
K32 K54
K47 K62
K52 K86
K65 K80
Acknowledgements:
This data was supplied by Ann Rawkins, Simon Clark and Graham Hatch.
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8.2 APPENDIX 2: Effect of ELISA incubation conditions
♦ — 2hr incubation 
♦ — Overnight incubation
3.0
Q
O
0.0
100001 0 1 0 01 1000
IFN-gamma concentration (pg/ml)
Effect on incubating samples for 2 hours at room temperature or overnight at 4°C on 
absorbance readings of a standard curve of known IFN-y concentrations. No difference 
between the two incubations were found, so all subsequent analysis was carried out 
overnight at 4°C.
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8.3 APPENDIX 3: Lymphocyte counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
Challenge study 1:
5e+6 ------------------------
D31
D53
D80
4313
9013
9187
1.2e+7
1.0e+74e+6
!.0e+6
3e+6
6.0e+6
2e+6
4.0e+6
1e+6 2.0e+6
0.0
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Challenge study 2:
8e+6------------------------E
1 / 50)
>3o
o
-C
109027
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109203
C54
D19
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1.4e+7
1.2e+7
6e+6 1 . 0 e + 7
i.0e+6Q .
E
> 3
4e+6
6.0e+6
4.0e+62e+6
2.0e+6
0 .0
oo CNJ O CDr-»co coCD
Challenge study 3:
C D O J O t- C N I - ^ C D C O O C N J  C O C N t- C N ^ C D O O O C N
W e ek s  pre/post M. tuberculosis ch a llen g e
Lymphocyte counts (assessed by forward scatter/side scatter) on the flow cytometer 
during M. tuberculosis infection.
Acknowledgements:
lmmunophenotyping results were supplied by Karen Gooch.
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8.4 APPENDIX 4: Granulocyte counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
Challenge study 1:
8e+6 ------------------------ 4313
9013
9187
D31
D53
D80
1.4e+7
1.2e+7
1.0e+7
!.0e+6
4e+6
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0. 0
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Challenge study 3:
D12
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1.4e+71.2e+7
1163
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1.2e+71.0e+7
1.0e+7l.0e+6
i.0e+6
6.0e+6
i.0e+6
4.0e+6 4.0e+6
2.0e+6 2.0e+6
0 .00.0
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W e ek s  p re/p ost M. tuberculosis ch a llen g e
Granulocyte counts (assessed by forward scatter/side scatter) on the flow cytometer 
during M  tuberculosis infection.
Acknowledgements:
Immunophenotyping results were supplied by Karen Gooch.
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8.5 APPENDIX 5: Monocyte counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
Challenge study 1:
1e+6 ---------------------------- D31
D53
D80
2.5e+6 4313
9013
9187
8e+5 2.0e+6
1.5e+66e+5
4e+5 1.0e+6
5.0e+52e+5
0.0
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Challenge study 3:
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Monocyte counts (assessed by forward scatter/side scatter) on the flow cytometer during 
M. tuberculosis infection.
A cknowledgements:
Immunophenotyping results were supplied by Karen Gooch.
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8.6 APPENDIX 6: CD3+ counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
7e+6 
6e+6 
5e+6 
4e+6 
3e+6 
2e+6 
1e+6
I
C/5
<u Challenge study 2:
Challenge study 3:
C Q C M O t— ( N ^ C O C O O C N J  C O C N ' T -  C N i ^ t C D C O O C N
W eek s pre/post M. tuberculosis challen ge
CD3+ counts (assessed by CDS antibody staining) on the flow cytometer during M. 
tuberculosis infection.
Acknowledgements:
Immunophenotyping results were supplied by Karen Gooch.
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8.7 APPENDIX 7: CD4+ counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
Challenge study 1:
D31
D53
D80
4313
9909013
9909187
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CD4+ counts (assessed by CD4 antibody staining) on the flow cytometer during M. 
tuberculosis infection.
Acknowledgements:
Immunophenotyping results were supplied by Karen Gooch.
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8.8 APPENDIX 8: CD8+ counts during M. tuberculosis infection
Rhesus macaques Cynomolgus macaques
D31
D53
D80
Challenge study 1:
(,5e+61.2e+6
-3.0e+61 .Oe+6
2.5e+6
l.0e+5
2.Oe+6
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4 Oe+5 1.0e+6
2.Oe+5 5.Oe+5
0.00 .0
Challenge study 2
CO O  CN
Challenge study 3
W e ek s  pre/post M. tuberculosis ch a llen ge
CD8+ counts (assessed by CD8 antibody staining) on the flow cytometer during M. 
tuberculosis infection.
Acknowledgements:
Immunophenotyping results were supplied by Karen Gooch.
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8.9 APPENDIX 9: Proliferative responses during M. tuberculosis infection (rhesus
macaques)
11,1 1 3 H - p r o l i f e r a t io n  (1 ^ ig /m l P P D )  
3 H - p r o l i f e r a t io n  ( 5 p g /m l P P D )  
3 H - p r o l i f e r a t io n  ( 1 0 p g /m l P P D )  
— • —  IF N -y  E L IS P O T  ( 1 0 p g /m l P P D )
Weeks post M. tuberculosis infection
Weeks post M. tuberculosis infection
Weeks post M. tuberculosis infection
Weeks post M. tuberculosis infection
3 0 0 0
2 5 0 0
2000
1 5 0 0
1000
5 0 0
0
6 0 0 0
5 0 0 0
4 0 0 0
3 0 0 0
2000
1000
0
Proliferative responses (as assessed by H-incorporation) in rhesus macaques during M  
tuberculosis infection.
(Note: only animals where a complete timecourse was available are shown).
A cknowledgements:
Proliferation results were supplied by Karen Gooch.
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8.10 APPENDIX 10: Proliferative responses during M. tuberculosis infection
(cynomolgus macaques)
a8™ 8 3 H - p r o l i f e r a t io n  ( 1 p g /m l P P D )  
t =  3 H - p r o I i f e r a t io n  ( 5 p g /m l P P D )  
3 H - p r o l i f e r a t io n  ( lO p g / m l  P P D )  
— • —  IF N -y  E L IS P O T  ( lO p g / m l  P P D )
9909013
Weeks post M. tuberculosis infectionWeeks post M. tuberculosis infection
1090279909187
Weeks post M. tuberculosis infectionWeeks post M. tuberculosis infection
109203109181
Weeks post M. tuberculosis infection Weeks post M. tuberculosis infection
Proliferative responses (as assessed by H-incorporation) in cynomolgus macaques 
during M. tuberculosis infection.
(Note: only animals where a complete timecourse was available are shown).
Acknowledgements:
Proliferation results were supplied by Karen Gooch.
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8.11 APPENDIX 11: Bacteriological findings in spleen of M. tuberculosis infected
macaques
Cynomolgus macaques
Animal no. Logio cfu/g
1111 0 . 6 8
1163 0
2151 0
109027 0
109181 1.70
109203 0
9909187 0
9909013 0
4313 0
Rhesus macaques
Animal no. Logio cfu/g
D12 2.53
D28 1.56
D42 1.26
D19 2.79
D60 0
C54 1.35
D53 4.50
D31 2.40
D80 0
Bacteriological loads in spleens of M. tuberculosis infected macaques.
Acknowledgements:
Bacteriology results were supplied by Simon Clark.
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8.12 APPENDIX 12: Bacteriological findings in hilar lymph nodes of M. 
tuberculosis infected macaques
Rhesus macaques
Animal no. Log io cfu/g
D12 4.84
D28 4.99
D42 4.17
D19 4.74
D60 0
C54 3.73
D53 5.51
D31 0
D80 4.12
Cynomolgus macaques
Animal no. Log io cfu/g
1111 3.65
1163 3.90
2151 4.15
109027 3.89
109181 Not done
109203 3.56
9909187 4.18
9909013 4.86
4313 3.88
Bacteriological loads in hilar lymph nodes of M. tuberculosis infected macaques.
Acknowledgements:
Bacteriology results were supplied by Simon Clark.
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8.13 APPENDIX 13: X-ray scores during M. tuberculosis infection of macaques
Rhesus macaques
Week
no. D31 D53 D80 D19 D60 C54 D12 D28 D42
0 0 0 0 0 0 0 0 0 0
2 0 1 0 2 0 0 - - -
4 0 3 0 4 0 3 4 3 3
6 0 4 0 4 - - 4+ 4 3
8 0 0 1 3 4
10 0 0 1 3 4
12 0 0 3 3 4+
Cynomolgus macaques
Week
no. 4313 9013 9187 9203 9181 9027 1111 1163 2151
0 0 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 - - -
4 0 0 0 0 3 0 0 0 0
6 0 1 1 - - - 0 0 0
8 0 1 1 0 3 3 0 0 0
10 0 1 1 0 4 3 2 0 0
12 0 1 1 1 4 3 3 0 0
0 = - no infiltrate
1 = + modest infiltrate on one side only
2 = ++ extensive infiltrate on one side only
3 = +++ modest infiltrate on both sides of lungs
4 = ++++ extensive infiltrate on both sides of lungs
4+ will be used to show if the condition seen previously has worsened
X-ray scores of macaques during M. tuberculosis infection
A cknowledgements:
X-rays results were analysed by Fergus Gleeson (Churchill Hospital, Oxford).
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8.14 APPENDIX 14: Bacteriological counts in BCG-vaccinated macaques
Rhesus macaques:
Bacteriological count (c 'u/g or cfu/ml)
Animal 1040 Animal 1252
Spleen 0 0
Liver 0 0
Kidney 0 0
Mesenteric LN 0 0
Hilar LN 0 0
Left axillary LN 0 0
Right axillary LN 0 0
Saliva 0 0
Urine 0 0
Faeces 0 0
Cynomolgus macaques:
Bacteriological count (c u/g or cfu/ml)
Animal 1007 Animal 9911021
Spleen 0 0
Liver 0 0
Kidney 0 0
Mesenteric LN 0 0
Hilar LN 0 0
Left axillary LN 0 0
Right axillary LN 0 0
Saliva 0 0
Urine 0 0
Faeces 0 0
Bacteriological counts in two rhesus macaques (1040 and 1252) and two cynomolgus 
macaques (1007 and 9911021) which had been vaccinated with BCG for 74 weeks.
Acknowledgements:
Bacteriology results were supplied by Simon Clark.
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8.15 APPENDIX 15: Intracellular cytokine staining results during BCG
vaccination
Pre 0 1 3 4 5 6 7
K80
—— K59
K52
K50
- ± - K44
—• — K43
—►— K20
—▼— K61
—■— K65
—▲— K69
—• — K79
—•— K86
K62
■ K54
K32
• K47
10 11 12
0.5
CD4
Cl
L l_
CD
0.0
CDQ_ 61 2 3 5 8 9 10 11 12Pre 0 4 7
CD8
o.o
3 5 6 8 9 10 11 12Pre 0 1 2 4 7
Weeks post-BCG vaccination 
Intracellular cytokine staining results of rhesus macaques that were vaccinated with BCG 
(blue lines) or unvaccinated (green lines).
Acknowledgements: Intracellular cytokine results were supplied by Karen Gooch.
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8.16 APPENDIX 16: BCG and BCG/MVA85A vaccination and M. tuberculosis 
infection IFN-y ELISPOT timecourse
BCG-vaccinated
BCG-vaccinated with 
MVA85A boost
12000
10000
CO o /
5 0 0 0  -EE CD
CO CL
O ) CD
z
L L
O 4 0 0 0  -
7/5
o
o
©o 3 0 0 0  -
0 ) O )
CL c
to
0) 2 0 0 0  -
Q o
CL 0)
CL co 1000  -
Unvaccinated
MVA85A
M. tuberculosis
L fiD  CDx— CM CO CM CD 0 0  O  CM CD 0 0  O  CO I f )  P '- O ) x— CO
0 ) 0 ) 0 )  x— x— x— t— x— CM CM CM CM CM CO CO
CL 0 l CL
I O N  x -  CO
CD CD r^ - h -
2 2 5 0 0
X -  CM CO CM -St CD 0 0  O  CM MT CD 0 0  O  CO LO h -  CD x— CO h -  x -  L rtO  O ) CO I'-~ x— I f i  N  x -  CO
Q) Q) Q) x— x - x - x - v - C M  CM CM CM CM CO CO CO "M- x j-  ID  LO CD C D C D  h -  r-~
cl cl cl
Schedule week number
IFN-y ELISPOT timecourse of rhesus macaques after vaccination with BCG and 
BCG/MVA85A with responses after M. tuberculosis infection to PPD (top graph) and 
summed Ag85A peptides (lower graph).
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8.17 APPENDIX 17: Intracellular cytokine staining results during MVA85A
immunisation
K 8 0  
— ♦—  K 5 9  
—T —  K 5 2
■  K 5 0  
—A —  K 4 4
K 4 3  
— —  K 2 0  
- T -  K61
■  K 6 5  
- A -  K 6 9  
- *  K 7 9  
— *—  K 8 6
3 .0
CD3
2.0  -
0.0
85 6 71 2 3 40
C/5
0 .5
CD4
0 .4  -
Q .
L i­
en
0.0
CL­
ODS
0 .4  -
0.0
85 6 72 3 410
Weeks post-MVA85A boost
Intracellular cytokine staining results of rhesus macaques that were immunised with 
MVA85A after previous vaccination with BCG (red lines) or un-MVA85A-immunised 
(blue lines).
Acknowledgements: Intracellular cytokine results were supplied by Karen Gooch.
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8.18 APPENDIX 18: Intracellular cytokine staining results during M. tuberculosis 
infection of vaccinated animals
12
CD3+
10 -
K 8 0
— -  - K 5 9
K 5 2
• K 5 0
—A — K 4 4
—• — K 4 3
— '— K 2 0
— r - K 61
■ K 6 5
— A — K 6 9
— 9 — K 7 9
— •— K 8 6
K 6 2
—m — K 5 4
—A — K 3 2
• K 4 7
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0 .5  -
0.0
2 5 3 015 205 1000
3 .0
CD8
2.0  -
0 .5  -
0.0
2 5 3 010 15 2050
Weeks post-M. tuberculosis infection 
Intracellular cytokine staining results of rhesus macaques that were immunised with
BCG (blue lines), BCG/MVA85A (red lines) or unvaccinated (green lines) after M.
tuberculosis infection.
Acknowledgements: Intracellular cytokine results were supplied by Karen Gooch.
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8.19 APPENDIX 19: Survival plots of vaccinated rhesus macaques after M. 
tuberculosis challenge
Survival time post-challenge
100
80
5 60 
E3</)
s “
° 40
20
1------------------ 1 HIL■  ■
i l i ------------------- a — m----------------------------------------------- m -m t
♦ ♦
— —j —I k
..................................
50 100 150 200 250
Time p o st-ch a llen g e  (days)
300
Control
BCG/MVA
350
Using log rank Test (non-parametric right sensorinq only)
Control BCG BCG MVA
Control - - -
BCG 0.048 - -
BCG MVA 0.642 0.102 -
= significantly different from one another 
= not significantly different from one another
Survival plot showing percentage survival of animals that were unvaccinated (blue line), 
BCG vaccinated (pink line) or BCG/MVA85A vaccinated (green line) after aerosol M. 
tuberculosis challenge.
Table shows statistical analysis between groups, with the only significant finding 
(P<0.05) that the BCG-vaccinated group were protected compared to the unvaccinated 
group.
Acknowledgement: Simon Clark assisted in the interpretation o f  survival data.
-342-
8.20 APPENDIX 20: Concentrations of IFN-y secreted after M. tuberculosis
challenge of vaccinated rhesus macaques
2 weeks post-infection 4 weeks post-infection
6000
p = 0.4712
5000
4000
3000
2000
1000
Survivors Non-survivors
3000
p = 0.9362
2500
2000
1500
1000
500
0
Non-survivorsSurvivors
6 weeks post-infection 8 weeks post-infection
O)a
co
COI—c
0ocoa
20000 p = 0.2298
17500
15000
12500
10000
Survivors Non-survivors
p = 0.128212000
10000
8000
6000
4000
2000
Survivors Non-survivors
10 weeks post-infection 12 weeks post-infection
50000
p =  0.1282 p =  0.5186
20000
• 40000  • •
15000 30000
10000  ■ 20000
5000 •
•  •
10000 •
0 ? \ 0  • ¥ ____________________________i ---------------------
Survivors Non-survivors Survivors Non-survivors
Concentration of IFN-y secreted in PPD-stimulated 6  day whole blood supernatants after 
M. tuberculosis challenge of animals vaccinated with BCG and BCG/MVA85A grouped 
according to survival time. Statistical analysis shows no difference between groups 
(Mann-Whitney test, significance P<0.05).
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8.21 APPENDIX 21: Anti-vaccinia antibodies in MVA85A boosted animals 
compared with survival
K20 (mid-term survivor) 
K61 (short-term survivor) 
K65 (long-term survivor) 
K69 (short-term survivor) 
K79 (short-term survivor) 
K86 (short-term survivor)
400
300 -
o  200 -
0 5
W eek 4 W eek 8Pre-MVA W eek 6
Time since MVA85A immunisation
Anti-vaccinia antibody responses in MVA85A boosted macaques show that the animal 
that survived for a year post-challenge had the lowest levels of anti-vector humoral 
immunity.
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